

EMJM – ERASMUS MUNDUS JOINT MASTER

PROGRAMME Leading International Vaccinology Education – LIVE

SUPPLEMENTARY DOCUMENT 2

LIVE ASSOCIATED PARTNERS

PREAMBLE

This file is the supplementary document 2 for the project of the Erasmus Mundus Joint Master “Leading International Vaccinology Education” (LIVE). LIVE is submitted to the Erasmus Mundus call of Feb 16th, 2023.

This document contains:

- The up-to-date table that provides the alphabetic list of associated institutions, their activities in the Master LIVE and active association period
- The same table, ranked with different keys: by country, PIC number or category subtypes.
- Alphabetically ranked, a short presentation of each partner and all letter of commitment / support.

Note: Next page, the **Table of Contents** is interactive and
hyperlinks refer to the paragraph

TABLE OF CONTENTS: CLICK TO NAVIGATE

| | | |
|----------|---|-----------|
| 1 | <i>Table of the institutions involved in the LIVE</i> | 4 |
| 1.1 | Alphabetic ranking of the institutions | 4 |
| 1.2 | Institutions ranked by region & country | 7 |
| 1.3 | Institutions ranked by their partner number registration | 10 |
| 1.4 | Institutions ranked by category | 13 |
| 1.5 | Institutions ranked by their year of association with the LIVE programme | 16 |
| 2 | <i>Interactions between the LIVE programme and the skills of associated partners</i> | 20 |
| 3 | <i>Associated Partners description & Letters of commitment</i> | 28 |
| 3.1 | ABL Lyon becomes Active biomarkers | 28 |
| 3.2 | Amal Therapeutics | 33 |
| 3.3 | Association Lyonbiopôle | 36 |
| 3.4 | Bavarian Nordic AS | 38 |
| 3.5 | Baylor College of Medicine - National School of Tropical Medicine | 41 |
| 3.6 | BIOASTER Fondation de coopération scientifique | 44 |
| 3.7 | BioMérieux SA | 47 |
| 3.8 | Boehringer Ingelheim Animal Health France | 50 |
| 3.9 | CanSinoBIO | 53 |
| 3.10 | Centre National de la Recherche Scientifique CNRS - Cancer Research Center of Lyon | 56 |
| 3.11 | Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé – CNRST IRSS | 59 |
| 3.12 | Centre Pasteur du Cameroun | 62 |
| 3.13 | Commissariat à l’Energie Atomique et aux énergies alternatives - CEA | 64 |
| 3.14 | CRODA | 67 |
| 3.15 | Dahousie University | 70 |
| 3.16 | Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) | 72 |
| 3.17 | Early makers group - Emlyon business school | 77 |
| 3.18 | European Vaccine Initiative - EVI | 80 |
| 3.19 | Fondation Mérieux | 83 |
| 3.20 | Fundacio Privada Institut de Recerca de la SIDA-CAIXA - IrsiCaixa | 86 |
| 3.21 | Fundacion Privada Instituto de Salud Global Barcelona – ISGLOBAL | 88 |
| 3.22 | GlaxoSmithKline Biologicals SA - GSK | 91 |
| 3.23 | HIPRA Scientific SL | 94 |
| 3.24 | IFAKARA Health Institute Trust | 97 |
| 3.25 | Incepta Vaccine Ltd | 99 |
| 3.26 | Innovative clinical research network in vaccinology: i-reivac | 102 |
| 3.27 | Institut de Investigacio en Ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA | 104 |
| 3.28 | Institut National de la santé et de la Recherche Médicale - Inserm - Clinical Trial Center in Vaccinology CIC-EC-CIIL | 107 |
| 3.29 | Instituto Butantan | 110 |
| 3.30 | International Vaccine Institute | 113 |
| 3.31 | Intravacc | 116 |
| 3.32 | Janssen Vaccines & Prevention B.V. | 116 |
| 3.33 | Karolinska Institutet*Department of Medicine_Solna | 119 |
| 3.34 | Katholieke Universiteit Leuven*Rega Institute for medical research | 122 |
| 3.35 | Laboratorio Reig Jofre SA | 126 |
| 3.36 | LoValTech | 129 |
| 3.37 | Luxembourg Institute of Health | 132 |
| 3.38 | Mérieux Alliance SA - Institut Mérieux | 134 |
| 3.39 | Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS | 137 |
| 3.40 | Ministero de Salud Publica | 139 |

| | | |
|------|--|-----|
| 3.41 | Moderna Therapeutics | 140 |
| 3.42 | MSD Vaccins – Pôle France | 143 |
| 3.43 | National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine | 146 |
| 3.44 | Sanofi Pasteur SA | 149 |
| 3.45 | Société d'Exploitation de Produits Pour les Industries Chimiques SEPPIC | 151 |
| 3.46 | Speransa Therapeutics | 154 |
| 3.47 | SPHERE CNRS | 157 |
| 3.48 | Stichting TuBerculosis Vaccine Initiative TBVI | 160 |
| 3.49 | THE Chancellor, Masters and Scholars of the University of Oxford - The Jenner Institute | 162 |
| 3.50 | The Pirbright Institute LBG | 165 |
| 3.51 | Transgene SA | 167 |
| 3.52 | TRON – Translationale Onkologie Ander Universitat Smedizin Der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GMBH | 170 |
| 3.53 | Universidade de São Paulo | 172 |
| 3.54 | Universita Degli Studi di Firenze - UniFi | 175 |
| 3.55 | Université Libre de Bruxelles | 178 |
| 3.56 | Université Paris XII Val de Marne - Vaccine Research Institute - VRI | 181 |
| 3.57 | Universiteit Antwerpen _ Center for the Evaluation of Vaccination – CEV | 184 |
| 3.58 | UNIVERSITY OF SASKATCHEWAN - Vaccine and Infectious Disease Organization - VIDO | 187 |
| 3.59 | Vaccine Formulation Institute (CH) - VFI | 190 |
| 3.60 | Vakzine Projekt Management GMBH | 192 |
| 3.61 | Valneva | 195 |
| 3.62 | World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS | 196 |

1 Table of the institutions involved in the LIVE

62 Total active partners from 23 countries (19 from partner countries) are involved in the LIVE consortium. All partners have provided a letter of commitment. Most of the 2023 supporting (without PIC) partners could create their PIC number and are now included in the 55 Institutions associated to the Master LIVE with a PIC number. 7 are supporting partners.

The LIVE partners can be classified in five categories:

- **19 Clin_Res, clinical or research centre;**
- **8 HEI, higher education institution;**
- **9 BPC, big pharma company;**
- **13 SMC, small and medium size company;**
- **13 State_Org, foundations, states & organizations.**

Column 6 gives their year of association with LIVE.

31 partners are working with us from 2015.

18 new partners are joining the LIVE programme for this 2023 call (column 6: “2022” and “2023”):

- 2 BPC: HIPRA Scientific SLU - CanSinoBIO
- 2 Clin_Res: The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute - TRON (Translational Onkologie an der Universitätsmedizin der Johannes Gutenberg)
- 3 HEI: Dalhousie University - Early makers group – University of Saskatchewan (Vaccine and Infectious Disease Organization)
- 6 SMC: Bavarian Nordic AS - CRODA Denmark A/S - Laboratório Reig Jofre SA - Moderna Therapeutics - Société d'Exploitation de Produits Pour les Industries Chimiques - Speransa Therapeutics
- 5 State_Org: Fundació privada Institut de Recerca de la SIDA-CAIXA - IFAKARA Health Institute Trust – LoValTech - Ministerio de salud pública - Stichting TuBerculosis Vaccine Initiative TBVI

In the next pages, the same table of associated and supporting partners is presented ranking by alphabet, region & country, programme partner number, institution type and association year.

[Then we summarize in a table the content of their commitment letters that you will find after all tables and](#) a short summary to present each institution.

1.1 Alphabetic ranking of the institutions

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|---------------------------|----------------|------------------|------------------|
| ABL LYON becomes Active Biomarkers (https://active-biomarkers.com/) | FR | Member States of the EU | 27 | SMC | 2015 |
| Amal Therapeutics (https://www.amaltherapeutics.com/) | CH | Region 14 | 12 | SMC | 2015 |
| Association Lyonbiopôle (https://lyonbiopole.com/) | FR | Member States of the EU | 23 | State_Org | 2015 |
| Bavarian Nordic AS (https://www.bavarian-nordic.com/) | DK | Member States of the EU | 47 | SMC | 2023 |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine (https://www.bcm.edu/education/national-school-of-tropical-medicine) | US | Region 12 - US and Canada | 46 | HEI | 2018 |
| BIOASTER Fondation de Coopération Scientifique (https://www.bioaster.org/) | FR | Member States of the EU | 24 | State_Org | 2015 |
| BioMérieux SA (https://www.biomerieux.com/corp/en.html) | FR | Member States of the EU | 30 | BPC | 2018 |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) (https://www.boehringer-ingelheim.com/animal-health/overview) | DE/FR | Member States of the EU | 31 | BPC | 2015 |
| CanSinoBIO (https://www.cansinotech.com/) | CN | Region 5 - Asia | Support | BPC | 2023 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|-------------------------------|----------------|------------------|------------------|
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon (http://www.crcl.fr/) | FR | Member States of the EU | 6 | Clin_Res | 2015 |
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS (http://www.cnrst.bf/index.php/irss/) | BF | Region 9 - Sub-Saharan Africa | 7 | Clin_Res | 2015 |
| Centre Pasteur du Cameroun (http://www.pasteur-yaounde.org/) | CM | Region 9 - Sub-Saharan Africa | 28 | Clin_Res | 2015 |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA (http://www.cea.fr/) | FR | Member States of the EU | 13 | Clin_Res | 2015 |
| CRODA Denmark A/S (https://www.croda.com/en-gb) | DK | Member States of the EU | 34 | SMC | 2022 |
| Dalhousie University (https://www.dal.ca/) | CA | Region 12 - US and Canada | 55 | HEI | 2023 |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) (https://ciri.ens-lyon.fr/) | FR | Member States of the EU | 14 | Clin_Res | 2015 |
| early makers group (https://msc-health-data-intelligence.com/en) | FR | Member States of the EU | 56 | HEI | 2023 |
| European Vaccine Initiative (EVI) (http://www.euvaccine.eu/) | DE | Member States of the EU | 15 | State_Org | 2015 |
| Fondation Mérieux (http://www.fondation-merieux.org) | FR | Member States of the EU | 8 | State_Org | 2015 |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa (https://www.irsicaixa.es/en) | ES | Member States of the EU | 42 | State_Org | 2023 |
| Fundación Privada Instituto de Salud Global Barcelona (https://www.isglobal.org/en/about-us) | ES | Member States of the EU | 16 | State_Org | 2015 |
| GlaxoSmithKline Biologicals SA*GSKBIO (http://www.gsk.com/) | BE | Member States of the EU | 20 | BPC | 2015 |
| HIPRA Scientific SLU (https://www.hipracovid19.com/en/about-hipra) | ES | Member States of the EU | 43 | BPC | 2023 |
| IFAKARA Health Institute Trust (https://ihi.or.tz/) | TZ | Region 9 - Sub-Saharan Africa | 57 | State_Org | 2023 |
| Incepta Vaccine Ltd (http://inceptavaccine.com/) | BD | Region 5 - Asia | 26 | SMC | 2018 |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) (https://www.ireivac.org/) | FR | Member States of the EU | Support | State_Org | 2015 |
| Institut de Investigació en ciències de la Salut Germans Trias i Pujol – IGTP-CERCA (http://www.germanstrias.org/) | ES | Member States of the EU | 41 | Clin_Res | 2018 |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) (https://www.inserm.fr/en) | FR | Member States of the EU | 9 | Clin_Res | 2015 |
| Instituto Butantan (https://en.butantan.gov.br/institute.php) | BR | Region 10 - Latin America | 18 | Clin_Res | 2015 |
| International Vaccine Institute (http://www.ivi.int/) | KR | Region 5 - Asia | 35 | Clin_Res | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| Intravacc (http://www.intravacc.nl/) | NL | Member States of the EU | Support | SMC | 2015 |
| Janssen Vaccines & Prevention B.V. (https://www.janssen.com/netherlands/) | NL | Member States of the EU | 29 | BPC | 2018 |
| Karolinska Institutet*Department of Medicine_Solna (https://ki.se/en) | SE | Member States of the EU | 49 | Clin_Res | 2019 |
| Katholieke Universiteit Leuven*Rega Institute (https://www.kuleuven.be/english/) | BE | Member States of the EU | 50 | Clin_Res | 2019 |
| Laboratorio Reig Jofre SA (https://reigjofre.com/en/) | ES | Member States of the EU | 44 | SMC | 2023 |
| LoValTech (https://lovaltechnology.com/en/editorial/) | FR | Member States of the EU | 48 | State_Org | 2023 |
| Luxembourg Institute of Health (https://www.lih.lu/) | LU | Member States of the EU | 51 | Clin_Res | 2019 |
| Mérieux Alliance SA*Institut Mérieux (http://www.institut-merieux.com/en/home/) | FR | Member States of the EU | 21 | BPC | 2015 |
| Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS (http://mbucas.cz/en/) | CZ | Member States of the EU | 32 | Clin_Res | 2018 |
| Ministerio de salud pública (https://www.salud.gob.ec/) | EC | Region 10 - Latin America | Support | State_Org | 2023 |
| Moderna Therapeutics (https://www.modernatx.com/) | US | Region 12 - US and Canada | 58 | SMC | 2023 |
| MSD vaccins - pôle France (www.msd.com) | FR/US | Member States of the EU | 52 | BPC | 2020 |
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine (https://nubip.edu.ua/en/node/1662) | UA | Region 2 - Neighbourhood East | 53 | HEI | 2019 |
| Sanofi Pasteur SA (https://www.sanofi.com/) | FR | Member States of the EU | 22 | BPC | 2015 |
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC (https://www.seppic.com/en) | FR | Member States of the EU | 40 | SMC | 2023 |
| Speransa Therapeutics (https://www.speransatherapeutics.com/) | DE | Member States of the EU | 45 | SMC | 2023 |
| Sphere CNRS-Université Paris 7 Diderot (http://www.sphere.univ-paris-diderot.fr/?lang=en) | FR | Member States of the EU | support | Clin_Res | 2015 |
| Stichting TuBerculosis Vaccine Initiative TBVI (https://www.tbvi.eu/) | NL | Member States of the EU | 36 | State_Org | 2022 |
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute (https://www.jenner.ac.uk/) | UK | Region 14 | 38 | Clin_Res | 2022 |
| The Pirbright Institute LBG (https://www.pirbright.ac.uk/our-science/impact-our-research) | UK | Region 14 | 10 | Clin_Res | 2015 |
| Transgène SA (https://www.transgene.fr/en/) | FR | Member States of the EU | 54 | SMC | 2015 |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH (https://tron-mainz.de/) | DE | Member States of the EU | 37 | Clin_Res | 2022 |
| Universidade de São Paulo_Institut de Ciências Biomédicas (https://www5.usp.br/) | BR | Region 10 - Latin America | 17 | HEI | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|---------------------------|----------------|------------------|------------------|
| Universita Degli Studi di Firenze (https://www.unifi.it/changelang-eng.html) | IT | Member States of the EU | 59 | HEI | 2015 |
| Université Libre de Bruxelles (https://www.ulb.be/en/ulb-homepage) | BE | Member States of the EU | 60 | HEI | 2015 |
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI (https://www.en.u-pec.fr/ https://vaccine-research-institute.fr/) | FR | Member States of the EU | 33 | Clin_Res | 2018 |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV (https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/) | BE | Member States of the EU | Support | Clin_Res | 2015 |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO (https://www.vido.org/) | CA | Region 12 - US and Canada | 39 | HEI | 2023 |
| Vaccine Formulation Institute (CH) - VFI (https://www.vaccineformulationinstitute.org/) | CH | Region 14 | 19 | State_Org | 2015 |
| Vakzine Projekt Management GmbH (https://www.vpm-consult.com/) | DE | Member States of the EU | 11 | SMC | 2015 |
| Valneva (https://valneva.com/) | FR | Member States of the EU | 25 | SMC | 2015 |
| World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS (https://www.who.int/) | CH | Region 14 | Support | State_Org | 2015 |

1.2 Institutions ranked by region & country

43 partners from 10 member States of the EU

19 partners in 13 partner countries

62 institutions in 23 countries

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------|----------------|------------------|------------------|
| GlaxoSmithKline Biologicals SA*GSKBIO (http://www.gsk.com/) | BE | Member States of the EU | 20 | BPC | 2015 |
| Katholieke Universiteit Leuven*Rega Institute (https://www.kuleuven.be/english/) | BE | Member States of the EU | 50 | Clin_Res | 2019 |
| Université Libre de Bruxelles (https://www.ulb.be/en/ulb-homepage) | BE | Member States of the EU | 60 | HEI | 2015 |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV (https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/) | BE | Member States of the EU | Support | Clin_Res | 2015 |
| CanSinoBIO (https://www.cansinotech.com/) | CN | Region 5 - Asia | Support | BPC | 2023 |
| Mikrobiologicky Ustav - AVCR, V.V.I. - Institute of Microbiology of the CAS (http://mbucas.cz/en/) | CZ | Member States of the EU | 32 | Clin_Res | 2018 |
| European Vaccine Initiative (EVI) (http://www.euvaccine.eu/) | DE | Member States of the EU | 15 | State_Org | 2015 |
| Speransa Therapeutics (https://www.speransatherapeutics.com/) | DE | Member States of the EU | 45 | SMC | 2023 |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz | DE | Member States of the EU | 37 | Clin_Res | 2022 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|-------------------------|----------------|------------------|------------------|
| gemeinnützige GmbH (https://tron-mainz.de/) | | | | | |
| Vakzine Projekt Management GmbH (https://www.vpm-consult.com/) | DE | Member States of the EU | 11 | SMC | 2015 |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) (https://www.boehringer-ingelheim.com/animal-health/overview) | DE/FR | Member States of the EU | 31 | BPC | 2015 |
| Bavarian Nordic AS (https://www.bavarian-nordic.com/) | DK | Member States of the EU | 47 | SMC | 2023 |
| CRODA Denmark A/S (https://www.croda.com/en-gb) | DK | Member States of the EU | 34 | SMC | 2022 |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa (https://www.irsicaixa.es/en) | ES | Member States of the EU | 42 | State_Org | 2023 |
| Fundación Privada Instituto de Salud Global Barcelona (https://www.isglobal.org/en/about-us) | ES | Member States of the EU | 16 | State_Org | 2015 |
| HIPRA Scientific SLU (https://www.hipracovid19.com/en/about-hipra) | ES | Member States of the EU | 43 | BPC | 2023 |
| Institut de Investigacio en ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA (http://www.germanstrias.org/) | ES | Member States of the EU | 41 | Clin_Res | 2018 |
| Laboratorio Reig Jofre SA (https://reigjofre.com/en/) | ES | Member States of the EU | 44 | SMC | 2023 |
| ABL LYON becomes Active Biomarkers (https://active-biomarkers.com/) | FR | Member States of the EU | 27 | SMC | 2015 |
| Association Lyonbiopôle (https://lyonbiopole.com/) | FR | Member States of the EU | 23 | State_Org | 2015 |
| BIOASTER Fondation de Coopération Scientifique (https://www.bioaster.org/) | FR | Member States of the EU | 24 | State_Org | 2015 |
| BioMérieux SA (https://www.biomerieux.com/corp/en.html) | FR | Member States of the EU | 30 | BPC | 2018 |
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon (http://www.crcl.fr/) | FR | Member States of the EU | 6 | Clin_Res | 2015 |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA (http://www.cea.fr/) | FR | Member States of the EU | 13 | Clin_Res | 2015 |
| Early makers group (https://msc-health-data-intelligence.com/en) | FR | Member States of the EU | 56 | HEI | 2023 |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) (https://ciri.ens-lyon.fr/) | FR | Member States of the EU | 14 | Clin_Res | 2015 |
| Fondation Mérieux (http://www.fondation-merieux.org) | FR | Member States of the EU | 8 | State_Org | 2015 |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) (https://www.ireivac.org/) | FR | Member States of the EU | Support | State_Org | 2015 |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) (https://www.inserm.fr/en) | FR | Member States of the EU | 9 | Clin_Res | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| LoValTech (https://lovaltechnology.com/en/editorial/) | FR | Member States of the EU | 48 | State_Org | 2023 |
| Mérieux Alliance SA*Institut Mérieux (http://www.institut-merieux.com/en/home/) | FR | Member States of the EU | 21 | BPC | 2015 |
| Sanofi Pasteur SA (https://www.sanofi.com/) | FR | Member States of the EU | 22 | BPC | 2015 |
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC (https://www.seppic.com/en) | FR | Member States of the EU | 40 | SMC | 2023 |
| Sphere CNRS-Université Paris 7 Diderot (http://www.sphere.univ-paris-diderot.fr/?lang=en) | FR | Member States of the EU | support | Clin_Res | 2015 |
| Transgène SA (https://www.transgene.fr/en/) | FR | Member States of the EU | 54 | SMC | 2015 |
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI (https://www.en.u-pec.fr/ https://vaccine-research-institute.fr/) | FR | Member States of the EU | 33 | Clin_Res | 2018 |
| Valneva (https://valneva.com/) | FR | Member States of the EU | 25 | SMC | 2015 |
| MSD vaccins - pôle France (www.msd.com) | FR/US | Member States of the EU | 52 | BPC | 2020 |
| Universita Degli Studi di Firenze (https://www.unifi.it/changelang-eng.html) | IT | Member States of the EU | 59 | HEI | 2015 |
| Luxembourg Institute of Health (https://www.lih.lu/) | LU | Member States of the EU | 51 | Clin_Res | 2019 |
| Intravacc (http://www.intravacc.nl/) | NL | Member States of the EU | Support | SMC | 2015 |
| Janssen Vaccines & Prevention B.V. (https://www.janssen.com/netherlands/) | NL | Member States of the EU | 29 | BPC | 2018 |
| Stichting TuBerculosis Vaccine Initiative TBVI (https://www.tbvi.eu/) | NL | Member States of the EU | 36 | State_Org | 2022 |
| Karolinska Institutet*Department of Medicine_Solna (https://ki.se/en) | SE | Member States of the EU | 49 | Clin_Res | 2019 |
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine (https://nubip.edu.ua/en/node/1662) | UA | Region 2 - Neighbourhood East | 53 | HEI | 2019 |
| Incepta Vaccine Ltd (http://inceptavaccine.com/) | BD | Region 5 - Asia | 26 | SMC | 2018 |
| International Vaccine Institute (http://www.ivi.int/) | KR | Region 5 - Asia | 35 | Clin_Res | 2015 |
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS (http://www.cnrst.bf/index.php/irss/) | BF | Region 9 - Sub-Saharan Africa | 7 | Clin_Res | 2015 |
| Centre Pasteur du Cameroun (http://www.pasteur-yaounde.org/) | CM | Region 9 - Sub-Saharan Africa | 28 | Clin_Res | 2015 |
| IFAKARA Health Institute Trust (https://ihi.or.tz/) | TZ | Region 9 - Sub-Saharan Africa | 57 | State_Org | 2023 |
| Instituto Butantan (https://en.butantan.gov.br/institute.php) | BR | Region 10 - Latin America | 18 | Clin_Res | 2015 |
| Universidade de São Paulo_Institut de Ciências Biomédicas (https://www5.usp.br/) | BR | Region 10 - Latin America | 17 | HEI | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|---------------------------|----------------|------------------|------------------|
| Ministerio de salud pública (https://www.salud.gob.ec/) | EC | Region 10 - Latin America | Support | State_Org | 2023 |
| Dalhousie University (https://www.dal.ca/) | CA | Region 12 - US and Canada | 55 | HEI | 2023 |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO (https://www.vido.org/) | CA | Region 12 - US and Canada | 39 | HEI | 2023 |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine (https://www.bcm.edu/education/national-school-of-tropical-medicine) | US | Region 12 - US and Canada | 46 | HEI | 2018 |
| Moderna Therapeutics (https://www.modernatx.com/) | US | Region 12 - US and Canada | 58 | SMC | 2023 |
| Amal Therapeutics (https://www.amaltherapeutics.com/) | CH | Region 14 | 12 | SMC | 2015 |
| Vaccine Formulation Institute (CH) - VFI (https://www.vaccineformulationinstitute.org/) | CH | Region 14 | 19 | State_Org | 2015 |
| World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS (https://www.who.int/) | CH | Region 14 | Support | State_Org | 2015 |
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute (https://www.jenner.ac.uk/) | UK | Region 14 | 38 | Clin_Res | 2022 |
| The Pirbright Institute LBG (https://www.pirbright.ac.uk/our-science/impact-our-research) | UK | Region 14 | 10 | Clin_Res | 2015 |

1.3 Institutions ranked by their partner number registration

55 partners associated with a PIC number to the LIVE programme
7 Supporting partners, organising networks, without PIC numbers

62 total partners

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|-------------------------------|----------------|------------------|------------------|
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon (http://www.crcl.fr/) | FR | Member States of the EU | 6 | Clin_Res | 2015 |
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS (http://www.cnrst.bf/index.php/irss/) | BF | Region 9 - Sub-Saharan Africa | 7 | Clin_Res | 2015 |
| Fondation Mérieux (http://www.fondation-merieux.org) | FR | Member States of the EU | 8 | State_Org | 2015 |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) (https://www.inserm.fr/en) | FR | Member States of the EU | 9 | Clin_Res | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| The Pirbright Institute LBG (https://www.pirbright.ac.uk/our-science/impact-our-research) | UK | Region 14 | 10 | Clin_Res | 2015 |
| Vakzine Projekt Management GmbH (https://www.vpm-consult.com/) | DE | Member States of the EU | 11 | SMC | 2015 |
| Amal Therapeutics (https://www.amaltherapeutics.com/) | CH | Region 14 | 12 | SMC | 2015 |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA (http://www.cea.fr/) | FR | Member States of the EU | 13 | Clin_Res | 2015 |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) (https://ciri.ens-lyon.fr/) | FR | Member States of the EU | 14 | Clin_Res | 2015 |
| European Vaccine Initiative (EVI) (http://www.euvaccine.eu/) | DE | Member States of the EU | 15 | State_Org | 2015 |
| Fundación Privada Instituto de Salud Global Barcelona (https://www.isglobal.org/en/about-us) | ES | Member States of the EU | 16 | State_Org | 2015 |
| Universidade de São Paulo_Institut de Ciências Biomédicas (https://www5.usp.br/) | BR | Region 10 - Latin America | 17 | HEI | 2015 |
| Instituto Butantan (https://en.butantan.gov.br/institute.php) | BR | Region 10 - Latin America | 18 | Clin_Res | 2015 |
| Vaccine Formulation Institute (CH) - VFI (https://www.vaccineformulationinstitute.org/) | CH | Region 14 | 19 | State_Org | 2015 |
| GlaxoSmithKline Biologicals SA*GSKBIO (http://www.gsk.com/) | BE | Member States of the EU | 20 | BPC | 2015 |
| Mérieux Alliance SA*Institut Mérieux (http://www.institut-merieux.com/en/home/) | FR | Member States of the EU | 21 | BPC | 2015 |
| Sanofi Pasteur SA (https://www.sanofi.com/) | FR | Member States of the EU | 22 | BPC | 2015 |
| Association Lyonbiopôle (https://lyonbiopole.com/) | FR | Member States of the EU | 23 | State_Org | 2015 |
| BIOASTER Fondation de Coopération Scientifique (https://www.bioaster.org/) | FR | Member States of the EU | 24 | State_Org | 2015 |
| Valneva (https://valneva.com/) | FR | Member States of the EU | 25 | SMC | 2015 |
| Incepta Vaccine Ltd (http://inceptavaccine.com/) | BD | Region 5 - Asia | 26 | SMC | 2018 |
| ABL LYON becomes Active Biomarkers (https://active-biomarkers.com/) | FR | Member States of the EU | 27 | SMC | 2015 |
| Centre Pasteur du Cameroun (http://www.pasteur-yaounde.org/) | CM | Region 9 - Sub-Saharan Africa | 28 | Clin_Res | 2015 |
| Janssen Vaccines & Prevention B.V. (https://www.janssen.com/netherlands/) | NL | Member States of the EU | 29 | BPC | 2018 |
| BioMérieux SA (https://www.biomerieux.com/corp/en.html) | FR | Member States of the EU | 30 | BPC | 2018 |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) (https://www.boehringer-ingelheim.com/animal-health/overview) | DE/FR | Member States of the EU | 31 | BPC | 2015 |
| Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS (http://mbucas.cz/en/) | CZ | Member States of the EU | 32 | Clin_Res | 2018 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI (https://www.en.u-pec.fr/ https://vaccine-research-institute.fr/) | FR | Member States of the EU | 33 | Clin_Res | 2018 |
| CRODA Denmark A/S (https://www.croda.com/en-gb/) | DK | Member States of the EU | 34 | SMC | 2022 |
| International Vaccine Institute (http://www.ivi.int/) | KR | Region 5 - Asia | 35 | Clin_Res | 2015 |
| Stichting TuBerculosis Vaccine Initiative TBVI (https://www.tbvi.eu/) | NL | Member States of the EU | 36 | State_Org | 2022 |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH (https://tron-mainz.de/) | DE | Member States of the EU | 37 | Clin_Res | 2022 |
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute (https://www.jenner.ac.uk/) | UK | Region 14 | 38 | Clin_Res | 2022 |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO (https://www.vido.org/) | CA | Region 12 - US and Canada | 39 | HEI | 2023 |
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC (https://www.seppic.com/en/) | FR | Member States of the EU | 40 | SMC | 2023 |
| Institut de Investigacio en ciencias de la Salut Germans Trias i Pujol – IGTP-CERCA (http://www.germanstrias.org/) | ES | Member States of the EU | 41 | Clin_Res | 2018 |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa (https://www.irsicaixa.es/en/) | ES | Member States of the EU | 42 | State_Org | 2023 |
| HIPRA Scientific SLU (https://www.hipracovid19.com/en/about-hipra) | ES | Member States of the EU | 43 | BPC | 2023 |
| Laboratorio Reig Jofre SA (https://reigjofre.com/en/) | ES | Member States of the EU | 44 | SMC | 2023 |
| Speransa Therapeutics (https://www.speransatherapeutics.com/) | DE | Member States of the EU | 45 | SMC | 2023 |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine (https://www.bcm.edu/education/national-school-of-tropical-medicine) | US | Region 12 - US and Canada | 46 | HEI | 2018 |
| Bavarian Nordic AS (https://www.bavarian-nordic.com/) | DK | Member States of the EU | 47 | SMC | 2023 |
| LoValTech (https://lovaltechnology.com/en/editorial/) | FR | Member States of the EU | 48 | State_Org | 2023 |
| Karolinska Institutet*Department of Medicine_Solna (https://ki.se/en) | SE | Member States of the EU | 49 | Clin_Res | 2019 |
| Katholieke Universiteit Leuven*Rega Institute (https://www.kuleuven.be/english/) | BE | Member States of the EU | 50 | Clin_Res | 2019 |
| Luxembourg Institute of Health (https://www.lih.lu/) | LU | Member States of the EU | 51 | Clin_Res | 2019 |
| MSD vaccins - pôle France (www.msd.com) | FR/US | Member States of the EU | 52 | BPC | 2020 |
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine (https://nubip.edu.ua/en/node/1662) | UA | Region 2 - Neighbourhood East | 53 | HEI | 2019 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| Transgène SA (https://www.transgene.fr/en/) | FR | Member States of the EU | 54 | SMC | 2015 |
| Dalhousie University (https://www.dal.ca/) | CA | Region 12 - US and Canada | 55 | HEI | 2023 |
| Early makers group (https://msc-health-data-intelligence.com/en) | FR | Member States of the EU | 56 | HEI | 2023 |
| IFAKARA Health Institute Trust (https://ihi.or.tz/) | TZ | Region 9 - Sub-Saharan Africa | 57 | State_Org | 2023 |
| Moderna Therapeutics (https://www.modernatx.com/) | US | Region 12 - US and Canada | 58 | SMC | 2023 |
| Università Degli Studi di Firenze (https://www.unifi.it/changelang-eng.html) | IT | Member States of the EU | 59 | HEI | 2015 |
| Université Libre de Bruxelles (https://www.ulb.be/en/ulb-homepage) | BE | Member States of the EU | 60 | HEI | 2015 |
| CanSinoBIO (https://www.cansinotech.com/) | CN | Region 5 - Asia | Support | BPC | 2023 |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) (https://www.ireivac.org/) | FR | Member States of the EU | Support | State_Org | 2015 |
| Intravacc (http://www.intravacc.nl/) | NL | Member States of the EU | Support | SMC | 2015 |
| Ministerio de salud pública (https://www.salud.gob.ec/) | EC | Region 10 - Latin America | Support | State_Org | 2023 |
| Sphere CNRS-Université Paris 7 Diderot (http://www.sphere.univ-paris-diderot.fr/?lang=en) | FR | Member States of the EU | support | Clin_Res | 2015 |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV (https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/) | BE | Member States of the EU | Support | Clin_Res | 2015 |
| World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS (https://www.who.int/) | CH | Region 14 | Support | State_Org | 2015 |

1.4 Institutions ranked by category

9 BPC, big pharma companies
19 Clin_Res, clinical and/or research centre
8 HEI, high education institutions
13 State_Org, foundations, states & organizations
13 SMC, small and medium size companies

62 Total partners

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------|----------------|------------------|------------------|
| BioMérieux SA (https://www.biomerieux.com/corp/en.html) | FR | Member States of the EU | 30 | BPC | 2018 |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) (https://www.boehringer-ingelheim.com/animal-health/overview) | DE/FR | Member States of the EU | 31 | BPC | 2015 |
| CanSinoBIO (https://www.cansinotech.com/) | CN | Region 5 - Asia | Support | BPC | 2023 |
| GlaxoSmithKline Biologicals SA*GSKBIO (http://www.gsk.com/) | BE | Member States of the EU | 20 | BPC | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| HIPRA Scientific SLU (https://www.hipracovid19.com/en/about-hipra) | ES | Member States of the EU | 43 | BPC | 2023 |
| Janssen Vaccines & Prevention B.V. (https://www.janssen.com/netherlands/) | NL | Member States of the EU | 29 | BPC | 2018 |
| Mérieux Alliance SA*Institut Mérieux (http://www.institut-merieux.com/en/home/) | FR | Member States of the EU | 21 | BPC | 2015 |
| MSD vaccins - pôle France (www.msd.com) | FR/US | Member States of the EU | 52 | BPC | 2020 |
| Sanofi Pasteur SA (https://www.sanofi.com/) | FR | Member States of the EU | 22 | BPC | 2015 |
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon (http://www.crcl.fr/) | FR | Member States of the EU | 6 | Clin_Res | 2015 |
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS (http://www.cnrst.bf/index.php/irss/) | BF | Region 9 - Sub-Saharan Africa | 7 | Clin_Res | 2015 |
| Centre Pasteur du Cameroun (http://www.pasteur-yaounde.org/) | CM | Region 9 - Sub-Saharan Africa | 28 | Clin_Res | 2015 |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA (http://www.cea.fr/) | FR | Member States of the EU | 13 | Clin_Res | 2015 |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) (https://ciri.ens-lyon.fr/) | FR | Member States of the EU | 14 | Clin_Res | 2015 |
| Institut de Investigacio en ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA (http://www.germanstrias.org/) | ES | Member States of the EU | 41 | Clin_Res | 2018 |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) (https://www.inserm.fr/en) | FR | Member States of the EU | 9 | Clin_Res | 2015 |
| Instituto Butantan (https://en.butantan.gov.br/institute.php) | BR | Region 10 - Latin America | 18 | Clin_Res | 2015 |
| International Vaccine Institute (http://www.ivi.int/) | KR | Region 5 - Asia | 35 | Clin_Res | 2015 |
| Karolinska Institutet*Department of Medicine_Solna (https://ki.se/en) | SE | Member States of the EU | 49 | Clin_Res | 2019 |
| Katholieke Universiteit Leuven*Rega Institute (https://www.kuleuven.be/english/) | BE | Member States of the EU | 50 | Clin_Res | 2019 |
| Luxembourg Institute of Health (https://www.lih.lu/) | LU | Member States of the EU | 51 | Clin_Res | 2019 |
| Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS (http://mbucas.cz/en/) | CZ | Member States of the EU | 32 | Clin_Res | 2018 |
| Sphere CNRS-Université Paris 7 Diderot (http://www.sphere.univ-paris-diderot.fr/?lang=en) | FR | Member States of the EU | support | Clin_Res | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|-------------------------------|----------------|------------------|------------------|
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute (https://www.jenner.ac.uk/) | UK | Region 14 | 38 | Clin_Res | 2022 |
| The Pirbright Institute LBG (https://www.pirbright.ac.uk/our-science/impact-our-research) | UK | Region 14 | 10 | Clin_Res | 2015 |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH (https://tron-mainz.de/) | DE | Member States of the EU | 37 | Clin_Res | 2022 |
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI (https://www.en.u-pec.fr/ https://vaccine-research-institute.fr/) | FR | Member States of the EU | 33 | Clin_Res | 2018 |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV (https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/) | BE | Member States of the EU | Support | Clin_Res | 2015 |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine (https://www.bcm.edu/education/national-school-of-tropical-medicine) | US | Region 12 - US and Canada | 46 | HEI | 2018 |
| Dalhousie University (https://www.dal.ca/) | CA | Region 12 - US and Canada | 55 | HEI | 2023 |
| Early makers group (https://msc-health-data-intelligence.com/en) | FR | Member States of the EU | 56 | HEI | 2023 |
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine (https://nubip.edu.ua/en/node/1662) | UA | Region 2 - Neighbourhood East | 53 | HEI | 2019 |
| Universidade de São Paulo_Institut de Ciências Biomédicas (https://www5.usp.br/) | BR | Region 10 - Latin America | 17 | HEI | 2015 |
| Universita Degli Studi di Firenze (https://www.unifi.it/changelang-eng.html) | IT | Member States of the EU | 59 | HEI | 2015 |
| Université Libre de Bruxelles (https://www.ulb.be/en/ulb-homepage) | BE | Member States of the EU | 60 | HEI | 2015 |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO (https://www.vido.org/) | CA | Region 12 - US and Canada | 39 | HEI | 2023 |
| ABL LYON becomes Active Biomarkers (https://active-biomarkers.com/) | FR | Member States of the EU | 27 | SMC | 2015 |
| Amal Therapeutics (https://www.amaltherapeutics.com/) | CH | Region 14 | 12 | SMC | 2015 |
| Bavarian Nordic AS (https://www.bavarian-nordic.com/) | DK | Member States of the EU | 47 | SMC | 2023 |
| CRODA Denmark A/S (https://www.croda.com/en-gb) | DK | Member States of the EU | 34 | SMC | 2022 |
| Incepta Vaccine Ltd (http://inceptavaccine.com/) | BD | Region 5 - Asia | 26 | SMC | 2018 |
| Intravacc (http://www.intravacc.nl/) | NL | Member States of the EU | Support | SMC | 2015 |
| Laboratorio Reig Jofre SA (https://reigjofre.com/en/) | ES | Member States of the EU | 44 | SMC | 2023 |
| Moderna Therapeutics (https://www.modernatx.com/) | US | Region 12 - US and Canada | 58 | SMC | 2023 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC (https://www.seppic.com/en) | FR | Member States of the EU | 40 | SMC | 2023 |
| Speransa Therapeutics (https://www.speransatherapeutics.com/) | DE | Member States of the EU | 45 | SMC | 2023 |
| Transgène SA (https://www.transgene.fr/en/) | FR | Member States of the EU | 54 | SMC | 2015 |
| Vakzine Projekt Management GmbH (https://www.vpm-consult.com/) | DE | Member States of the EU | 11 | SMC | 2015 |
| Valneva (https://valneva.com/) | FR | Member States of the EU | 25 | SMC | 2015 |
| Association Lyonbiopôle (https://lyonbiopole.com/) | FR | Member States of the EU | 23 | State_Org | 2015 |
| BIOASTER Fondation de Coopération Scientifique (https://www.bioaster.org/) | FR | Member States of the EU | 24 | State_Org | 2015 |
| European Vaccine Initiative (EVI) (http://www.euvaccine.eu/) | DE | Member States of the EU | 15 | State_Org | 2015 |
| Fondation Mérieux (http://www.fondation-merieux.org) | FR | Member States of the EU | 8 | State_Org | 2015 |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa (https://www.irsicaixa.es/en) | ES | Member States of the EU | 42 | State_Org | 2023 |
| Fundación Privada Instituto de Salud Global Barcelona (https://www.isglobal.org/en/about-us) | ES | Member States of the EU | 16 | State_Org | 2015 |
| IFAKARA Health Institute Trust (https://ihi.or.tz/) | TZ | Region 9 - Sub-Saharan Africa | 57 | State_Org | 2023 |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) (https://www.ireivac.org/) | FR | Member States of the EU | Support | State_Org | 2015 |
| LoValTech (https://lovaltechnology.com/en/editorial/) | FR | Member States of the EU | 48 | State_Org | 2023 |
| Ministerio de salud pública (https://www.salud.gob.ec/) | EC | Region 10 - Latin America | Support | State_Org | 2023 |
| Stichting TuBerculosis Vaccine Initiative TBVI (https://www.tbvi.eu/) | NL | Member States of the EU | 36 | State_Org | 2022 |
| Vaccine Formulation Institute (CH) - VFI (https://www.vaccineformulationinstitute.org/) | CH | Region 14 | 19 | State_Org | 2015 |
| World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS (https://www.who.int/) | CH | Region 14 | Support | State_Org | 2015 |

1.5 Institutions ranked by their year of association with the LIVE programme

The majority of the 44 partners already engaged in the previous programme LIVE have provided an updated letter of commitment.

18 new partners are joining the programme LIVE in 2022-2023

62 Total partners

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|---|---------|-------------------------------|----------------|------------------|------------------|
| ABL LYON becomes Active Biomarkers (https://active-biomarkers.com/) | FR | Member States of the EU | 27 | SMC | 2015 |
| Amal Therapeutics (https://www.amaltherapeutics.com/) | CH | Region 14 | 12 | SMC | 2015 |
| Association Lyonbiopôle (https://lyonbiopole.com/) | FR | Member States of the EU | 23 | State_Org | 2015 |
| BIOASTER Fondation de Coopération Scientifique (https://www.bioaster.org/) | FR | Member States of the EU | 24 | State_Org | 2015 |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) (https://www.boehringer-ingelheim.com/animal-health/overview) | DE/FR | Member States of the EU | 31 | BPC | 2015 |
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon (http://www.crcl.fr/) | FR | Member States of the EU | 6 | Clin_Res | 2015 |
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS (http://www.cnrst.bf/index.php/irss/) | BF | Region 9 - Sub-Saharan Africa | 7 | Clin_Res | 2015 |
| Centre Pasteur du Cameroun (http://www.pasteur-yaounde.org/) | CM | Region 9 - Sub-Saharan Africa | 28 | Clin_Res | 2015 |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA (http://www.cea.fr/) | FR | Member States of the EU | 13 | Clin_Res | 2015 |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) (https://ciri.ens-lyon.fr/) | FR | Member States of the EU | 14 | Clin_Res | 2015 |
| European Vaccine Initiative (EVI) (http://www.euvaccine.eu/) | DE | Member States of the EU | 15 | State_Org | 2015 |
| Fondation Mérieux (http://www.fondation-merieux.org) | FR | Member States of the EU | 8 | State_Org | 2015 |
| Fundación Privada Instituto de Salud Global Barcelona (https://www.isgglobal.org/en/about-us) | ES | Member States of the EU | 16 | State_Org | 2015 |
| GlaxoSmithKline Biologicals SA*GSKBIO (http://www.gsk.com/) | BE | Member States of the EU | 20 | BPC | 2015 |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) (https://www.ireivac.org/) | FR | Member States of the EU | Support | State_Org | 2015 |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) (https://www.inserm.fr/en) | FR | Member States of the EU | 9 | Clin_Res | 2015 |
| Instituto Butantan (https://en.butantan.gov.br/institute.php) | BR | Region 10 - Latin America | 18 | Clin_Res | 2015 |
| International Vaccine Institute (http://www.ivi.int/) | KR | Region 5 - Asia | 35 | Clin_Res | 2015 |
| Intravacc (http://www.intravacc.nl/) | NL | Member States of the EU | Support | SMC | 2015 |
| Mérieux Alliance SA*Institut Mérieux (http://www.institut-merieux.com/en/home/) | FR | Member States of the EU | 21 | BPC | 2015 |
| Sanofi Pasteur SA (https://www.sanofi.com/) | FR | Member States of the EU | 22 | BPC | 2015 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|---------------------------|----------------|------------------|------------------|
| Sphere CNRS-Université Paris 7 Diderot (http://www.sphere.univ-paris-diderot.fr/?lang=en) | FR | Member States of the EU | support | Clin_Res | 2015 |
| The Pirbright Institute LBG (https://www.pirbright.ac.uk/our-science/impact-our-research) | UK | Region 14 | 10 | Clin_Res | 2015 |
| Transgène SA (https://www.transgene.fr/en/) | FR | Member States of the EU | 54 | SMC | 2015 |
| Universidade de São Paulo_Institut de Ciências Biomédicas (https://www5.usp.br/) | BR | Region 10 - Latin America | 17 | HEI | 2015 |
| Universita Degli Studi di Firenze (https://www.unifi.it/changelang-eng.html) | IT | Member States of the EU | 59 | HEI | 2015 |
| Université Libre de Bruxelles (https://www.ulb.be/en/ulb-homepage) | BE | Member States of the EU | 60 | HEI | 2015 |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV (https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/) | BE | Member States of the EU | Support | Clin_Res | 2015 |
| Vaccine Formulation Institute (CH) - VFI (https://www.vaccineformulationinstitute.org/) | CH | Region 14 | 19 | State_Org | 2015 |
| Vakzine Projekt Management GmbH (https://www.vpm-consult.com/) | DE | Member States of the EU | 11 | SMC | 2015 |
| Valneva (https://valneva.com/) | FR | Member States of the EU | 25 | SMC | 2015 |
| World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS (https://www.who.int/) | CH | Region 14 | Support | State_Org | 2015 |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine (https://www.bcm.edu/education/national-school-of-tropical-medicine) | US | Region 12 - US and Canada | 46 | HEI | 2018 |
| BioMérieux SA (https://www.biomerieux.com/corp/en.html) | FR | Member States of the EU | 30 | BPC | 2018 |
| Incepta Vaccine Ltd (http://inceptavaccine.com/) | BD | Region 5 - Asia | 26 | SMC | 2018 |
| Institut de Investigacio en ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA (http://www.germanstrias.org/) | ES | Member States of the EU | 41 | Clin_Res | 2018 |
| Janssen Vaccines & Prevention B.V. (https://www.janssen.com/netherlands/) | NL | Member States of the EU | 29 | BPC | 2018 |
| Mikrobiologicky Ustav - AVCR, V.V.I. - Institute of Microbiology of the CAS (http://mbucas.cz/en/) | CZ | Member States of the EU | 32 | Clin_Res | 2018 |
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI (https://www.en.u-pec.fr/) https://vaccine-research-institute.fr/) | FR | Member States of the EU | 33 | Clin_Res | 2018 |
| Karolinska Institutet*Department of Medicine_Solna (https://ki.se/en) | SE | Member States of the EU | 49 | Clin_Res | 2019 |
| Katholieke Universiteit Leuven*Rega Institute (https://www.kuleuven.be/english/) | BE | Member States of the EU | 50 | Clin_Res | 2019 |
| Luxembourg Institute of Health (https://www.lih.lu/) | LU | Member States of the EU | 51 | Clin_Res | 2019 |

| Institution Full Name (website) | Country | Region | Partner number | Institution type | Association year |
|--|---------|-------------------------------|----------------|------------------|------------------|
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine (https://nubip.edu.ua/en/node/1662) | UA | Region 2 - Neighbourhood East | 53 | HEI | 2019 |
| MSD vaccins - pôle France (www.msd.com) | FR/US | Member States of the EU | 52 | BPC | 2020 |
| CRODA Denmark A/S (https://www.croda.com/en-gb) | DK | Member States of the EU | 34 | SMC | 2022 |
| Stichting TuBerculosis Vaccine Initiative TBVI (https://www.tbvi.eu/) | NL | Member States of the EU | 36 | State_Org | 2022 |
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute (https://www.jenner.ac.uk/) | UK | Region 14 | 38 | Clin_Res | 2022 |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH (https://tron-mainz.de/) | DE | Member States of the EU | 37 | Clin_Res | 2022 |
| Bavarian Nordic AS (https://www.bavarian-nordic.com/) | DK | Member States of the EU | 47 | SMC | 2023 |
| CanSinoBIO (https://www.cansinotech.com/) | CN | Region 5 - Asia | Support | BPC | 2023 |
| Dalhousie University (https://www.dal.ca/) | CA | Region 12 - US and Canada | 55 | HEI | 2023 |
| Early makers group (https://msc-health-data-intelligence.com/en) | FR | Member States of the EU | 56 | HEI | 2023 |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa (https://www.irsicaixa.es/en) | ES | Member States of the EU | 42 | State_Org | 2023 |
| HIPRA Scientific SLU (https://www.hipracovid19.com/en/about-hipra) | ES | Member States of the EU | 43 | BPC | 2023 |
| IFAKARA Health Institute Trust (https://ihi.or.tz/) | TZ | Region 9 - Sub-Saharan Africa | 57 | State_Org | 2023 |
| Laboratorio Reig Jofre SA (https://reigjofre.com/en/) | ES | Member States of the EU | 44 | SMC | 2023 |
| LoValTech (https://lovaltechnology.com/en/editorial/) | FR | Member States of the EU | 48 | State_Org | 2023 |
| Ministerio de salud pública (https://www.salud.gob.ec/) | EC | Region 10 - Latin America | Support | State_Org | 2023 |
| Moderna Therapeutics (https://www.modernatx.com/) | US | Region 12 - US and Canada | 58 | SMC | 2023 |
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC (https://www.seppic.com/en) | FR | Member States of the EU | 40 | SMC | 2023 |
| Speransa Therapeutics (https://www.speransatherapeutics.com/) | DE | Member States of the EU | 45 | SMC | 2023 |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO (https://www.vido.org/) | CA | Region 12 - US and Canada | 39 | HEI | 2023 |

2 Interactions between the LIVE programme and the skills of associated partners

2.1 Skills of associated partners

All associated partners who provided a letter of commitment have been alphabetically included on the left of this table and an “V” is inserted on the right, according to the content of their letter and/or the already performed actions in this programme LIVE by these partners.

The table is dedicated to specific contributions of associated partners, sustaining the durability of the LIVE master and the employability of the graduated students.

| Institution Full name | Country | LIVE promotion selection | LIVE scholarship management funding | Site visit or presentation | Co-organize module | Practices technical platform | Guest speakers | MOOC e-learning dvpt | Data Scientist in Vaccinology dvpt | Internship proposal supervision | Sponsoring | Employment for LIVE graduates | PhD position for LIVE graduates | Student exchanges |
|---|---------|--------------------------|-------------------------------------|----------------------------|--------------------|------------------------------|----------------|----------------------|------------------------------------|---------------------------------|------------|-------------------------------|---------------------------------|-------------------|
| ABL LYON becomes Active Biomarkers | FR | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | ✓ | ✓ | |
| Amal Therapeutics | CH | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | | | | |
| Association Lyonbiopôle | FR | | | | | | ✓ | | | | | | | |
| Bavarian Nordic AS | DK | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | | | |
| Baylor College of Medicine - National School of Tropical Medicine, Dpt of Pediatric Tropical Medicine | US | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | | | |
| BIOASTER Fondation de Coopération Scientifique | FR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | ✓ |
| BioMérieux SA | FR | ✓ | | ✓ | | ✓ | ✓ | | ✓ | ✓ | | ✓ | ✓ | |
| Boehringer Ingelheim Animal Health France (ex-Merial SAS) | DE/FR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | |
| CanSinoBIO | CN | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Centre National de Recherche Scientifique CNRS - Centre de Recherche en Cancérologie de Lyon | FR | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | |

| Institution Full name | Country | LIVE promotion selection | LIVE scholarship management funding | Site visit or presentation | Co-organize module | Practices technical platform | Guest speakers | MOOC e-learning dvpt | Data Scientist in Vaccinology dvpt | Internship proposal supervision | Sponsoring | Employment for LIVE graduates | PhD position for LIVE graduates | Student exchanges |
|---|---------|--------------------------|-------------------------------------|----------------------------|--------------------|------------------------------|----------------|----------------------|------------------------------------|---------------------------------|------------|-------------------------------|---------------------------------|-------------------|
| Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé - CNRST IRSS | BF | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Centre Pasteur du Cameroun | CM | ✓ | | | | | | | | ✓ | | | ✓ | |
| Commissariat à l'Energie Atomique et aux énergies alternatives - CEA | FR | ✓ | ✓ | ✓ | ✓ (1) | ✓ | ✓ | ✓ | ✓ | ✓ | | | ✓ | |
| CRODA Denmark A/S | DK | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI) | FR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Early makers group | FR | ✓ | | | ✓ (2) | | | | | | | | | ✓ |
| European Vaccine Initiative (EVI) | DE | ✓ | | ✓ | | ✓ | ✓ | ✓ | | ✓ | | ✓ | ✓ | |
| Fondation Mérieux | FR | ✓ | | ✓ | | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | | |
| Fundacio privada Institut de Recerca de la SIDA-CAIXA*IrsiCaixa | ES | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Fundación Privada Instituto de Salud Global Barcelona | ES | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ |
| GlaxoSmithKline Biologicals SA*GSKBIO | BE | ✓ | | ✓ | ✓ (3) | ✓ | ✓ | ✓ | ✓ | ✓ | | | | |
| HIPRA Scientific SLU | ES | ✓ | | ✓ | | | | | | | | | | |
| Incepta Vaccine Ltd | BD | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Innovative Clinical Research Network in Vaccinology (i-REIVAC) | FR | ✓ | | ✓ | | ✓ | ✓ | | ✓ | ✓ | | | | ✓ |

| Institution Full name | Country | LIVE promotion selection | LIVE scholarship management funding | Site visit or presentation | Co-organize module | Practices technical platform | Guest speakers | MOOC e-learning dvpt | Data Scientist in Vaccinology dvpt | Internship proposal supervision | Sponsoring | Employment for LIVE graduates | PhD position for LIVE graduates | Student exchanges |
|---|---------|--------------------------|-------------------------------------|----------------------------|--------------------|------------------------------|----------------|----------------------|------------------------------------|---------------------------------|------------|-------------------------------|---------------------------------|-------------------|
| Institut de Investigacio en ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA | ES | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ |
| Institut National de la Santé et de la Recherche Médicale (Inserm) - Centre d'Investigation Clinique - Epidémiologie Clinique n°1408 (CIC-EC) - Center for Infection & Immunity of Lille (CIIL) | FR | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | | | |
| Instituto Butantan | BR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| International Vaccine Institute | KR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| Janssen Vaccines & Prevention B.V. | NL | | | ✓ | | | ✓ | | | ✓ | | | | |
| Karolinska Institutet*Department of Medicine_Solna | SE | ✓ | | ✓ | | ✓ | ✓ | ✓ | | ✓ | | ✓ | ✓ | |
| Katholieke Universiteit Leuven*Rega Institute | BE | ✓ | | | | | | | | ✓ | | | | |
| Laboratorio Reig Jofre SA | ES | ✓ | | ✓ | | | | | ✓ | ✓ | | | | |
| LoValTech | FR | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | ✓ | ✓ | |
| Luxembourg Institute of Health | LU | ✓ | | ✓ | | ✓ | ✓ | | ✓ | ✓ | | ✓ | ✓ | |
| Mérieux Alliance SA*Institut Mérieux | FR | ✓ | ✓ | | | | | | | | | | | |
| Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS | CZ | ✓ | | ✓ | | ✓ | ✓ | | | ✓ | | | ✓ | |
| Moderna Therapeutics | US | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| MSD vaccins - pôle France | FR/US | | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | |


| Institution Full name | Country | LIVE promotion selection | LIVE scholarship management funding | Site visit or presentation | Co-organize module | Practices technical platform | Guest speakers | MOOC e-learning dvpt | Data Scientist in Vaccinology dvpt | Internship proposal supervision | Sponsoring | Employment for LIVE graduates | PhD position for LIVE graduates | Student exchanges |
|--|---------|--------------------------|-------------------------------------|----------------------------|--------------------|------------------------------|----------------|----------------------|------------------------------------|---------------------------------|------------|-------------------------------|---------------------------------|-------------------|
| National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine | UA | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | |
| Sanofi Pasteur SA | FR | ✓ | ✓ | ✓ | | ✓ | ✓ | | | ✓ | ✓ | | | |
| Société d'Exploitation de Produits Pour les Industries Chimiques*SEPPIC | FR | | | ✓ | | ✓ | ✓ | | | ✓ | | | | |
| Speransa Therapeutics | DE | ✓ | | ✓ | | ✓ | ✓ | | ✓ | ✓ | | | | |
| Sphere CNRS-Université Paris 7 Diderot | FR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | |
| Stichting Immuno Valley*Immuno Valley | NL | ✓ | | | | | ✓ | ✓ | | ✓ | | ✓ | | |
| The Chancellor, Masters and Scholars of the University of Oxford -The Jenner Institute, University of Oxford UOXF | UK | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| The Pirbright Institute LBG | UK | ✓ | | | | | | | | ✓ | | | | |
| Transgène SA | FR | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | ✓ | ✓ | |
| TRON - Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH | DE | ✓ | | | | | ✓ | | | ✓ | | | | |
| Universidade de São Paulo_Institut de Ciências Biomédicas | BR | ✓ | | | ✓ (4) | | | ✓ | | ✓ | | ✓ | ✓ | |
| Universita Degli Studi di Firenze | IT | ✓ | | ✓ | | ✓ | ✓ | ✓ | | ✓ | | | | |
| Université Libre de Bruxelles | BE | ✓ | | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | | | | ✓ |

| Institution Full name | Country | LIVE promotion selection | LIVE scholarship management funding | Site visit or presentation | Co-organize module | Practices technical platform | Guest speakers | MOOC e-learning dvpt | Data Scientist in Vaccinology dvpt | Internship proposal supervision | Sponsoring | Employment for LIVE graduates | PhD position for LIVE graduates | Student exchanges |
|---|---------|--------------------------|-------------------------------------|----------------------------|--------------------|------------------------------|----------------|----------------------|------------------------------------|---------------------------------|------------|-------------------------------|---------------------------------|-------------------|
| Université Paris XII Val de Marne (UPEC) - Vaccine Research Institute - VRI | FR | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Universiteit Antwerpen - Center for Evaluation of Vaccination - CEV | BE | ✓ | | | ✓ (5) | | | ✓ | | ✓ | | ✓ | ✓ | |
| University of Saskatchewan - Vaccine and Infectious Disease Organization*VIDO | CA | ✓ | ✓ | ✓ | | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Vaccine Formulation Institute (CH) - VFI | CH | ✓ | | | ✓ (6) | | | | | | | | | |
| Vakzine Projekt Management GmbH | DE | ✓ | | ✓ | | ✓ | ✓ | ✓ | | ✓ | | ✓ | | |
| Valneva | FR | ✓ | | | | | | | | | | | | |

- (1) S3_Immunomonitoring
- (2) S3_Pharmaceutical Ecosystem
- (2) S3_Innovation and Public Health
- (2) S3_Ecosystems and Platform Business Models
- (2) S3_Patient-Centric Ecosystems
- (2) S3_Transforming Early Makers
- (3) S2_Vaccine development and manufacturing
- (4) S1 Immunology and vaccinology and laboratory training
- (5) S2_clinical drug research
- (5) S2_Immune system in early life, pregnant women and elderly
- (5) S2_Novel technology in vaccine administration routes and adjuvants
- (5) S2_Summer school on vaccinology
- (6) S3_Adjuvants and Vaccine formulation




Distribution of internships around the World



2.4 Public-private distribution

Students do their internships either in the public or private sector. Below the public-private distribution:

Internships: public-private breakdown



3 Associated Partners description & Letters of commitment

3.1 ABL Lyon becomes Active biomarkers



Founded in 2011 by Innate Pharma and Transgene (formerly Platine Pharma and Services, then ABL Lyon), our company is a leader in soluble and cellular biomarker analysis in the context of clinical trials.

We offer expert services to advance innovative therapies from pre-

clinical to clinical testing. In 2014, Platine Pharma services was acquired by ABL Inc, a global contract manufacturing and laboratory research service provider, a full subsidiary of Institut Mérieux.

Alongside its senior managers, Turenne Santé acquired our company, creating a new entity named Active Biomarkers. In September 2022, Active Biomarkers joined KCAS, adding its European capacity and expertise to KCAS and FlowMetric's existing facilities in Kansas, Philadelphia and Milan, Italy.

Active Biomarkers' team has decades of experience in immunological-based assays. We develop tailored assays to support human clinical trials and pre-clinical animal studies. Our everyday mission is to design and run bioanalyses to help our clients better understand the impact of their cutting-edge therapies, document the mechanisms of action, correlates of protection, pharmacokinetic / pharmacodynamic, and other critical safety and efficacy data.

<https://active-biomarkers.com/>



ABL Lyon
321 avenue Jean Jaurès
Bâtiment Domilyon
69007 Lyon – France
Tel : +33(0)4 37 70 87 00

Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: ABL LYON
Status: CRO / Bioanalysis
Full Address: Bâtiment Domilyon, 321 avenue Jean Jaurès, 69007 LYON
Country: FRANCE
Tel: +33 4 37 70 87 00
Fax: +33 4 37 70 67 98
Website: www.abl-immuno.com

I, the undersigned, legal representative of ABL LYON, hereby confirm that our institution, ABL LYON, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of immune and biomarker monitoring in the context of drug development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

**ABL Lyon**

321 avenue Jean Jaurès
Bâtiment Domilyon
69007 Lyon – France
Tel : +33(0)4 37 70 87 00

Therefore, I confirm that our organization ABL LYON strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Christine BAIN.

Signature of the Legal representative

Name: Marc ESSODAIGUI

Position: General Manager

Date: February 5, 2018

Place: LYON



Signature of the contact person

Name: Christine BAIN

Position: Scientific Director

Date: February 5, 2018

Place: February 5, 2018





Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: ABL Europe SAS
Status: Joint Stock Company
Full Address: 4 rue Laurent Fries, 67400 Illkirch Graffenstaden
Site: 317 avenue Jean Jaurès, 69007 Lyon
Holding Head Offices : ABL Biomanufacturing Holding, 261 rue Marcel Mérieux, 69007 Lyon
Country: France
Tel: 06 70 25 63 96 (Beatrice Barbier/Legal Director)
Website: www.abl-biomanufacturing.com

I, the undersigned, Thierry Van Nieuwenhove, legal representative of ABL Europe SAS, hereby confirm that our institution, ABL Europe, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of ABL Europe.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology (depending on our available resources)
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students (if applicable),

ABL Europe S.A.S.
 Société par actions simplifiée au capital de 2.600.173 Euros
 R.C.S Strasbourg 813 526 928 - Code APE : 2120Z
 4, rue Laurent Fries - Parc d'Innovation - 67400 Illkirch-Graffenstaden – France
 Etablissements secondaires : 317 avenue Jean Jaurès - 69007 Lyon - France
 Boulevard Gonthier d'Andernach - Parc d'Innovation - 67400 Illkirch Graffenstaden - France
 Téléphone : 03 88 55 10 00 Fax : 03 88 55 10 07
www.abl-biomanufacturing.com





- Promote the LIVE Master program on our website and during our trade shows or participation to congresses if applicable.

1/2

Therefore, I confirm that our organization ABL Europe strongly supports this LIVE Master program.
The contact person appointed to represent our company in the LIVE Master will be Beatrice Barbier.

Signature of the Legal representative

Name: Thierry Van Nieuwenhove

Position: CEO

Date: February 14, 2023

Place: Lyon

Signature of the contact person

Name: Beatrice Barbier

Position: Legal Director

Date: February 14, 2023

Place: Lyon

DocuSigned by:
Beatrice Barbier
3C041888D38454...

2/2

ABL Europe S.A.S.
Société par actions simplifiée au capital de 2.600.173 Euros
R.C.S Strasbourg 813 526 928 - Code APE : 2120Z
4, rue Laurent Fries - Parc d'Innovation - 67400 Illkirch-Graffenstaden – France
Etablissements secondaires : 317 avenue Jean Jaurès - 69007 Lyon - France

3.2 Amal Therapeutics



AMAL Therapeutics (AMAL) is a biotech, developing unique therapeutic vaccines and a distinct unit of the Discovery Research organization of the Boehringer Ingelheim group of companies.

Our aim is to overcome the challenges around effective anti-cancer therapy by stimulating a patient's immune system in a unique way, in order to create immunological memory, as well as target a broad range of patients.

We have developed KISIMA®, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of three elements essential to generate potent immunity: a proprietary cell-penetrating peptide for antigen delivery, a proprietary TLR- peptide agonist as adjuvant and a modutable multi-antigenic cargo that can be tailored for various indications. While the power of KISIMA® can be harnessed to discover and develop therapeutic vaccines for different indications, our vision is to transform the prospects of cancer patients.

We aim to offer effective cancer therapies by complementing existing standards of care (e.g. chemo-and radiotherapies) without adding to their known toxicities, and by working in synergy with them, including with immune-checkpoints inhibitors. ATP128, our lead program in metastatic colorectal cancer has entered into the clinic in July 2019.

<http://www.amaltherapeutics.com/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: AMAL Therapeutics SA
Status: Spin off of the University of Geneva
Full Address: C/O foundation pour recherches médicales, Av. de la roseraie 64, 1205 Geneva
Country: Switzerland
Tel: +41 22 379 46 88
Website: www.amaltherapeutics.com

I, the undersigned, legal representative of AMAL Therapeutics SA, hereby confirm that our institution, AMAL Therapeutics, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of therapeutics cancer vaccines.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.

Amal Therapeutics SA

c/o Fondation pour Recherches Médicales

64 av. de la Roseraie, 1205 Geneva


TYA n°CHE-270.837.659



- Propose a partial (CHF 1500 / month for 6 months) grant for Master students or trainees

Therefore, I confirm that our organization AMAL Therapeutics strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Jean François Mayol.

Signature of the Legal representative



Name: Madiha Derouazi

Position : Chief Executive Officer

Date : 1st of February 2018

Place : Geneva, Switzerland

Signature of the contact person

Name: Jean François Mayol

Position : Head of Research in Vitro

Date : 1st of February 2018

Place : Geneva, Switzerland



Amal Therapeutics SA

c/o Fondation pour Recherches Médicales

64 av. de la Roseraie, 1205 Geneva

TVA n°CHE-270.837.659

3.3 Association Lyonbiopôle



Lyonbiopôle Auvergne-Rhône-Alpes was accredited as a competitiveness cluster by the French State in 2005 and is the drive of the health innovation ecosystem in Auvergne-Rhône-Alpes, ensuring that it is connected, developed and promoted. We bring together, advise and work with 270 members – companies, academics and hospitals – with their plans to innovate, grow, expand internationally and host new projects. We support these biotech, medtech and digital health-tech partners to build the medicine of the future and to make tomorrow's health innovations available to patients. In addition to providing access to an exceptional industrial, academic and clinical network, throughout the year we conduct scientific and economic activities to meet the needs of our members and to support them.

<https://lyonbiopole.com/>



LYONBIPOLE
AUVERGNE-RHÔNE-ALPES
LE RÉSEAU INNOVATION SANTÉ

N/Réf : COR001_20220116_Support LBP

Objet : Letter of Commitment to support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: LYONBIPOLE

Status: Associated partners

Full Address: 63 Avenue Tony Garnier 69003 Lyon

Country: FRANCE

Tel: +33 (0)4 72 76 53 30

Website: www.lyonbiopole.com

The undersigned, legal representative of Lyonbiopole, hereby confirm that our institution, Lyonbiopole, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

Lyonbiopole is the one-stop shop for healthcare innovation in Auvergne-Rhône-Alpes. The aim of Lyonbiopole is to support the emergence and development of innovative technologies, products and services for a more personalized medicine to the patient's benefit within. Lyonbiopole gathers a community composed of SMBs, large groups, academics and clinical players. 208 members of which 4 world class industrial funders, 172 innovative SMBs and 17 research and clinical centers.

Within the program, our organization will offer support and expertise by communicating towards and mobilizing our members and in particular SMBs, on the LIVE Master program actions giving the LIVE Master program feedback on the industrial sector expectations.

Therefore, I confirm that our organization Lyonbiopole strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Justine MERLIN

Signature of the Legal representative
Name: AGOSTINO-ETCHETTO Florence
Position: Executive Director
Date: 16/01/2023
Place: Lyon



Signature of the contact person
Name: MERLIN Justine
Position: Project Manager
Date: 16/01/2023
Place: Lyon



3.4 Bavarian Nordic AS



Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. By 2025 we aspire to be one of the largest pure play vaccine companies, improving and saving lives by excelling in R&D innovation, manufacturing and commercialization

We develop innovative life-saving vaccines: We have a strong heritage in vaccine development and with a proven technology, we continue to make innovations to help fight existing and emerging diseases.

We are the best-in-class vaccine manufacturer: We are experts in live virus vaccine manufacturing and with the recent addition of fill and finish capabilities we have enabled end-to-end commercial-scale manufacturing.

We are driven by commercial excellence: We have established a commercial infrastructure with presence in key markets in Europe and the USA to drive profitable growth of our expanding portfolio of vaccines.

<https://www.bavarian-nordic.com/>

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Bavarian Nordic A/S
Status: Validated
Full Address: Philip Heymans Alle 3, DK-2900 Hellerup, Denmark
Country: Denmark
Tel: +45 3326 8383
Website: www.bavarian-nordic.com

I, the undersigned, legal representative of Bavarian Nordic A/S, hereby confirm that our institution, Bavarian Nordic, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccine development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Propose topics for internship opportunities (6 months during semester 4), and/or short summer internships to the students.



Therefore, I confirm that our organization Bavarian Nordic strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Florian Lienert.

Signature of the Legal representative / contact person

Name: Florian Lienert

Position: Director Global Medical Affairs

DocuSigned by:
Florian Lienert
 Signer Name: Florian Lienert
Signing Reason: I approve this document
Signing Time: 03-Feb-2023 | 14:54 CET
3FF40AEA18D844B382670F2EC9029725

3.5 Baylor College of Medicine - National School of Tropical Medicine



Baylor College of Medicine is a health sciences university that creates knowledge and applies science and discoveries to further education, healthcare and community service locally and globally.

Tropical medicine is the study of the world's major tropical diseases and related conditions, which include a group of 17 neglected tropical diseases (sometimes referred to as 'NTDs') such as hookworm infection, schistosomiasis, river blindness, elephantiasis, trachoma, Chagas disease, Buruli ulcer, and leishmaniasis, as well as HIV/AIDS, tuberculosis, and malaria. The field also includes related disorders in malnutrition and even some non-communicable diseases.

The National School of Tropical Medicine (NSTM) at Baylor College of Medicine is the only school of tropical medicine in the United States solely committed to addressing the world's most pressing tropical diseases that disproportionately afflict "the bottom billion," the world's poorest people who live below the World Bank poverty level.

NSTM has a nationally and internationally recognized robust educational programs focused on Neglected Tropical Diseases and Infections of Poverty. Together with faculty from the Section of Pediatric Tropical Medicine in the Department of Pediatrics and faculty from other key departments, centers and schools within Baylor College of Medicine and the Texas Medical Center, the school continues to build infrastructure capacity for education focused on Neglected Tropical Diseases and Infections of Poverty in the United States and globally.

<https://www.bcm.edu/education/national-school-of-tropical-medicine>



To: LIVE Master In Vaccinology program

Re: Letter of Collaboration as Associated Partner


February 8, 2023

To Whom it May Concern,

Baylor College of Medicine, on behalf of its National School of Tropical Medicine, hereby confirm that our institution is willing to collaborate and support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona and the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

1. Within the program our organization will offer expertise in the area of lecturing and research collaborations in Tropical Medicine and vaccinology
2. Our organization will contribute to the overall mission of the live program and will assist in the promotion and implementation of the program in particular through participating in the design of the project goals
3. Our organization also commits to
 - Contribute to providing links and introductions especially in Latin American countries to increase the number of students in these targeted countries
 - Transfer knowledge and skills of the development of vaccines from the bench to the industrial world (e.g., by proposing seminars tutorials lectures specific practical training, visits to our sites, etc.) to the students
 - Contribute to curriculum development related to vaccinology
 - Contribute to the design of innovative tracks of the LIVE Master program, to educate in vaccinology
 - Proposed topics for research collaborations and internship opportunities for the students
 - Propose to collaborate in writing grant applications to further the mission of the LIVE Master program

Therefore, I confirmed that our organization strongly supports this LIVE Master program. The contact person appointed to represent our institution in the LIVE Master program will be Dr. Maria Elena Bottazzi.

Desiggned by

 Carolyn L. Smith, PhD

Name: Carolyn L. Smith, PhD

Position: Dean, Graduate School of Biomedical Sciences and Vice President of Education Affairs

Date: 2/14/2023 | 12:31 PM CST

Place: Baylor College of Medicine

DocuSign Envelope ID: AA0B8315-F67C-4C27-AA2A-8C2848219DB3

DocuSigned by
[Signature]
[Name]

Name: Maria Elena Bottazzi, PhD, FASTMH
Position: Senior Associate Dean, National School of Tropical Medicine. Professor, Departments of
Pediatrics and Molecular Virology and Microbiology
Date: 2/14/2023 | 1:50 PM CST
Place: Baylor College of Medicine

APPROVED AS TO FORM
Office of the General Counsel
Baylor College Of Medicine
By [Signature] 02/14/2023



3.6 BIOASTER Fondation de coopération scientifique



BIOASTER is a Technological Research Institute created in April 2012 by Institut Pasteur and Lyonbiopole at the initiative of the French government and private life science companies. BIOASTER is a not-for-profit scientific cooperation foundation dedicated to microbiology and infectious diseases, tackling diseases linked to or caused by bacteria, viruses, parasites, and fungi. We offer a new approach to R&D, by integrating scientific and technological innovations through collaborations in applied translational science. By fostering multidisciplinary collaborations turned towards open innovation, BIOASTER accelerates the development of health products focused on patient needs. With an industry expertise in the fields of diagnostics, vaccines, antimicrobials, and microbiome development, technologies developed at BIOASTER encompass ad hoc complex pre/clinical studies, multi-omics analyses, microsystems, organ on a chip, cellular/molecular optical engineering, high content data integration and machine learning/artificial Intelligence. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries.

<https://www.bioaster.org/>



Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: BIOASTER
Status: Foundation
Full Address: 40 avenue Tony Garnier – 69007 Lyon
Country: France
Tel: +33(0)4 69 84 26 00
Fax: +33(0)4 69 84 25 80
Website: <http://www.bioaster.org>

I, the undersigned, legal representative of BIOASTER, hereby confirm that our institution, BIOASTER, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of system vaccinology and system analytics for vaccinology development and vaccine quality control optimization.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement, which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - participate in student exchanges to broaden their skills to grasp the changing world



Therefore, I confirm that our organization BIOASTER strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Cyril Guyard.

Signature of the Legal representative

Name: Alexandre Moulin

Position: Deputy CEO - Administration and Public Affairs

Date: 14/12/2022

Place: Lyon



Signature

numérique de

MOULIN Alexandre

Date : 2022.12.22

10:40:08 +01'00'

Signature of the contact person

Name: Cyril Guyard

Position: Chief Scientific Officer

Date: 14/12/2022

Place: Lyon



Signature numérique de
GUYARD Cyril
DN: cn=GUYARD Cyril,
email=Cyril.GUYARD@bioaster.org
Date : 2022.12.16 15:44:50
+01'00'

3.7 BioMérieux SA



bioMérieux was created in 1963, but [our roots](#) go all the way back to the 19th century, with Marcel Mérieux, a student of Louis Pasteur. A family-owned company, bioMérieux has grown to become a world leader in the field of *in vitro* diagnostics. Our entrepreneurial adventure is driven by an unrelenting commitment to improve public health worldwide. We specialize in:

Clinical applications: We develop and produce diagnostic solutions that help healthcare professionals quickly and reliably determine a pathology or the source of a contamination and provide them with crucial information for optimal patient care.

Industrial applications: We also apply our expertise to meeting industrial microbiology needs, building innovative, precise technologies that ensure the quality and safety of food and pharmaceutical products. The Company is present in 45 countries and serves more than 160 countries with the support of a large network of distributors.

Beginning with Marcel Mérieux's development of the first anti-tetanus serum over a century ago, innovation has always been at the heart of bioMérieux. This pioneering spirit continues to drive our R&D teams that combine their state-of-the-art scientific knowledge with emerging techniques and new technologies to drive progress in pathogen detection and identification.

bioMérieux develops high-performance solutions that are based on three key areas of *in vitro* diagnostics:

- Microbiology: we are the world leader in clinical microbiology and industrial microbiological control;
- Immunoassays: we are specialized in high medical value tests;
- Molecular biology: we are a pioneer and leader in the syndromic molecular diagnosis of infectious diseases.

<https://www.biomerieux.com/corp/en.html>



Letter of Commitment
to support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: **bioMérieux**
Status: Industry
Full Address: 376 Chemin de l'Orme, 69280 Marcy-l'Étoile
Country: France
Tel: +33 (0)4 78 87 20 00
Fax: +33 (0)4 78 87 20 90
Website: <http://www.biomerieux.com/en>

I, the undersigned, legal representative of bioMérieux, hereby confirm that our organization, bioMérieux, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of *in vitro* diagnostics.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students.
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students





Therefore, I confirm that our organization bioMérieux strongly supports this LIVE Master program.
The contact person appointed to represent our company in the LIVE master will be François MALLET.

Signature of the Legal representative

Name: Alexandre PACHOT

Position: Director of the Medical Diagnostic Discovery Department (MD³)

Date: February 5th, 2018

Place: Marcy l'Etoile



Signature of the contact person

Name: François MALLET

Position: Senior Expert, Medical Diagnostic Discovery Department (MD³)

Date: February 5th, 2018

Place: Marcy l'Etoile



3.8 Boehringer Ingelheim Animal Health France



Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. www.boehringer-ingelheim.com/animal-health

CorA: 715826



**Letter of Commitment
To support the LIVE – « Leading International
Vaccinology Education”
Joint Master Program**

Organization: BOEHRINGER INGELHEIM ANIMAL HEALTH France
Status: SCS Company - company number 590 800 215
Address: 29 avenue Tony Garnier, 69007 Lyon
Country: FRANCE
Tel: +33.(0)4.72.72.30.00
Website: www.boehringer-ingelheim.fr

Boehringer Ingelheim Animal Health France
Site de Borel
29 avenue Tony Garnier
69007 Lyon – France
Tel. : +33 (0)4 72 72 30 00
Fax : +33 (0)4 72 72 34 91
www.boehringer-ingelheim.fr

I, the undersigned, Legal representative of BOEHRINGER INGELHEIM ANIMAL HEALTH France, hereby confirm that our institution, BOEHRINGER INGELHEIM ANIMAL HEALTH France, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universidad de Barcelona & Universidad Automa de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) With the program, our organization will offer support and expertise in the area of vaccinology, immunology and animal health.
- 2) In respect to our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - a. Contribute to transfer of knowledge and skills from industrial word to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students;
 - b. Contribute to the MOOC development related to vaccinology;
 - c. Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology;
 - d. Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internship to the students.

Boehringer Ingelheim Animal Health France
Siège social au
29 avenue Tony Garnier
69007 Lyon – France
Société en commandite simple
au capital de 23 743 685,75 euros
590 800 215 R.C.S. LYON





Therefore, I confirm that our organization BOEHRINGER INGELHEIM ANIMAL HEALTH France strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE Master will be Magali HAINAUT.

Signature of the Legal Representative
BOEHRINGER INGELHEIM ANIMAL HEALTH France

DocuSigned by:

209465203000431...

Name: François GISCARD D'ESTAING
Position: Director Legal and Compliance
Date: 11-janv.-2023
Place: Lyon

Boehringer Ingelheim Animal Health France
Site de Boréal
29 avenue Tony Garnier
69007 Lyon - France
Tel. : +33 (0)4 72 72 30 00
Fax : +33 (0)4 72 72 34 91
www.boehringer-ingelheim.fr

Signature of the Contact Person
BOEHRINGER INGELHEIM ANIMAL HEALTH France

DocuSigned by:

CA13382102974EE...

Name: Magali HAINAUT
Position: Head of Global Innovation
Date: 09-janv.-2023
Place: Lyon

3.9 CanSinoBIO



Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & development, manufacturing and commercialization of innovative, high-quality and affordable vaccine products for human use.

CanSinoBIO has been listed on the Main Board of Hong Kong Exchange and Clearing Limited (HKEx: 6185.HK) and on the Sci-Tech Innovation Board (STAR Market, SHSE: 688185) of the Shanghai Stock Exchange, making it the first "A+H" dual-listed vaccine company in the history of China's Science and Technology Innovation Board.

Our marketed products include: Convidecia®Air® [Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation], Convidecia® [Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)], Menphecica® [Group A and Group C Meningococcal Conjugate Vaccine (CRM197 Vector)], Menhycia® [Group ACYW135 Meningococcal Conjugate Vaccine (CRM197 Vector)], and Ad5-EBOV. At present, the Company is developing and conducting clinical trials of several products including potential best-in-class and first-in-class vaccines in China and globally innovative and potential global best-in-class vaccines.

CanSinoBIO has developed five key platform technologies, including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant VLP technology, mRNA vaccine technology as well as formulation and delivery technology. In addition, the Company owns a number of core intellectual property rights and proprietary technologies related to vaccine products. CanSinoBIO has established a rich portfolio of a pipeline products preventing more than ten diseases, including COVID-19, Ebola virus disease, tuberculosis, meningitis, pertussis, diphtheria, tetanus, shingles etc., and is participating in innovative R&D collaboration with multiple research institutions across the world.

We have constructed large-scale manufacturing bases in Tianjin and Shanghai, with a floor area of over 100,000 square meters. Both have been designed and constructed, and are operating in accordance with international standards to manufacture multiple novel vaccines. In addition, local filling production lines have been set up in Mexico, Pakistan, and Malaysia to establish joint manufacture. Our full-fledged marketing and supply system that covers China, Southeast Asia, the Middle East, Latin America, and other countries/regions ensures the rapid distribution of vaccine products across the world.

As a leader in innovative vaccine R&D, we are deeply committed to the protection of global public health through the fulfillment of our social and international responsibilities, and the development and supply of high-quality vaccine products.

<https://www.cansinotech.com/>



The organization: CanSino Biologics Inc
Status: for profit, listed company
Full Address: 185 South Ave., TEDA West District, Tianjin, 300457
Country: China
Tel: +86-400-922-2099
Fax: +86-022-58213677
Website: <https://www.cansinotech.com/>

The undersigned, Mrs Ivy LIU, Senior Vice President of Organizational Management and Human Resources, hereby confirm that our institution, CanSino Biologics Inc, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccine development, manufacturing, commercialization and policy.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Potentially and in consideration of the company's resourcing requirements, propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization CanSino Biologics Inc strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Pierre MORGON, Executive Vice President Portfolio Strategy and Supranational Affairs, Managing Director Europe.

Signature page overleaf.



Signature of the representative

Name: Mrs Ivy LIU



Position: Senior Vice President of Organizational Management and Human Resources

Date: 13th February 2023

Place: Tianjin, China

Signature of the contact person



Name: Dr Pierre A. MORGON

Position: Executive Vice President Portfolio Strategy and Supranational Affairs, Managing Director Europe

Date: 13th February 2023

Place: Geneva, Switzerland

3.10 Centre National de la Recherche Scientifique CNRS - Cancer Research Center of Lyon



The Cancer Research Center of Lyon (CRCL, UMR Inserm 1052 CNRS 5286 - Center Léon Bérard) is a research structure affiliated with the University Claude Bernard Lyon 1, the national health and research bodies (Inserm and CNRS), the Léon Bérard Comprehensive Cancer Center (CLB) and with the Lyon University Hospitals (HCL)

as clinical partners. The CRCL was officially created in January 2011 and its contract was recently renewed for the 2020-2026 period. It comprises 24 teams, totalling about 500 members, including 150 researchers and lecturers. The CRCL aims at increasing its international visibility and the attractiveness of the Lyon cancer research cluster, at facilitating the transfer of knowledge from fundamental cancer research to clinical applications in oncology, and at developing teaching and training in oncology.

One of the main goals of the CRCL is to support the development of strong translational research to enable patients to rapidly benefit from breakthroughs in basic research. This bridge from "bench to bedside" was rendered possible due to the strong collaboration between clinicians and pathologists of the CLB and HCL and scientific teams of the CRCL, creating a continuity between basic research and clinical applications.

<http://www.cnrs.fr/en>, <http://www.crcl.fr/>



UMR Inserm 1052 - CNRS 5286
Centre Léon Bérard
Director: Prof. Alain Puisieux

Centre Léon Bérard - Cheney D
 28 rue Laennec
 F- 69373 LYON Cedex 08
Assistant :
 Phone # 33 (0) 478 782 781
 Fax # 33 (0) 478 782 720
claire.couvreur@lyon.unicancer.fr

To whom it may concern

Lyon, 6th February, 2018

Subject: Letter of Commitment to support the LIVE
"Leading International Vaccinology Education" Joint Master Program
Ref.: 2018.051.AP.CC

The organization: Cancer research centre of Lyon (CRCL)
Status: Academic research structure, Inserm 1052, CNRS 5286, Claude Bernard
 Lyon I University, Léon-Bérard Comprehensive Cancer Center
Full Address: Cheney D, Centre Léon Bérard, 28 rue Laennec, F-69008 LYON
Country: France
Tel.: +33 478 782 781 (assistant)
Fax.: +33 478 782 720
Website: www.crcl.fr

I, the undersigned Alain Puisieux, Director of the Cancer Research Centre of Lyon (CRCL) hereby confirm that our organization, the CRCL, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of oncology research.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating to the project governance, and supporting the yearly recruitment campaigns.

1/2

3) Our organization also commits to:

- Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students.
- Contribute to the MOOC development related to vaccinology
- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- Propose complete or partial grant (amount to be defined with the Steering Committee) for Master students, not granted through the Erasmus+ grant scheme and/or propose funding support to the Master program organization and management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives.
- Propose complete or partial PhD grant/positions for the students, and/or employment opportunities to broaden the employability perspectives of the graduated students.
- Propose teaching support.

Therefore, I confirm that our organization, the CRCL, strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE Master will be Caroline Moyret-Lalle.

Signature of the Legal representative

Name: PUISIEUX Alain
Position: Director of the CRCL
Date: February 6th, 2018
Place: Lyon



Signature of the contact person

Name: MOYRET-LALLE Caroline, PhD
Position: Claude Bernard Lyon I University professor and CRCL representative for teaching and education
Date: February 6th, 2018
Place: Lyon



2/2.

3.11 Centre National de Recherche Scientifique et Technologique - Institut de Recherche en Sciences de la Santé – CNRST IRSS



Founded in 1997, the Institute of Research in Health Sciences (Institut de Recherche en Sciences de la santé - IRSS) is one of the 4 specialized units of the National Center of Scientific and Technologic Research. The missions of the IRSS are to:

- Conduct research that can provide solutions to priority health problems
- To coordinate research in the health sector in Burkina

- To valorize and disseminate the results of the research.

Research programs are focused on the following themes:

- infectious and parasitic diseases;
- health policies and systems;
- maternal and child health;
- nutrition;
- traditional pharmacopoeia and medicinal plants;
- traditional medicine and ethnomedicine;
- drugs;
- pesticides, chemicals and health.

<http://www.cnrst.bf/index.php/irss/>

MINISTÈRE DE LA RECHERCHE
SCIENTIFIQUE ET DE L'INNOVATION

BURKINA FASO
Unité - Progrès - Justice

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE ET TECHNOLOGIQUE



DIRECTION REGIONALE
DE L'OUEST

Bobo-Dioulasso, 29th January 2018

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: IRSS/Direction Régionale de l'Ouest (IRSS-DRO)
Status: Public organization
Full Address: 399, Avenue de la Liberté, 01 BP 545 Bobo-Dioulasso
Country: Burkina Faso
Tel: 00226 20974868
Fax: 00226 20974868
Website: www.irss.bf

I, the undersigned, legal representative of IRSS-DRO, hereby confirm that our institution, IRSS-DRO, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of clinical trials and field and on-site studies.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from field site to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology

- Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

OTHER: IRSS will also make available the following facilities for implementation of the project:

- ✓ Laboratory facilities for molecular biology, Cell culture Room, Serological/Chemical Room, nutrition, Parasito-entomology and Insectarium
- ✓ Clinical laboratory (Haematology, biochemistry, ECG,...)
- ✓ Office spaces for MSc, PhD and postdoc students
- ✓ Internet connexion with WIFI
- ✓ Field-based research training for students
- ✓ Electronic data collection using tablets/mobile, e-archiving and sharing and transfer, ...

Therefore, I confirm that our organization IRSS-DRO strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Prof Jean Bosco OUEDRAOGO.

Signature of the Legal representative

Name: Roch K. DABIRE

Position: Director Regional

Date: 29 January 2018

Place: Bobo-Dioulasso



Signature of the contact person

Name: Jean-Bosco OUEDRAOGO

Position: Head of Malaria & Neglected Tropical Diseases Unit

Date: 29 January 2018

Place: Bobo-Dioulasso



3.12 Centre Pasteur du Cameroun



The Pasteur Center of Cameroon (CPC) is a technical body of Cameroon's Ministry of Public Health, a hospital institution with financial autonomy and legal personality. It was established in 1959 in Yaounde; it has had an annex in Garoua (CPCAG) since 1985, and since 2004 it has had an office in Douala.

The CPC is a member of the International Network of Pasteur Institutes (RIIP).

Center Pasteur contributes to the fight against disease and the promotion of health through the care of Cameroonian patients and the prevention of international health risks through the surveillance of endemic and epidemic diseases, scientific research and the training of health personnel.

Thus, this mission is divided into 3 strategic areas:

- To make available to the maximum number of Cameroonian patients and customers an offer in medical biology and in Hygiene and Environment at the lowest possible price; hence our slogan: "Excellence in biology accessible to all".
- To contribute to the fight against infectious diseases in Central Africa through biological and epidemiological surveillance activities,
- To establish national recognition and make the CPC an internationally recognized Scientific Research Institute.

Research Programs: HIV/AIDS, Hepatitis, Poliomyelitis, Human Influenza, Arbovirus, Tuberculosis, Buruli ulcer, Other programs...

<http://www.pasteur-yaounde.org/>

REPUBLIQUE DU CAMEROUN
Paix - Travail - Patrie



REPUBLIC OF CAMEROON
Peace - Work - Fatherland

« L'Excellence en Biologie accessible à tous »
The General Manager

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Centre Pasteur du Cameroun
Status: Public administrative establishment of the Ministry of Public Health from Cameroon with legal and financial autonomy
Full Address: CPC, 451 Rue 2005; Yaoundé 2; BP 1274, Yaounde
Country: Cameroon
Tel: + 237 222 23 10 15
Website: www.pasteur-yaounde.org

I, the undersigned legal representative of Centre Pasteur du Cameroun, hereby confirm that our organization, Centre Pasteur du Cameroun, is willing to support the LIVE Master program coordinated by the University Claude Bernard Lyon 1 (France) in collaboration with the following higher education institutions: University Jean Monnet Saint-Etienne (France), Autonomous University of Barcelona (Spain), University of Antwerp (Belgium).

- 1) Within the program, our organization will offer support and expertise in the area of courses and trainings in the fields of vaccinology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating to the project governing, and support in the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Propose topics for Master theses and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD positions for the students.

Therefore, I confirm that our organization, Centre Pasteur du Cameroun, strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE Master will be Suzanne BELINGA.

Signature of the Legal representative

Name: Elisabeth CARNIEL

Position: General Manager

Date: 07/02/2018

Place: Yaounde

Signature of the contact person

Name: Suzanne BELINGA

Position: Medical Director

Date: 07/02/2018

Place: Yaounde

CENTRE PASTEUR OF CAMEROON – National Reference Laboratory for Public Health
Member of the International Network of Pasteur Institutes

Page 1 sur 1

P.O. Box 1274, Street 2005, Yaounde 2 CAMEROON – Internet : www.pasteur-yaounde.org
Tel: (237)222 23 10 15 / 222 23 18 03 – Telecopy : (237) 222 23 15 64 – Email : cpc@pasteur-yaounde.org

3.13 Commissariat à l'Energie Atomique et aux énergies alternatives - CEA



The French Alternative Energies and Atomic Energy Commission (CEA) is a key player in research, development and innovation in four main areas: defence and security, low carbon energies (nuclear and renewable energies), technological research for industry, fundamental research in the physical sciences and life sciences. Drawing on its widely acknowledged expertise, the CEA actively participates in collaborative projects with a large number of academic and industrial partners. The CEA is established in nine centers spread throughout France. It works in partnership with many other research bodies, local authorities and universities. Within this context, the CEA is a stakeholder in a series of national alliances set up to coordinate French research in energy (ANCRE), life sciences and health (AVIESAN), digital science and technology (ALLISTENE), environmental sciences (AllEnvi) and human and social sciences (ATHENA). Widely acknowledged as an expert in its areas of skill, the CEA is actively involved in the European Research Area and its international presence is constantly growing. The CEA is the only French research organization to be listed in the Clarivate 2020 ranking and is the leading French research organization filing patents in Europe, according to the European Patent Office (EPO) 2021 ranking.

<https://www.cea.fr/english>



Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: CEA/DRF/Jacob/ImVa/IDMIT

Status: Research and Technology Center

Full Address: Bt 62, 18 rue du Panorama BP 6, 92265, Fontenay-aux-Roses.

Country: France

Tel: 00.33.1.46.54.73.74

Fax: 00.33.1.46.54.77.26

Website: <http://www.cea.fr/drf/Pages/Accueil.aspx>

I, the undersigned, **Dr. Roger Le Grand**, Head of IDMIT Department in the Fundamental Research Division, hereby confirm that our organization, **French Alternative Energies and Atomic Energy Commission (CEA)**, is willing to support the LIVE Master program coordinated by the University Claude Bernard Lyon 1 (France) in collaboration with the following higher education institutions: University Jean Monnet Saint-Etienne (France), Autonomous University of Barcelona (Spain), University of Antwerp (Belgium).

Within the LIVE Master project, our organization as “**partner B**” will offer the following contribution, support and expertise:

- 1) Give courses in the LIVE Master teaching program according to our **technological and fundamental** expertise.
- 2) Welcome LIVE Master students for their internship (6 months at semester 4): at least 1 student every 2 years
- 3) Considering the possibility to provide partial scholarships in agreement with the opportunities of our research unit
- 4) Welcome master students for site-specific visit (1 visit of 1-2 days for all students every 2 years)
- 5) Give practical trainings in LIVE-Master program according to our expertise in:
“**Advanced technologies for preclinical immune monitoring**”.

- 6) For graduated LIVE-Master students: considering possible PhD funding.

In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating to the project governance and supporting the yearly recruitment campaigns.

The Department IDMIT (Infectious Diseases Modelling and Innovative Therapies) of the CEA Fundamental Research Division, headed by Dr. Roger Le Grand, will also:

- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- Consider the opportunity to propose complete or partial grant (amount to be defined with the Steering Committee) for Master students, not granted through the Erasmus+ grant scheme
- Consider the opportunity to propose complete or partial PhD grant/positions for the students
- Support the Master program in its organization and management, thereby contributing to the development strategy of the program, in particular its sustainability and enlargement perspectives.
- Organize an annually **"LIVE Students welcome, teaching and practical courses"**
- Contribute to the MOOC development related to vaccinology
- Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.

Therefore, I confirm that our organization strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE master will be **Dr. Roger Le Grand** and the deputy director of IDMIT Department, **Dr. Frédéric Ducancel**.

Signature of the contact person

Name: **Dr. Roger Le Grand**

Position: Head of the IDMIT Department

Date: 07th of February 2023

Place: CEA/Fontenay-aux-Roses/France

Dr Roger LE GRAND

*Director, Center for Immunology of Viral,
Auto-Immune, Hematological and Bacterial diseases*
UMR1184, IDMIT Department
Université Paris-Saclay, Inserm, CEA

3.14 CRODA



Croda Pharma is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations. The company is focused on empowering biologics drug delivery, through its vaccine adjuvant systems, small molecule, protein, and nucleic acid delivery platforms. With a wide range of solutions for both human and animal health markets, the pharmaceutical portfolio is unsurpassed in its excellence. Croda Pharma's products, along with its in-house formulation and regulatory expertise, allows the company to meet its customers' most demanding formulation needs. The company is committed to enabling the next generation of drug delivery systems.

Leveraging over 80 years of expertise, Croda Pharma collaborates with vaccine manufacturers to tailor and develop optimal vaccine formulations using their excipients, lipids, and adjuvants. With an established portfolio of GMP and high-performance adjuvants, including Alhydrogel™ and Adjuphos™, the company also assists vaccine developers through lipids for the delivery of nucleic acid-based therapeutics. Their experts develop and manufacture high purity and innovative lipids to solve the stability and delivery issues associated with mRNA delivery and next-generation vaccines and therapeutics.

Croda Pharma is on a mission to support the development of the novel adjuvants of tomorrow. The company is committed to making these adjuvants available for preclinical and clinical R&D programs, with both industrial and academic partners.

Croda Pharma continues to expand its offering in innovative speciality excipients, vaccine adjuvant systems, and lipids. By enabling over 250 ongoing clinical projects, targeting a range of therapeutic areas including oncology, malaria, HIV, and diabetes, they strive to empower biopharma and improve lives across the globe. As a part of Croda, the company is dedicated to being the most sustainable supplier of innovative ingredients, becoming Climate, Land, and People Positive by 2030.

<https://www.croda.com/en-gb>

CRODA

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Croda Denmark A/S

Status: Private company

Full Address: Elsenbakken 23, DK-3600 Frederikssund

Country: Denmark

Tel: +45 70 25 00 20

Website: <https://www.croda.com/en-gb/about-us/where-we-operate/europe-and-eemea/denmark>

I, the undersigned, legal representative of Croda Denmark A/S, hereby confirm that our institution, Croda, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccine Adjuvant Systems.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose a complete (50,000 Euros / 2 years of study / 1 Master non-EU student; 35,000 Euros / 2 years of study / 1 Master EU student) or a partial grant for Master students, not granted through the Erasmus+ grant scheme, and/or propose funding support to the Master program organization and management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives. The use of this funding

CRODA

(35,000 Euros / 2 years of study / 1 Master EU student) will be framed by an agreement signed between our institution and UCBL.

- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization Croda strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dennis Christensen.

A handwritten signature in blue ink, appearing to read 'Peter Holm Tygesen'.

Signature of the Legal representative

Name: Peter Holm Tygesen

Position: Managing Director Vaccien Adjuvant Systems

Date: 01/11-2022

Place: Frederikssund

A handwritten signature in blue ink, appearing to read 'Dennis Christensen'.

Signature of the contact person

Name: Dennis Christensen

Position: Head of Global Research & Development, Adjuvant Systems

Date: 01/11-2022

Place: Frederikssund

3.15 Dalhousie University



DALHOUSIE UNIVERSITY

Dalhousie University was founded in 1818. Located in Nova Scotia, Canada (Mi'kma'ki) with four campuses in Halifax and Truro, and satellite locations in Yarmouth and Saint John, New Brunswick, our broad range of academic programs attract and retain a diverse mix of incredible students, scholars, researchers and staff who work together with interdisciplinary perspective and a focus on service. Our 13 academic Faculties expand understanding through teaching excellence and a drive for discovery that results in more than \$190 million in research funding each year. As Atlantic Canada's primary research-intensive university and a member of the U15 Group of Canadian Universities, our research and innovation includes world-leading researchers working in labs, studios and in the field. Building on our legacy of groundbreaking research and outstanding scholarship, we are focused on providing a unique, interactive and collaborative environment that supports all our students, instructors, researchers and staff to achieve excellence.

<https://www.dal.ca/>

About Professor Tobias Kollmann

PhD, M.D., SFUW

Head, Systems Vaccinology

Professor of Systems Biology, Professor of Paediatric Infectious Diseases

Currently: Telethon Kids Institute, Perth Children's Hospital, University of Western Australia

Moving in September 2023 to Dalhousie University

Professor Tobias Kollmann is a paediatric infectious diseases physician with a deep passion for making an impact at the convergence of clinical care and fundamental research. He directs the Systems Biology team at Telethon Kids, where multi-disciplinary research aims to direct the early life trajectory towards a healthy, resilient life. Professor Kollmann completed both his MD and PhD at the Albert Einstein College of Medicine, New York, USA. He then conducted his Residency and Fellowship at the University of Washington, Seattle, USA, before joining the Paediatric Infectious Disease Division at the University of British Columbia (UBC), Canada in 2005. Professor Kollmann was Head, Paediatric Division of Infectious Diseases at UBC before relocating to Australia.

For nearly three decades his work has focused on the molecular mechanisms responsible for age-dependent susceptibility to infectious and other diseases and has identified key drivers of immune development in early life. To accomplish this, his team have developed high-throughput, single-cell analysis platforms that allow the extraction of the most information out of the small samples obtainable from young babies. These platforms have now become the technological backbone of several larger cohort studies around the world.

Professor Kollmann is the Chief Executive Officer of the Born Strong Initiative, a collaboration with the Human Vaccines Project (HVP). The Born Strong Initiative is an ambitious program with the goal of globally by 2032 cutting in half the number of preventable stillbirths, preterm births, neonatal infection, and developmental challenges by enhancing the power of maternal and newborn resilience. The Born Strong Initiative will test a range of interventions to see if we can alter the trajectory of pregnancy away from an adverse outcome towards a healthy, full-term pregnancy, enhancing resilience for the newborn for life.

Professor Kollmann also is the Director of both The Precision Health Accelerator that provides complete end-to-end solutions enabling parallel multi-omic analysis, and of The Virtual Academy that brings together the world's leading life science and data science experts, a cutting-edge research platform designed to accelerate access to systems biology approaches for researchers, facilitating and maximizing the progress.

As a member of the WHO Expert Advisory Group on Non-specific Immunological Effects of Vaccination committee, Professor Kollmann is international leader in vaccinology.



Professor Tobias Kollmann
Professor of Systems Biology, moving from
University of Western Australia to Dalhousie
University, Canada.

De : Tobias Kollmann <tkollm@mac.com>

Envoyé : lundi 13 février 2023 02:43

À : DELPRAT CHRISTINE <CHRISTINE.DELPRAT@univ-lyon1.fr>

Objet : To support the EMJM LIVE3 as Associated Partner with new institution

Importance : Haute

Dear Christine.

I am moving from Perth, Australia back to Canada (Dalhousie University in Halifax to be specific) as of Sept this year.

I am in the process to set the connection with the LIVE3 program up with Dalhousie.

To me this would make the most sense, given I will be not too long in Perth from now.

Tobi

-

Professor Tobias Kollmann

Professor of Systems Biology, Professor of Paediatric Infectious Diseases

Telethon Kids Institute, Perth Children's Hospital, University of Western Australia

Perth, Australia



THE UNIVERSITY OF
WESTERN
AUSTRALIA

De : Christine DELPRAT <christine.delprat@univ-lyon1.fr>

Envoyé : lundi 13 février 2023 04:01

À : 'Tobias Kollmann' <tkollm@mac.com>

Objet : Re: To support the EMJM LIVE3 as Associated Partner with new institution

Dear Tobi,

Great and thanks for the info!

You are the key person in the field of Systems Vaccinology regardless the institution ☺ and therefore, we are fixing the PIC of Dalhousie Univ. 998539535 with LIVE 3. Please send the legal representative signature asap, we will update the SupDoc2 LIVE3 partnership accordingly by Sept 2023 at the latest and as soon as we receive it; that's fine, we know you very well and are very happy to benefit from your expertise for the LIVE3 2023-28 programme.

By the way, I am happy to tell you that, from the last batch of LIVE+ 2022 graduates, we have our 1st LIVE Alumni doing a PhD in Australia at the Univ. of Canberra (Casual Academia, Australian National University), far away of you in Perth but still in Australia. It is a pleasure to send you the two documents to update with your new institution and position as requested at Dalhousie Univ. (DU).

All the best at DU!

Chris

Prof. Christine DELPRAT

Professor of Immunology – PU CL.EX., University of Lyon – UCBL, France, Master LIVE Coordinator



Co-funded by the
Erasmus+ Programme
of the European Union



(new logo) <https://live.univ-lyon1.fr>

3.16 Ecole Normale Supérieure de Lyon - Centre International de Recherche en Infectiologie (CIRI)



The Centre for Research in Infectious Diseases (CIRI) is a joint research unit created in 2013 by Lyon 1 University, Inserm, CNRS and the ENS Lyon in partnership with VetAgro Sup, the Institut Pasteur and the Hospices Civils de Lyon. The CIRI gathers the scientific and medical research communities with complementary disciplinary

backgrounds grouped in 3 specialties working together with the objective to understand host-microbe interactions to better fight infectious diseases.

Through a multidisciplinary approach combining microbiology (bacteriology and virology), immunology, cell biology, clinical research and epidemiology, plus a strong interface with the industry, the CIRI intends to be a research Centre opened to therapeutic innovation and to act a major player in the areas of medical prevention and treatment of infectious diseases.

The CIRI is meant to implement an essential further step of the development of the research in Infectiology in Lyon through a highly structured co-operation between academic and clinical research communities, on the Charles Mérieux campus. It will play a pivotal role by structuring the interactions between academic and private research, and by promoting socio-economic opportunities through strong partnerships with operators involved in the innovation or pre-industrial development, including the Lyon Biopôle and the IRT BioAster. The CIRI will thus constitute a strong interface with industry, with increased collaborations with key actors in the domain of human and animal health on the Lyon area and optimal potential for valorization of results.

The CIRI currently includes nearly 300 researchers, faculty members, graduate students, engineers and technicians in ca. twenty teams that have been enrolled because of their strong expertise in key basic disciplines for the study of infectious diseases (i.e., microbiology, immunology and cell biology) and also of their capacity or specific interest to translate novel knowledge, of scientific or technological nature, in translational research programs and applied research.

<http://www.ens-lyon.fr/en/>

<https://ciri.ens-lyon.fr/>

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Ecole Normale Supérieure de Lyon

Status:

Full Address: 15 parvis René Descartes – BP 7000 69342 Lyon Cedex 07

Country: FRANCE

Tel: +33 (0) 4.37.37.60.00

Fax: +33 (0) 4.37.37.63.60

Website: <http://www.ens-lyon.fr/>

I, the undersigned, legal representative of ENS de Lyon, hereby confirm that our institution, ENS de Lyon, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of i) basic virology, bacteriology, and immunology; ii) immuno-therapy, gene therapy and vaccinology; and iii) epidemiology and eco-infectiology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.

- Propose a complete (50,000 Euros / 2 years of study / 1 Master non-EU student; 35,000 Euros / 2 years of study / 1 Master EU student) or partial grant for Master students, not granted through the Erasmus+ grant scheme, and/or propose funding support to the Master program organization and management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives. The use of this funding (within financial support for students or managers) will be framed by an agreement signed between our institution and UCBL.
- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization ENS de Lyon strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be François-Loïc Cosset.

Signature of the Legal representative

Name: Jean-François PINTON

Position: Président

Date: 30/01/2018

Place: Lyon



Signature of the contact person

Name: François-Loïc COSSET

Position: Director of the CIRI - International Center for Infectiology Research

Date: 30/01/2018

Place: Lyon





Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: CIRI

Status: RESEARCH LABORATORY

Full Address: CIRI- INSERM U1111 – CNRS UMR5308 – UNIVERSITE LYON 1, ENS DE LYON – 50
AVENUE TONY GARNIER 69007 LYON

Country: FRANCE

Tel: 0472728732

Website: <https://ciri.ens-lyon.fr/>

I, the undersigned, legal representative of CIRI, hereby confirm that our institution, CIRI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of CIRI: infectious diseases and immunology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students.
 - Contribute to the MOOC development related to vaccinology.
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.



- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization CIRI strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be François-Loïc Cosset.

Signature of the Legal representative

Dr François-Loïc COSSET

Directeur

Name: COSSET François-Loïc

CIRI - Centre International de Recherche en Infectiologie
INSERM U1111 - ENRS UMR5308
Université Lyon 1 - ENS de Lyon
46 allée d'Italie
69364 Lyon Cedex 07 France

Position: DIRECTOR

Date: 18/01/2023

Place: 50 AVENUE TONY GARNIER 69007 LYON

Signature of the contact person

Dr François-Loïc COSSET

Directeur

Name: COSSET François-Loïc

CIRI - Centre International de Recherche en Infectiologie
INSERM U1111 - ENRS UMR5308
Université Lyon 1 - ENS de Lyon
46 allée d'Italie
69364 Lyon Cedex 07 France

Position: DIRECTOR

Date: 18/01/2023

Place: 50 AVENUE TONY GARNIER 69007 LYON

3.17 Early makers group - Emlyon business school



emlyon business school was founded in **1872** by the Lyon Chamber of Commerce and Industry. It is a **private higher-education establishment** recognized by the French State. It is one of the oldest **business schools** in Europe. emlyon is among the 1% of **global business schools** to be accredited by the three international accreditation systems: AACSB, EQUIS and AMBA. As such, it merits its status as a global-ranking **school of business and management**.

The School hosts **9,020 students** representing **125 nationalities** in **undergraduate and postgraduate programs**, along with nearly 6,900 participants in **executive education** programs. The School counts six campuses around the world: Lyon, Saint-Étienne, Paris, Shanghai, Bhubaneswar and Mumbai. It draws on a network of **190 international academic partners** and leads a community of **38,600 alumni** in **130 different countries**.

emlyon's distinctive academic signature **early makers** molds learning into a lifelong endeavor to have an impact on the world and offers a real alternative in its environment. It sees learning as not only a transfer of academic knowledge but also a "course of learning experiences" that equips students to forge a constant link between thought and action: **"doing to learn, learning to do"**.

Through these collective and individual learning experiences, emlyon has set out to **train responsible managers capable of taking up the challenges of today and tomorrow**. This general-interest calling lies at the heart of the school's identity and is written into its articles of association since July 2021 when it transitioned to the status of a **benefit corporation**.

Mines Saint Etienne is one of the most prestigious engineering schools in France and its mission is to support the economy by:

- **Educating highly qualified managers** with strong technical and scientific skills;
- **Developing applied research** to meet the needs of industry;
- **Contributing to companies'** innovation, creation & competitiveness worldwide.

Mines Saint Etienne's academic standing is committed to excellence, to a wealth of subject fields, and we desire to offer each student a curriculum tailored to his or her goals and the realities of the economic world.

The **MSc in Health Management and Data Intelligence** is the outcome of the partnership between Mines Saint Etienne, a renowned engineering school, and **emlyon** business school, one of Europe's top business schools devoted to lifelong learning for entrepreneurial and international management.

The two institutions joined forces and created this program in response to the health industry's need for future managers that will be able to master the specifics of operations disrupted by artificial intelligence impacts. With campuses in Lyon and Saint Etienne in Auvergne Rhône Alpes region, both institutions embody excellence in their domain, and foster an innovative learning environment for students.

<https://em-lyon.com/en>

<https://msc-health-data-intelligence.com/en>

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: early makers group SA / emlyon business school

Status: Etablissement d'enseignement supérieur technique privé

Full Address: 23 avenue Guy de Collongue, 69130 Ecully

Country: France

Tel: +33 (0)4 78 33 78 00

Fax: NA

Website: <https://em-lyon.com/>

I, the undersigned, legal representative of early makers group SA, hereby confirm that our institution, emlyon business school, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of management and economics in the biopharmaceutical industry context.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master program, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization commits to facilitate exchanges of selected students for them to attend a range of courses offered by the Université Claude Bernard Lyon 1 and by emlyon business school. As discussed with Prof. Christine Delprat, we will consider exchanging each year a maximum of five students who consider starting a career in the pharma industry or related public health organizations, during fall semesters (S3-M2) of the period 2023-2028, for 15 credits (ECTS) per student. We commit that no additional participation costs will be charged to the selected students who benefit from the exchange.

The courses offered by emlyon business school, which are part the MSc in Health Management & Data Intelligence, will contribute to the understanding by selected LIVE students of specific health management practices and related technological issues. They might include:

- a. The Pharmaceutical Ecosystem (economic overview of the biopharma industry, 2 ECTS)
- b. Innovation and Public Health (investing in innovation in relation to public health, 2 ECTS)
- c. Ecosystems and Platform Business Models (digital technologies and new business models in health, 2 ECTS)

- d. Patient-Centric Ecosystems (bottom-up client-oriented instead of MD top-down approach, 2 ECTS)
- e. Transforming Early Makers (collaborative design of a value proposition for a project, 6 ECTS)

The courses offered by the Université Claude Bernard Lyon 1, which are part of the LIVE Master program, contribute to enhancing the knowledge by selected emlyon Master in Management (MiM) students on fundamental and applied aspects of vaccinology. They might include:

- a. Epidemiology (3 ECTS)
- b. Immunology and Cancer (3 ECTS)
- c. Clinical Vaccine Development (3 ECTS)
- d. Communicating on Vaccines and Public Health (6 ECTS)

Therefore, I confirm that our organization emlyon business school strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Prof. Bruno Versaevel.

Signature of the Legal representative

Name: Isabelle Huault

Position: Director General

Date: Feb. 13, 2023

Place: Ecully (France)

Signé par Isabelle Huault
Le 13/02/2023

Signed with
 universign 

Signature of the contact person

Name: Bruno Versaevel

Position: Professor

Date: Feb. 13, 2023

Place: Ecully (France)



3.18 European Vaccine Initiative - EVI



The European Vaccine Initiative (EVI) is a European non-profit Product Development Partnership (PDP) that supports the development of safe, effective and affordable vaccines against diseases of poverty and emerging infectious diseases, through collaboration and coordination.

With more than 200 partners worldwide, EVI uses the power of collaboration, innovation, open science, partnerships, and advocacy to move vaccines forward.

EVI's portfolio and activities are diverse. Since its inception in 1998, EVI has collaborated in the development of more than 40 vaccine formulations against diseases like malaria, leishmaniasis, Zika virus and diarrhoeal diseases, 9 of which progressed into mid-stage clinical development. EVI is also supporting vaccine development through cross-cutting projects ranging from the development of non-animal approaches for vaccine quality control testing and assay harmonisation, to the establishment of a sustainable European vaccine infrastructure that can accelerate vaccine development across several disease areas, among many other projects and activities. We undertake training and support capacity strengthening for vaccine R&D in both Europe and low- and middle-income countries.

We aim to spearhead global vaccine development efforts by engaging with partners from academia and other research institutions, the private sector, governments and civil society organisations, including partners from low- and middle-income countries affected by diseases of poverty.

<http://www.euvaccine.eu/>



 www.euvaccine.eu
 +49 6221 56-35967
 contact.us@euvaccine.eu

UniversitätsKlinikum Heidelberg
 Voßstraße 2, Geb. 4040
 69115 Heidelberg, Germany



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Not-for-Profit NGO

Status: Association

Full Address: Voßstraße 2, Geb. 4040

69115 Heidelberg

Country: Germany

Tel: +49 (0)6221 56-35967

Website: www.euvaccine.eu

I, the undersigned, legal representative of European Vaccine Initiative e.V, hereby confirm that our institution, EVI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of project management of vaccine product development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates



 www.euvaccine.eu
 +49 6221 56-35967
 contact.us@euvaccine.eu

UniversitätsKlinikum Heidelberg
Voßstraße 2, Geb. 4040
69115 Heidelberg, Germany



Therefore, I confirm that our organization EVI strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Catarina Luis.



Signature of the Legal representative

Name: Ole Olesen

Position: Executive Director

Date: 02.01.2023

Place: Heidelberg



Signature of the contact person

Name: Catarina Luís

Position: Communication & Senior Project Manager

Date: 02.01.2023

Place: Heidelberg

3.19 Fondation Mérieux



Fondation Mérieux, an independent family foundation with public interest status, is committed to fighting, in the field, the infectious diseases that affect developing countries by building capacities, particularly in clinical laboratories.

With its network of laboratories, the foundation's work is focused on diagnosis, an essential aspect of patient care and an indispensable tool for disease surveillance and control. Taking a global health approach, the foundation also works in the field to help the most vulnerable, with a strong emphasis on mothers and children.

From its very beginning in 1967, the Mérieux Foundation has united public and private sector partners around a common mission. Active today in over twenty countries, the Foundation works to strengthen the skills of healthcare professionals in the field to ensure its programs have a long-lasting impact. It catalyses local and international initiatives to help the most vulnerable populations gain fairer access to healthcare. Our philosophy of action:

- A collaborative dynamic driven by partnerships with local healthcare stakeholders, international organizations, academic research, companies and NGOs,
- A long-term vision with sustained support leading to autonomy and local ownership of infrastructures and programs,
- Building networks for international cooperation to share experience and pool skills,
- A global health approach from humans to animals, taking into account healthcare, but also nutrition, environmental safety, education and socio-economic support for patients.

<http://www.fondation-merieux.org>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Fondation Mérieux

Status: Independent family foundation, research organization with public interest status

Full Address: 17 rue Bourgelat – 69002 Lyon

Country: France

Tel: + 33 4 72 40 79 79

Fax: +33 4 72 40 79 50

Website: www.fondation-merieux.org

I, the undersigned, legal representative of Fondation Mérieux, hereby confirm that our organization, Fondation Mérieux, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions : Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of infectious diseases.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from Applied Research Studies to academic world (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.



- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- Propose opportunities, and/ or field missions opportunities within our network GABRIEL, to postgraduate students at their own costs to broaden the employability perspectives of the graduated students and the links between laboratories.

Therefore, I confirm that our organization Fondation Mérieux strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Juliet BRYANT, Emerging pathogens Laboratory Director.



Signature of the Legal representative

Name: Benoit MIRIBEL

Position: General Director

Date: February 9, 2018

Place: Lyon, France



Signature of the contact person

Name: Hubert ENDTZ

Position: Scientific Director

Date: February 9, 2018

Place: Lyon, France

3.20 Fundacio Privada Institut de Recerca de la SIDA-CAIXA - IrsiCaixa



The IrsiCaixa AIDS Research Institute is an international landmark and **leading centre for research into the eradication of HIV/AIDS and related diseases**. IrsiCaixa researchers also tackle other biomedical challenges, such as those associated with the microbiome and emerging infectious diseases.

The IrsiCaixa AIDS Research Institute was created as a private non-profit foundation in 1995 with the support of “**la Caixa**” and the **Ministry of Health** of the Government of Catalonia. Its director is Dr. Bonaventura Clotet, who is also president of the Fight Infections Foundation and clinical director of infectious diseases of the territorial management of the North Metropolitan Area of the Institut Català de la Salut. IrsiCaixa is located in this hospital, next to the Fight AIDS Foundation, which makes for **a unique model of collaboration** between researchers, healthcare professionals, patients and community representatives. This transfer of knowledge between key stakeholders makes for novel solutions that facilitate progress towards eradication of HIV infection.

IrsiCaixa research is based on a **combined strategy** to eradicate AIDS, based on five strategic lines that include the development of vaccines and antibodies against HIV. Twelve research groups and more than 100 researchers based at IrsiCaixa carry out **translational research** in collaboration with research and healthcare centres worldwide. The resulting publications are amongst those with the highest impact factors in this field. IrsiCaixa also participates in **clinical trials** to evaluate novel therapeutic strategies and cooperates with low-income countries in the **global fight** against the pandemic.

IrsiCaixa places special emphasis on the formal training of young scientists, on innovation and on transfers of knowledge generated in its laboratories.

IrsiCaixa also coordinates educational and participatory programmes aimed at **promoting health and wellness** and at aligning research with the needs and expectations of citizens.

In fact, advances at IrsiCaixa are achieved in constant dialogue with a community advisory committee (CAC), an external body that facilitates **communication between the scientific community**, health professionals, civil society organizations and patients.

<https://www.irsicaixa.es/en>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: IrsiCaixa AIDS Research Institute

Status: Active Research Organization

Address: University Hospital “Germans Trias i Pujol”, Ctra. de Canyet s/n, 08916 Badalona

Country: Spain

Region: Catalunya

Telephone: +34 934656374

Website: www.irsicaixa.es/en

I, the undersigned, legal representative of IrsiCaixa, hereby confirm that our institution, IrsiCaixa, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of immunovirology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial and research world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates

Therefore, I confirm that our organization IrsiCaixa strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Lidia Ruiz.

Signature of the Legal representative

Name: Bonaventura Clotet

Position: Director

Date: 20/12/2022

Place: Badalona

46106081M
BONAVENTURA
CLOTET (R:
G60813227)

Digitally signed by BONAVENTURA CLOTET (R: G60813227)
DN: cn=BONAVENTURA CLOTET (R: G60813227), o=IrsiCaixa, ou=IrsiCaixa, email=bona@irsicaixa.es, c=ES
Date: 2022.12.22 10:42:01 +01'00'

Signature of the contact person

Name: Lidia Ruiz

Position: Scientific and academic coordinator

Date: 20/12/2022

Place: Badalona

Lidia Ruiz -
47710526Q

Digitally signed by Lidia Ruiz -
47710526Q
DN: cn=Lidia Ruiz - 47710526Q,
o=IrsiCaixa, ou=IrsiCaixa, email=lrui@irsicaixa.es, c=ES
Date: 2022.12.22 10:42:01 +01'00'

3.21 Fundacion Privada Instituto de Salud Global Barcelona – ISGLOBAL



The Barcelona Institute for Global Health (ISGlobal) was set up in 2010 as a result of an innovative alliance between the "la Caixa" Foundation, academic institutions and government bodies to contribute to the efforts undertaken by the international community to address the challenges in global health.

ISGlobal is a consolidated hub of excellence in research that has grown out of work first started in the world of health care by the Hospital Clínic and the Parc de Salut MAR and in the academic sphere by the University of Barcelona and Pompeu Fabra University. Its working model is based on the generation of scientific knowledge through Research Programmes and Groups, and its translation through the areas of Education and Training, Innovation, and Analysis and Global Development.

Its ultimate goal is to help close the gaps in health disparities between and within different regions of the world that affect the most vulnerable populations.

Scientific research is the backbone of ISGlobal's work. This activity is carried out with a focus on translational research and in collaboration with many partners and associates. Since the merger with the Centre for Research in Environmental Epidemiology (CREAL) in June 2016, ISGlobal focuses its research efforts on two main research areas: on one hand, infectious diseases and maternal, reproductive and child health; on the other hand, non-communicable diseases and environmental health. Its multidisciplinary approach allows it to encompass a wide range of fields and topics, ranging from molecular biology to clinical and epidemiological research.

<https://www.isglobal.org>

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: **Barcelona Institute for Global Health (ISGlobal)**

Status: **Private**

Full Address: **Rosselló 132, 08036 - Barcelona**

Country: **Spain**

Tel: **+34 93 227 9892**

Website: **www.isglobal.org**

I, the undersigned, legal representative of the Barcelona Institute for Global Health (ISGlobal), hereby confirm that our institution, ISGlobal, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

1. Within the program, our organization will offer support and expertise in the area of vaccinology, immunology and infectious diseases.
2. In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
3. Our organization also commits to:
 - contribute to transfer of knowledge and skills (e.g., by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - propose full or partial (e.g., public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates
 - participate in student exchanges to broaden their skills to grasp the changing world

A partnership of:



Therefore, I confirm that our organization ISGlobal strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Núria CASAMITJANA (Director of Education and Training) and Dr Carlota DOBAÑO (Research Professor).

Signature of the Legal representative:

25445668D
GONZALO
VICENTE (R:
G65341695)

Firmado digitalmente
por 25445668D
GONZALO VICENTE (R:
G65341695)
Fecha: 2023.01.12
14:33:00 +01'00'

Name: Gonzalo Vicente

Position: General Manager

Date: January 10th 2023

Place: Barcelona, Spain

Signature of the contact person:

CASAMITJANA
BADIA NURIA -
461098635

Firmado digitalmente por
CASAMITJANA BADIA NURIA -
461098635
Fecha: 2023.01.10 20:28:00
+01'00'

Name: Núria CASAMITJANA

Position: Director of Education & Training

Date: January 10th 2023

3.22 GlaxoSmithKline Biologicals SA - GSK



GSK is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people over the next 10 years. We prevent and treat disease with vaccines, specialty and general medicines. We focus on science of the immune system, human genetics, and advanced technologies investing in 4 core therapeutic areas and future opportunities to impact health at scale. We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.

Our culture: Ambitious for patients to deliver what matters better and faster. Accountable for impact with clear ownership and support to succeed. Do the right thing with integrity and care because people count on us. Vaccines at a glance: We have more than 20 vaccines to help protect people from a range of diseases throughout their lives. We supply vaccines to people living in over 160 countries. Almost 17,000 GSK people around the globe work on vaccines. We have 21 vaccine candidates in our pipeline as we seek to develop new vaccines against infectious diseases.

<http://www.gsk.com/>

GlaxoSmithKline Biologicals SA

Siège social :

Rue de l'Institut, 89

B-1330 Rixensart

Belgium

Tel. +32 (0) 2 656 81 11

Fax. +32 (0) 2 656 80 00

Siège d'exploitation :

Avenue Fleming, 20

B-1300 Wavre

Belgium

Tel. +32 (0) 10 85 51 11

Fax. +32 (0) 10 85 90 00

www.gsk.com

Attn: Professor Peter Delpitte

14th February 2023

Ref: Letter of Commitment to support the LIVE – “Leading International Vaccinology Education” Joint Master Program

I, the undersigned, legal representative of Glaxo SmithKline, hereby confirm that our institution, GSK, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccine research, manufacturing and regulatory affairs.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) No financial contribution shall be made by GSK
- 4) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - *OTHER:* Organization has requested GSK to become one of the contributors of the LIVE Master and to organize two weeks of vaccinology courses for the years 2024, 2025, 2026. As a contribution, GSK will host the Activity and appoint GSK experts to provide courses on vaccine development and manufacturing. The courses will be organized in GSK Belgian site and will include a tour of GSK manufacturing sites.

Therefore, I confirm that our organization GSK strongly supports this LIVE Master program.

The contact person appointed to represent our company in the LIVE master will be Yan Sergerie.

Signature of the Legal representative

Name: Yan Sergerie

Position: GMPL Global Medical Portfolio Lead

Date: Feb 14th, 2023

Place: Wavre, Belgium

A handwritten signature in black ink, appearing to read 'Yan Sergerie', is written over a horizontal dashed line.

Signature of the contact person

Name: Yan Sergerie

Position: GMPL Global Medical Portfolio Lead

Date: Feb 14th, 2023

Place: Wavre, Belgium,

A handwritten signature in black ink, appearing to read 'Yan Sergerie', is written over a horizontal dashed line.

3.23 HIPRA Scientific SL



HIPRA is a **biotechnological pharmaceutical company** focused on **prevention for animal and human health**, with a broad range of **highly innovative vaccines**. With its claim “Building immunity for a healthier world”, HIPRA affirms its commitment to contributing with solutions that **improve world health**.

R&D projects are the basis of the knowledge. HIPRA has **more than 50 years of experience** dedicated to the research and development of different vaccines. With a unique organizational model, HIPRA **controls all the processes of the value chain**, generating singular know-how and becoming a reference in the research, production, and commercialization of biologics. HIPRA is the company that has launched the most biotech vaccines in the last 10 years, with a total of 22 vaccines.

HIPRA has a **solid international presence** in more than 40 countries, with its own subsidiaries, 3 R+D centres and 6 production centres strategically located in Europe (Spain) and America (Brazil).

Moreover, its extensive international distribution network keeps open marketing channels with nearly 100 other countries, thereby covering the 5 continents.

HIPRA is **ranked 5th of the global leaders in the veterinary industry** developing vaccines for Animal Health.

The beginnings of HIPRA date back to **1971** when a group of young entrepreneurs acquired a small laboratory in Madrid founded in 1954, called HIPRA (by the surnames of its former creators: Hidalgo and Prada), and moved to Amer (Girona). The year **1991**, with a workforce of 100 people and a turnover of 10 million euros, was a crucial year in HIPRA's history. A new highly motivated management team redefines the company's expansion policy. Thus begins an important period of technical and commercial expansion. As of the year **2000**, began the internationalization of HIPRA with the implementation of our own subsidiaries around the world. In **2009** the strategic positioning was refined with the clear mission of being the world leader in prevention, with differential and innovative products and, therefore, it stopped investing in pharmacological products. In **2020**, and in a context of the COVID-19 pandemic, a new challenge was faced using its extensive experience in innovative vaccines, the development of the vaccine against this new virus based on recombinant protein. In **2021** the new Human Health division was created to develop new innovative products. The same year GoodGut was acquired, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.

<https://www.hipracovid19.com/en/about-hipra>



Hipra Scientific, S.L.U.
Avda. la Selva, 135, 17170 Amer (Girona), Spain
Tel.: (34) 972 43 06 60 · hipra@hipra.com · www.hipra.com

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: HIPRA SCIENTIFIC SLU
Status: Large Enterprise
Full Address: Avda. La Selva, 135 – 17170 Amer (Girona) - SPAIN
Country: Spain
Tel: +34 (9)72 430660
Fax: +34 (9)72 430661
Website: www.hipra.com

I, the undersigned, legal representative of HIPRA SCIENTIFIC, SLU, hereby confirm that our institution, HIPRA SCIENTIFIC SLU, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccine development and production.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program through:
 - participating in transfer of knowledge and skills from industrial world to academic i.e., by proposing seminars and visits to our site to the students.

In return, HIPRA SCIENTIFIC SLU would appreciate publicity of the collaboration in the appropriate forums.

Therefore, I confirm that our organization HIPRA SCIENTIFIC SLU strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Anna Bartrina, R&D Secretary.

Signature of the Legal representative



Name: Elia Torroella
Position : Executive Vice-President R&D and Regulatory Affairs
Date : 9th. January 2023
Place : Amer

HIPRA

Hipra Scientific, S.L.U.
Avda. la Selva, 135, 17170 Amer (Girona), Spain
Tel.: (34) 972 43 06 60 - hipra@hipra.com - www.hipra.com

Signature of the contact person



Name: Anna Bartrina
Position : R&D Secretary
Date : 9th. January 2023
Place : Amer

3.24 IFAKARA Health Institute Trust



Ifakara Health Institute (IHI) is a leading health research organization in Africa, with a strong track record of developing, testing and validating innovations for health. We are driven by core strategic mandate for research, training

and services. The institute's work spans across the full research lifecycle from basic science to policy and translation.

IHI work is organized in three research departments, six research units and seven technical units. The research departments are: Environmental Health & Ecological Sciences, Interventions & Clinical Trials, and Health Systems, Impact Evaluation & Policy.

The research units are: Grants and Contracts, Training & Capacity Building, Laboratories, Data Systems and Platforms, Vector Control Product Testing, and Chronic Diseases Clinics. The technical units, which are supporting research (our primary activity) are: Internal Audit, Knowledge Management and Communications, Finance Management, Human Resources, Procurement Management, Branch Management and Information & Communication Technology. We have three major offices in Tanzania (Ifakara, Bagamoyo & Dar es Salaam).

Mission: To develop and sustain a district-focused health research institute capable of generating new knowledge and information for public health policy and action.

Vision: To be a center of excellence and innovation in health research and development, aiming at maximizing population health gain.

<https://ihi.or.tz/>

About Dr Ally Olotu

Ally Ibrahim OLOTU, Senior research clinician, Ifakara Health Institute, Tanzania

PhD, M.D., <https://profiles.tdr-global.net/Ally.Ibrahim.Olotu/publications>

- DPhil in Clinical Medicine from University of Oxford, Oxford, United Kingdom 1 Oct 2009 - 1 Oct 2014
- Doctor of Medicine Degree from University of Dar es Salaam, Dar es Salaam, Tanzania 1 Jan 1996 - 1 Dec 2001

Dr Ally Olotu is research physician with expertise in malaria epidemiology and clinical trials addressing malaria interventions such as malaria vaccines. After 2 years of clinical practice at Aga Khan Hospital in Dar es salaam, Tanzania he worked as a research clinician within several clinical studies of malaria pathogenesis at KEMRI-Wellcome Trust, Kenya. In 2005, he was awarded a WHO/TDR Career Development Fellowship in malaria vaccine development and spent a year at GSK Biologicals in Rixensart, Belgium where he received training in malaria vaccine research and development and clinical trials management. He was also involved in coordinating two malaria vaccine trials in West Africa and played a role in the development of clinical trial protocols and standard operating procedures. He was a Co-PI in a multi-center trial evaluating the safety and efficacy of a candidate malaria vaccine RTS,S/AS01, in Kenya and Tanzania, and participated in setting up a clinical trial facility which provided support to the trial in Kenya. After the end of the industry-sponsored study in 2010, he initiated an investigator-led extension which formed the basis of his DPhil work on the Long-term efficacy of a Pre-erythrocytic malaria vaccine and epidemiology of malaria which was completed in 2014. In 2015, He joined the Ifakara Health Institute and worked with Equatorial Guinea Malaria Vaccine Initiative research project in Malabo, Bioko Island as a lead investigator. Over the last 2 years, and working with both the public and private partners, he participated in the development of the protocols and SOPs for a whole sporozoite vaccine trial and trained a clinical trial team which successfully implemented the first ever clinical trial in the history of Equatorial Guinea. His main contribution has been on the investigation of the long-term efficacy of a candidate malaria vaccine (RTS,S/AS01) in young children living in a malaria endemic country. He has described the interaction between the vaccine efficacy and malaria exposure and studied immunological markers of vaccine efficacy and of naturally-acquired infection. His research to-date has led to several publication in peer reviewed journals. In 2013 he won the Oxford University Nuffield Department of Medicine Graduate Research Prize for his DPhil work. He is currently collaborating with Oxford University, Sanaria Inc, and Swiss Tropical Public Health Institute.

| | |
|--|---|
|  <p>ISO 9001: 2015 certified IFAKARA HEALTH INSTITUTE research training services</p> | <p>Dr Ally OLOTU PhD, M.D., Senior research clinician, Ifakara Health Institute, Tanzania</p> |
|--|---|

De : Ally Olotu <aolotu@ihi.or.tz>

Envoyé : samedi 11 février 2023 15:47

À : DELPRAT CHRISTINE <CHRISTINE.DELPRAT@univ-lyon1.fr>

Cc : Kafuruki Shubis <kshubis@ihi.or.tz>

Objet : Re: LIVE2023 call - To support the EMJM LIVE3 as Associated Partner

Dear Christine

Many thanks for sharing this. We would very much like to be associated with the program. I am looping in our head of training for information. We will get back to you with the commitment letter before the end of February 2023.

Best regards

Ally

Ally Ibrahim OLOTU, Senior research clinician

Ifakara Health Institute, Tanzania

+255 718927104 (Mobile)

ndaskoiolotu@gmail.com (Personal)

aolotu@ihi.or.tz (Work)

Ifakara Health Institute (COSTECH), Ifakara, INTERVENTION, BAGAMOYO, COAST, Tanzania

De : Christine DELPRAT <christine.delprat@univ-lyon1.fr>

Envoyé : samedi 11 février 2023 16:10

À : 'Ally Olotu' <aolotu@ihi.or.tz>

Cc : 'Kafuruki Shubis' <kshubis@ihi.or.tz>

Objet : RE: To partner with the EMJM LIVE3 as Associated Partner

Dear Ali,

Excellent!

We welcome with a great pleasure each year 5-6 African smart and motivated students. LIVE is helping developing African countries thanks to LIVE African graduates and networking. The LIVE3 partnership will help mutually: LIVE3 students to benefit from your expertise in Malaria and you from IHI in Tanzania with African colleagues from Cameroun, Mali, Burkina Faso involved in the writing of the DELTAII project. We are very happy to benefit from your expertise in Malaria for the next LIVE3 2023-28 programme. Receiving the signed letter at the end of February for the Ifakara Health Institute is fine, I will update to implement, welcome to LIVE3!

All the best!

Christine

Prof. Christine DELPRAT

Professor of Immunology – PU CL.EX., University of Lyon – UCBL, France, Master LIVE Coordinator

3.25 Incepta Vaccine Ltd



Incepta Vaccine Ltd

Incepta Vaccine Ltd is the first human vaccine manufacturing company in Bangladesh. The manufacturing unit is situated at Zirabo, Savar which is conveniently located at the outskirts of Dhaka city. It is established with an objective to introduce modern concepts in manufacturing vaccine by acquiring advanced knowledge and technique. Prime objective of this company is to protect vast populations of Bangladesh as well as developing world from various infectious diseases at an affordable cost. It has a vision to develop novel vaccines against diseases of the developing world. Incepta Vaccine Ltd, a state-of-the-art facility fully compliant with WHO GMP requirements, is a large vaccine manufacturing facility that has the capacity to manufacture 180 million single dose vials and ampoules per year. A large pool of scientists are engaged in different areas of specialties like research and development, quality control, quality assurance, production and other related areas.

<http://inceptavaccine.com/>



Head Office : 40 Shahid Tajuddin Ahmed Sarani, Tejgaon I/A, Dhaka-1208, Bangladesh
Phone : +880-2-8891688-703, Fax : +880-2-8891190, Web : www.inceptavaccine.com
Factory : Dewan Idris Road, Bara Rangamatia, Zirabo, Savar, Dhaka.

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Incepta Vaccine Ltd.
Status: Private Limited
Full Address: 40, Shahid Tajuddin Ahmed Sarani, Tejgaon I/A, Dhaka-1208
Country: Bangladesh
Tel: +880-2-8891688-703
Fax: +880-2-8891190
Website: www.inceptavaccine.com

I, the undersigned, legal representative of Incepta Vaccine Ltd., hereby confirm that our institution, Incepta Vaccine Ltd., is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccine process development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students



ABDUL MUKTADIR
Managing Director
Incepta Vaccine Ltd.

Innovative concept into practice



Head Office : 40 Shahid Tajuddin Ahmed Sarani, Tejgaon I/A, Dhaka-1208, Bangladesh
Phone : + 880-2-8891688-703, Fax : + 880-2-8891190, Web : www.inceptavaccine.com
Factory : Dewan Idris Road, Bara Rangamatia, Zirabo, Savar, Dhaka.

- Propose if any technology and method are developed through this programme, our organization would like to offer the opportunities of technology and method validation as well as technology transfer and if possible commercialization of any products.

Therefore, I confirm that our organization Incepta Vaccine Ltd. strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Mohammad Mainul Ahasan, PhD.



Signature of the Legal representative

ABDUL MUKTADIR
Managing Director
Incepta Vaccine Ltd.

Name: Abdul Muktadir

Position: Managing Director

Date: 11.02.2018

Place: Dhaka, Bangladesh



Signature of the contact person

Name: Mohammad Mainul Ahasan, PhD

Position: Manager

Date: 11.02.2018

Place: Dhaka, Bangladesh

Innovative concept into practice

3.26 Innovative clinical research network in vaccinology: i-reivac



I-REIVAC, a network dedicated to clinical research in vaccinology

Created in 2007, I-REIVAC (Innovative clinical research network in vaccinology), has been awarded the F-CRIN network of excellence label in 2014. It conducts phase 1 to 3 industrial and academic clinical trials, on preventive immunization in healthy volunteers and specific population (immunocompromised, elderly, pregnant women, comorbidities, ...); large scale epidemiological studies in vaccine preventable diseases; and developing social sciences approach to improve vaccine program acceptability.

Coordinated by Professor Odile Launay, an infectious disease specialist and vaccinology researcher, the network brings together clinical centers, centers for biological resources and immunology laboratories. It gathers partners with complementary expertise at national and European level: clinicians, vaccinologists, biologists, immunologists, epidemiologists, researchers in Human and Social Sciences, all strongly involved in research on vaccinology.

The network aims at developing and promoting vaccine research. Its objectives are:

- To enhance the visibility and competitiveness of France in vaccination research,
- To develop a quality and attractive scientific program for industrial and university partners,
- To promote French excellence thanks to:
 - International university studies coordinated by French researchers,
 - Preclinical tests in collaboration with pharmaceutical industries, biotech's, etc.
- To develop European and international strong and efficient collaboration.

<https://www.ireivac.org/>



Prof. Odile LAUNAY

Coordination I-REIVAC-COVIREIVAC
Hôtel Dieu
1 place du Parvis Notre Dame
75004 Paris, France

Fait à Paris, le 3 février 2023

Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

After approbation of our steering committee, I am pleased to confirm that the I-REIVAC network is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our network will offer support and expertise in the area of clinical research on vaccinology.
- 2) The I-REIVAC network will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) The I-REIVAC network also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - participate in student exchanges to broaden their skills to grasp the changing world

Therefore, I confirm that the I-REIVAC network strongly supports this LIVE Master program. The contact person appointed to represent our network in the LIVE master will be Prof. Odile LAUNAY.

Prof. Odile LAUNAY
Université Paris Cité / I-REIVAC network coordinator
Au nom du comité de pilotage du réseau I-REIVAC

PO Claire REKACEWICZ
I-REIVAC network deputy coordinator



3.27 Institut de Investigacio en Ciencies de la Salut Germans Trias i Pujol – IGTP-CERCA



The Germans Trias i Pujol Research Institute (IGTP) is a public research centre in the Autonomous region of Catalonia in Northern Spain dedicated to increasing scientific knowledge and transferring it to improve the care and lives of patients.

The institute is attached to one of the large teaching hospitals in the Barcelona area, the Germans Trias University Hospital (HUGTP), and is located on the biomedical campus that surrounds it, Campus Can Ruti. It is a CERCA centre, a member of the biocluster supported and supervised by the Autonomous Catalanian Government. It is also accredited as a Centre of Excellence by the Instituto Carlos III (Spanish Government) and in this capacity acts as an umbrella organization for scientific research on the campus, where it works closely with the other centres.

The mission of the IGTP is to create a multi-disciplinary and multi-institutional environment that opens the gates to highly efficient translational research with a view to improving people's health and quality of life.

The Germans Trias Institute carries out research within 9 areas:

- Science of Behaviour and Substance Abuse
- Immunology and Inflammation
- Cardiovascular and Respiratory Diseases
- Infectious Diseases
- Endocrine and Diseases of the Metabolism, Bones and Kidneys
- Diseases of the Liver and Digestive Tract
- Cancer
- Neuroscience
- Community Health

Scientists working in these areas publish an average of over 500 papers a year, contribute to improved treatment and healthcare protocols, produce patents and set up spin-off companies in order to improve the lives of patients.

<http://www.germanstrias.org/>

Germans Trias i Pujol Research Institute (IGTP)
Carretera de Can Ruti, Camí de les Escoles s/n
08916 Badalona, Barcelona, Spain

Tel: +34 93 554 3050
Fax: +34 93 465 14 72
www.igtp.cat



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP)

Status: Validated

Institution address (with country): Crtra. de Can Ruti, Camí de les Escoles, s/n ; 08916
08916, Badalona, Catalonia, Spain

Institution web site: <http://www.germanstrias.org/>

I, the undersigned, legal representative of Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (IGTP), hereby confirm that our institution, IGTP, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of the evaluation of vaccine candidates and clinical studies and trials in the field of infectious diseases.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates
 - participate in student exchanges to broaden their skills to grasp the changing world

Germans Trias i Pujol Research Institute (IGTP)
Carretera de Can Ruti, Camí de les Escoles s/n
08916 Badalona, Barcelona, Spain

Tel: +34 93 554 3050
Fax: +34 93 465 14 72
www.igtp.cat



Therefore, I confirm that our organization IGTP strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Cristina Vilaplana.

Signature of the Legal representative

Name: Carles Esquerré

Position: Managing director

Date: 9th January, 2023

Place: Badalona, Catalonia, Spain

Signature of the contact person

Name: Dr. Cristina Vilaplana

Position: Head of the Experimental Tuberculosis Unit

Date: 5th January, 2023

Place: Badalona, Catalonia, Spain

3.28 Institut National de la santé et de la Recherche Médicale - Inserm - Clinical Trial Center in Vaccinology CIC-EC-CIIL

Inserm

La science pour la santé
From science to health

The CIC-EC of Saint-Etienne was created in February 2003. The CIC is a structure accredited by INSERM. The major assignments entrusted were to develop the methodological aid and IT support to multicentric clinical trials and clinical epidemiological research taking on all or part of this research work. The CIC-EC was therefore aimed at clinical research development particularly within labelled teams of the CHU of Saint-Etienne. In 2008, the CIC-EC has been expanded to new fields of clinical research as cancer and vaccinology. The CIC-EC Vaccinology has been developed by the Pr. F. Lucht (medical doctor in infectious diseases) and the Dr. S. Paul (immunologist and expert in vaccinology). In 2009, the CIC-EC Vaccinology has been labelled by ANRS (French network for HIV vaccine research) and REIVAC (French network of clinical investigators in Vaccinology). The CIC has participated in more than 20 clinical trials in the field of vaccine development both with academic labs and companies. The expertise of the CIC-EC Vaccinology renamed as CIC1408 in 2013 is the evaluation of mucosal vaccines. In 2014, the REIVAC network has been labelled by the F-Crin network to develop excellence in the field of Vaccinology in Europe. The CIC manages trials accepted by its technical committee, and primarily in line with the research areas defined by its steering committee:

- A vascular and hemostasis theme including an antithrombotic and vascular diseases axis, a hemophilia - hemostasis axis and a neurovascular axis,
- An immunology theme comprising a vaccinology axis, a chronic inflammatory bowel disease (IBD) axis and an inflammatory joint pathology axis,
- A prevention theme including a prevention axis in oncology and a prevention and control of infections axis,
- A general medicine theme.

<https://www.inserm.fr/en>

http://www.chu-st-etienne.fr/Professionnels/Recherche/Presentation_DRCI/Pro_CIC_EC.asp

<https://www.ciil.fr/>

**CENTRE D'INVESTIGATION CLINIQUE
EPIDEMIOLOGIE CLINIQUE
(CIC-EC)**

HÔPITAL NORD
Bâtiment Recherche
Saint Priest en Jarez

Saint Priest en Jarez,
Le 31/01/2018

Coordonnateur :
Pr. Bernard TARDY

Médecins délégués :
Dr. Andréa BUCHMULLER
Dr. Adel MERAH

Département statistiques :
Mme Emilie PRESLES
Mme Silvy LAPORTE

Attachées
de Recherche Clinique et
Techniciennes de Recherche
Clinique :
M. Madjid AKROUR
Mme Corinne BERNABE
Mme Carole CHAUVET
Mme Maëlle DETOC
Mme Séverine MARCHAND
Mme Juanita TECHER

Infirmières :
Mme Anne ASSAF
Mme Dalila LEMOUCHE

Laboratoire de Recherche en
Hémostase :
Dr Brigitte TARDY-PONCET
Mme Caroline CHAUDIER

Secrétariat :
Mme Sandrine AYALA
Mme Edith VENET

Tél : 04 77 12 77 88
Fax : 04 77 12 78 20
E-mail : cic@chu-st-etienne.fr

Thématique Thrombose :
Pr Hervé DECOUSUS
Dr Sandrine ACCASSAT
Dr Andréa BUCHMULLER
Dr Adel MERAH

Thématique cancer :
Pr Franck CHAUVIN
Dr Aurélie BOURMAUD

Thématique Vaccinologie
Pr Frédéric LUCHT
Pr E. Botelho-Nevers
Dr Pascale FOUILLOUX
Dr Stéphane PAUL

**Letter of Commitment
To support the LIVE – “Leading International Vaccinology
Education”
Joint Master Program**

The organization: Centre d'Investigation Clinique (Clinical Trial Center in
Vaccinology) 1048

Status: Inserm

Full Address: CHU St Etienne 42055 St Etienne Cedex 02

Country: France

Tel: + 33 4 77 12 07 90

Fax: + 33 4 77 12 07 88

Website: [www.chu-st-](http://www.chu-st-etienne.fr/professionnelsante/recherche/structurecommissions/cic)

etienne.fr/professionnelsante/recherche/structurecommissions/cic

I, the undersigned, legal representative of CIC 1048-Vaccinology Unit, hereby confirm that our organization, CIC 1048-Vaccinology Unit, is willing to support the LIVE Master program coordinated by the University Claude Bernard Lyon 1 (France) in collaboration with the following higher education institutions: University Jean Monnet Saint-Etienne (France), Autonomous University of Barcelona (Spain), University of Antwerp (Belgium).

- 1) Within the program, our organization will offer support and expertise in the area of clinical vaccinology and preventable infectious diseases.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall

promotion and implementation of the program, in particular through participating to the project governance, and supporting the yearly recruitment campaigns.

3) Our organization also commits to :

- Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.

Therefore, I confirm that our organization CIC 1048-Vaccinology Unit strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE master will be Pr RF Lucht.

Signature of the Legal representative


Name: Pella Dominique

Position: regional delegate of Inserm

Date: 31/01/2018

Place: Inserm DR Rhône-Alpes, Auvergne
69675 BRON cedex
Tél. 04 72 13 88 00 - Fax: 04 72 13 88 01

D. PELLA
Délégué Régional




Signature of the contact person

Name: Lucht R. Frédéric

Position: Head of the CIC 1408 Vaccinology Unit-CHU St Etienne

Date: 26/02/2015



Place: CIC-CHU St Etienne

3.29 Instituto Butantan



With 121 years of history, Butantan works to prevent diseases like Covid-19, flu, tetanus, diphtheria, hepatitis A and B, chikungunya, whooping cough, dengue, HPV and rabies. In 2021, Butantan produced:

- 100 million doses of Covid-19 vaccine
- 80 million doses of flu vaccine
- 28 million doses of vaccines Against hepatitis A and B, HPV, DTaP and rabies
- 560 thousand units of serum against venoms, bacterial toxins and the rabies virus

Instituto Butantan is the main producer of immunobiologicals in Brazil. It is responsible for a considerable percentage of the national production of hyperimmune sera and vaccine antigens, which make up the vaccines used in the National Immunization Program (Programa Nacional de Imunizações, PNI) of the Brazilian Ministry of Health. Our technological development activities in the production of health inputs are associated with the production of vaccines, antitoxins and antivenoms, and biopharmaceuticals for human use.

<https://en.butantan.gov.br/institute.php>



**Secretaria de Ciência, Pesquisa
e Desenvolvimento em Saúde
Instituto Butantan**



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Instituto Butantan

Status: Partner B

Full Address: Av. Vital Brasil 1500, São Paulo, SP, 05503-900

Country: Brazil

Tel: 2627-9300

Website: www.butantan.gov.br

I, the undersigned, legal representative of Instituto Butantan, hereby confirm that our institution, Instituto Butantan, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of research and clinical development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.




Secretaria de Ciência, Pesquisa
e Desenvolvimento em Saúde
Instituto Butantan



- propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates

Therefore, I confirm that our organization Instituto Butantan strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Luciana C.C. Leite.



PROF. DR. ESPER G. KALLÁS
DIRETOR DO INSTITUTO BUTANTAN

Signature of the Legal representative

Name: Esper G. Kallás

Position: Director of Instituto Butantan

Date: 13/01/2023

Place: São Paulo, SP, Brasil



Signature of the contact person

Name: Luciana C.C. Leite

Position: Senior Researcher at Laboratory of Vaccine Development

Date: 13/01/2023

Place: São Paulo, SP, Brasil

3.30 International Vaccine Institute



The International Vaccine Institute (IVI) is a non-profit International Organization established in 1997 as an initiative of the United Nations Development Programme (UNDP). We are among the few organizations in the world dedicated to vaccines and vaccination for global health.

Our mission is to Discover, develop and deliver safe, effective and affordable vaccines for global public health. IVI is headquartered in Seoul and hosted by the Republic of Korea with 39-member countries and the WHO on its treaty. IVI focuses on vaccines against infectious diseases affecting the World's most impoverished. We aim to make vaccines available and accessible for vulnerable populations in developing countries. We live in an increasingly globalized world where new and emerging infectious diseases can become global health threats. IVI also focuses on vaccines against infectious diseases of major global health concern.

<http://www.ivi.int/>

5th January 2023

Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: The International vaccine Institute
Status: Not-for profit
Address: SNU Research Park, 1 Gwanak-ro, Gwanak-gu, Seoul
Country: Korea
Telephone: +82-2-881-1365, Fax: +82-2-872-2801
Website: www.ivi.int

I, the undersigned, legal representative of IVI, hereby confirm that our institution, IVI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Infectious disease and vaccine science training.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

- *OTHER*: Internship opportunities, connection with the industry, exposure to project implementation in developing countries

Therefore, I confirm that the International Vaccine Institute strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Sushant Sahastrabuddhe.

Signed by the Legal representative

A handwritten signature in black ink, appearing to read 'Jerome H. Kim', written over a horizontal line.

Name: Jerome H. Kim, MD
Position: Director General
Date: 5th January 2023
Place: Seoul, Republic of Korea

Signed by the Contact Person

A handwritten signature in black ink, appearing to read 'Dr. Sushant Sahastrabuddhe', written over a horizontal line.

Name: Dr. Sushant Sahastrabuddhe
Position: Associate Director General
Date: 5th January 2023
Place: Seoul, Republic of Korea

3.31 Intravacc



Even the most promising vaccines don't always make it out of the laboratory into large-scale production. We at Intravacc are fully aware of the challenges on the long road of vaccine development. We substantially reduce the risks and costs involved with developing vaccines. How? By bridging the gap between your concept and late stage clinical studies.

The Netherlands-based Intravacc, part of the Utrecht Science Park location Bilthoven, is one of the world's leading organizations with many years of experience in translational vaccinology. As an established independent clinical development and manufacturing organization (CDMO) in the vaccine industry, Intravacc offers a wide range of expertise and is the bridge between your discovery and the start of your phase I/II clinical trials in humans.

<https://www.intravacc.nl/>

3.32 Janssen Vaccines & Prevention B.V.



There are more than 30,000 of us working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease and HIV to Alzheimer's and cancer, we are mobilizing on issues that touch everyone's lives. Our mission is to transform people's lives and fundamentally change the way diseases

are managed, interpreted and prevented. We believe that the best way to change things is to challenge them. So every day, in more than 150 countries, we bring together cutting-edge science and the most creative minds in the industry to approach disease in a different way. We seek not only to innovate, but to provide people with the tools to make informed decisions and achieve the best possible health outcomes. We are developing treatments for patients in six major therapeutic areas:

- Cardiovascular and metabolic disease
- Immunology
- Infectious diseases and vaccines
- Neuroscience
- Oncology
- Pulmonary hypertension

<https://www.janssen.com/netherlands/>



**Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program**

The organization: Janssen Vaccines & Prevention B.V
Status: Limited liability company under Dutch law
Full Address: Archimedesweg 4-6, 2333 CN Leiden


Country: The Netherlands
Tel: +31 71 519 7646
Fax: N/A
Website: <http://www.janssen.com/infectious-diseases-and-vaccines>

I, the undersigned, legal representative of Janssen Vaccines & Prevention B.V, hereby confirm that our company, Janssen Vaccines & Prevention B.V, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer (non-financial) support and expertise in the area of vaccinology and infectious diseases;
- 2) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from the industrial world to the academic world (e.g. by tutorials, lectures, specific practical training, visits to our site, etc.) to students;
 - Propose topics for master theses and internship opportunities, and/or short summer internships to the students.

Therefore, I confirm that our organization supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Selina Khan.

Signature of the Legal representative
Name: Maarten Santman
Position: Senior Legal Counsel
Date: 6 February 2018
Place: Leiden



Signature of the contact person
Name: Selina Khan
Position: Principal Scientist
Date: 6 February 2018
Place: Leiden

Janssen Vaccines & Prevention B.V.

Archimedesweg 4-6
2333 CN Leiden
The Netherlands

P.O. Box 2048
2301 CA Leiden
The Netherlands

+31 (0) 71 519 91 00 tel
+31 (0) 71 519 98 00 fax
CoC 28074607

www.janssen.com



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: Janssen Vaccines & Prevention

Status:

Full Address: Archimedesweg 4-6, 2333 CN Leiden

Country: The Netherlands

Tel: +31 71 519 9100

Website: <https://www.janssen.com/netherlands/>

I, the undersigned, legal representative of Janssen Vaccines & Prevention B.V. (hereinafter "Janssen"), hereby confirm that our company, Janssen, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer (non-financial) support and expertise in the area of infectious disease and vaccinology.
- 2) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, lectures, visits to our site, etc., to the students
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.

Therefore, subject to the execution of the appropriate agreements, I confirm that our organization Janssen strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Roland Zahn, PhD.

Signature of the Legal representative

Name: Roland Zahn, PhD

Position: Sr Scientific Director, Head Preclinical characterization

Date: February 15, 2023

Place: Leiden

Signature of the contact person

Name: Roland Zahn, PhD

Position: Sr Scientific Director, Head Preclinical characterization

Date: February 15, 2023

Place: Leiden

Digitally signed
by Roland Zahn
Date:
2023.02.16
14:00:22 +01'00'

Janssen Vaccines & Prevention B.V.

Archimedesweg 4-6
2333 CN Leiden
The Netherlands

P.O. Box 2048
2301 CA Leiden
The Netherlands

+31 (0) 71 519 91 00 tel
+31 (0) 71 519 98 00 fax
CoC 28074607

www.janssen.com

3.33 Karolinska Institutet*Department of Medicine_Solna



**Karolinska
Institutet**

Karolinska Institutet is one of the world's leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic medical research conducted in Sweden and offers the country's broadest range of education in medicine and health sciences. The Nobel Assembly at Karolinska Institutet selects the Nobel laureates in Physiology or Medicine.

Karolinska Institutet was founded by King Karl XIII in 1810 as an "academy for the training of skilled army surgeons". Today, Karolinska Institutet is a modern medical university and one of the foremost in the world.

With our close relationship to the clinical milieu, a well-established infrastructure and a stable financial situation, Karolinska Institutet has excellent prerequisites for sustaining high quality research and education.

Karolinska Institutet (KI) offers a wide range of programmes and courses in medicine and healthcare to meet society's need for skills in the field. This enables us to conduct high-quality, relevant interprofessional education and training, through which students from different programmes learn with, from and about each other in the interests of effective collaboration as students and, later, as healthcare professionals.

Karolinska Institutet conducts research and education on two campuses (Solna and Flemingsberg) and at a number of the county's hospitals.

There are some 6,500 FTE students on KI's programmes and courses. The teachers often conduct research alongside their educational duties, giving their students access to the latest knowledge in the entire field of medicine. Students, teachers and researchers together constitute an interesting and stimulating academic environment.

Many of KI's programmes include placements that offer real-world clinical practice and education.

KI is also engaged in large-scale international exchanges that give students opportunities to pursue some of their studies abroad.

<https://ki.se/en>



**Karolinska
Institutet**

Date
9 April, 2019

DNR

Page
1 / 2

**Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program**

The organization: Karolinska Institutet, Department of Medicine Solna

Status: Higher education institution

Full Address: Karolinska Institutet, SE-171 77 Stockholm, Sweden

Country: Sweden

Tel: +46 8 524 800 00

Website: <http://ki.se>

I, the undersigned, legal representative of the Department of Medicine Solna, Karolinska Institutet, hereby confirm that our department is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of basic vaccinology, immunology and the use of preclinical non-human primate models.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students and host students for such activities at the department.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students



**Karolinska
Institutet**

Page
2 / 2

Therefore, I confirm that our organization Karolinska Institutet strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be **Professor Karin Loré**.



Signature of the Legal representative

Name: Kristina Broliden

Position: Professor, Head of Department of Medicine Solna

Date: 2019-04-15

Place: Stockholm




**Karolinska
Institutet**

Signature of the Legal representative

Name: Björn Kull

Position: Head of Unit, Grants Office

Date: 23/4-2019

Place: Stockholm

Signature of the contact person

Name: Karin Loré

Position: Professor

Date: 2019-04-09

Place: Stockholm

3.34 Katholieke Universiteit Leuven*Rega Institute for medical research



KU LEUVEN

KU Leuven is dedicated to education and research in nearly all fields. Its fifteen faculties offer classes and degree-granting academic programmes, whilst research activities are organised by departments and research groups. These faculties and departments are clustered into three thematic groups: Humanities and Social Sciences, Science, Engineering and Technology (SET), and Biomedical Sciences. Each of these groups sponsors its own doctoral school for organising and awarding doctoral degrees. KU Leuven boasts thirteen campuses, spread across 10 cities in Flanders.

The Rega Institute was founded in 1954 by Professor Piet De Somer and named after the 18th century philanthropist and professor Josephus Rega of Leuven. It hosts part of the Department of Microbiology, Immunology and Transplantation. Since its inception, the Rega Institute hosts also the Section of Medicinal Chemistry of the Department of Pharmaceutical Sciences and it is thus a true interdepartmental and interdisciplinary research institute. The Rega Institute has always been a jewel in the crown of research and innovation at the University of Leuven on the basis of publications, citations and prestigious scientific prizes of its members.

<https://www.kuleuven.be/english/> , <https://rega.kuleuven.be/>



RECTOR'S OFFICE



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”


Joint Master Program

The organization: KU Leuven
Status: Associated Partner
Full Address: Oude Markt 13, 3000 Leuven
Country: Belgium
Tel: +32 16 32 40 67
Fax: +32 16 32 41 96
Website: <https://www.kuleuven.be/english/>

I, the undersigned, legal representative of KU Leuven, hereby confirm that our institution, through KU Leuven, Rega Institute, Laboratory of Virology and Chemotherapy, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Molecular Vaccinology and Vaccine Discovery.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
Propose topics for master thesis and internship opportunities (6 months during semester 4), to the students.

Therefore, I confirm that our organization KU Leuven, through Rega Institute, Laboratory of Virology and Chemotherapy strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Kai Dallmeier (Herestraat 49, box 1030; tel. +32 16 379020).



Signature of the Legal representative

Name: prof. L. Sels

Position: Rector

Date: 7/6/2019

Place: Leuven, Belgium



Signature of the contact person

Name: Dr. Kai Dallmeier

Position: Group Leader Molecular Vaccinology and Vaccine Discovery

Date: 17/06/2019

Place: Leuven, Belgium




KU LEUVEN-Rega Institute

Dr. Kai Dallmeier

kai.dallmeier@kuleuven.be

Tel. +32 16 321864



REGA INSTITUTE FOR MEDICAL RESEARCH
DEPARTMENT OF MICROBIOLOGY, IMMUNOLOGY AND
TRANSPLANTATION
HERESTRAAT 49 - BOX 1043
3000 LEUVEN, BELGIË



Prof. Peter Delputte

Associate Coordinator *LIVE International Master in Vaccinology*

LEUVEN Leuven, February 16th 2023

Letter of interest – To whom it will concern

Dear Dr. Delputte

Herewith I would like to express my strong interest to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the Universitat de Barcelona & Universitat Autònoma de Barcelona, Universiteit Antwerpen and the Université Jean Monnet.

In the past years we have regularly been hosting MSc students, participated in lectures and symposia of the LIVE program, and have been impressed and appreciating the high quality of the project. Within the future program, our organization is willing to offer support and expertise in the area of *Experimental Virology and Vaccine Discovery*, mainly by proposing topics for master thesis and internship opportunities to the students enrolled in the program.

I wish the coordinators all the best for the continuation of their ambitious, successful and valuable efforts.

Sincerely yours,



Kai Dallmeier

3.35 Laboratorio Reig Jofre SA



Founded in 1929 in Barcelona, Spain, REIG JOFRE is a pharmaceutical company listed on the Spanish Stock Exchange market, under the ticker RJF, dedicated to the research, development, manufacture and marketing of pharmaceutical products and food supplements.

REIG JOFRE structures its product development activity in three business areas:

- Pharmaceutical Technologies specialized in the development and manufacture of sterile and lyophilized injectable pharmaceutical products, as well as antibiotics derived from penicillin.
- Specialty Pharmacare focused on the research, development, manufacture and commercialization of specialties in the areas of dermatology and osteoarticular, mainly.
- Consumer Healthcare with the line of food supplements marketed under the Forté Pharma brand mostly in France, Belgium, Spain and Portugal, as well as other OTC products.

REIG JOFRE has more than 1,100 employees, 4 development and production centres in Europe (2 in Toledo, 1 in Barcelona and 1 in Sweden), subsidiaries in 8 countries (Spain, France, Portugal, Belgium, Sweden, United Kingdom, Poland, and Singapore) and 155 business partners in more than 70 countries.

<https://reigjofre.com/en/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Laboratorio Reig Jofre S.A.

Status: listed company

Full Address: Gran Capità 10, 08970 Sant Joan Despí (Barcelona)

Country: Spain

Tel: +34934806710

Website: www.reigjofre.com

I, the undersigned, legal representative of Laura Moya Alvarado, hereby confirm that our institution, Laboratorio Reig Jofre S.A., is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of pharmaceutical production, including vaccines.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic by proposing a seminar and a visits to our site to the students
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and welcome and mentoring one student
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology

Therefore, I confirm that our organization Laboratorio Reig Jofre S.A. strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Elisabet Rosell I Vives /Isabel Amat Riera.

Signature of the Legal representative
Name: Laura Moya Alvarado

Position: Corporate HR Director

Date: 11 January 2023

Place: Sant Joan Despí, Barcelona

36531784X Firmado digitalmente por
LAURA 36531784X
MOYA (R: LAURA MOYA (R:
A96184882) A96184882)
A96184882) Fecha: 2023.01.13
13:57:00 +01'00'

Signature of the contact person

Name: Elisabet Rosell I Vives

Position: Head of Biological Sciences

Date: 11 January 2023

Place: Sant Joan Despí, Barcelona

ELISABET Digitally signed
ROSELL by ELISABET
VIVES - DNI ROSELL VIVES -
46323853J DNI 46323853J
Date: 2023.01.14
07:23:39 +01'00'

3.36 LoValTech



LovalTech was created in January 2022, to set a technology platform for the development of next generation vaccines capable to protect the world population against infectious diseases, not or badly covered by the current vaccines.

The situation from the last 2 years with the Covid-19 pandemic, its 6,8 million deaths, 670 million cases and 16 billion doses of vaccines injected, led us to work on an innovative Covid vaccine, knowing that current vaccines are effective and protect against serious forms of the disease, but knowing also that we will only emerge from this global health crisis by stopping the contagiousness and the transmission of the virus and by giving access to vaccination to whole population, especially to low- income countries.

This is why we are committed to carrying out the development of this protein vaccine for nasal administration resulting from BIOMAP research team (University/INRAE-Tours-France) of Professor Isabelle Dimier-Poisson, also Managing Director and CSO of LoValTech.

We took over this project from the end of the preclinical stages which have shown the efficacy of our vaccine candidate on the original virus and its various variants, as well as its ability to stop viral transmission. Our nasal vaccine will be used first as a booster for populations already vaccinated and secondly in first intention for non-vaccinated populations, knowing that we have the desire to put our vaccine available to emerging countries on terms compatible with their income.

We are currently working on the preparation and implementation of the clinical phases in humans, with a target of placing on the market by 2024-2025. This Covid vaccine will clearly be the “proof of concept” for our innovative vaccine technology platform to combat infectious disease outbreaks.

We would like to thank our partners for their support during these preparation phases and their support in the next steps.

Drop the masks and return to life before Covid-19 will be our motto!

<https://lovaltechnology.com/en/editorial/>



Isabelle DIMIER-POISSON
CSO and scientific director of LoValTech
MAME
49, Boulevard Preuilly 37000 – TOURS (France)
☎ : 33 (0)2 26 84 22 39
E.mail : isabelle.dimier@lovaltechnology.com

**Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program**

The organization: LoValTech
Status: SAS SIREN 909405466
Full Address: MAME 49 Boulevard Preuilly 37000 TOURS
Country: France
Tel: +33626842239
Website: <https://lovaltechnology.com>

I, the undersigned, legal representative of LoValTech hereby confirm that our institution, LoValTech, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccinology, mucosal immunology and vaccine development strategies.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization LoValTech strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Isabelle DIMIER-POISSON.

Signature of the Legal representative
Name: Dimier-Poisson Isabelle
Position: CSO and Scientific director
Date: 05/02/2023
Place: Tours - France

Signature of the contact person
Name: Dimier-Poisson Isabelle
Position: CSO and Scientific director
Date: 05/02/2023
Place: Tours, France

Isabelle DIMIER-POISSON

A handwritten signature in blue ink, consisting of a series of loops and a long, sweeping stroke extending upwards and to the right.

3.37 Luxembourg Institute of Health



The Luxembourg Institute of Health (LIH) is a public biomedical research organisation focused on precision health and invested in becoming a leading reference in Europe for the translation of scientific excellence into meaningful benefits for patients.

LIH places the patient at the heart of all its activities, driven by a collective obligation towards society to use knowledge and technology arising from research on patient-derived data to have a direct impact on people's health. Its dedicated teams of multidisciplinary researchers strive for excellence, generating relevant knowledge linked to immune related diseases and cancer.

The institute embraces collaborations, disruptive technology and process innovation as unique opportunities to improve the application of diagnostics and therapeutics with the long-term goal of preventing disease.

LIH aims to perform research that transcends the boundaries of classical disease definition. Its translational and transversal research strategy, combined with the increasing appreciation of the role of the immune system in determining disease, has led LIH to focus on two priority areas, with inflammation and immunity as the common thread: cancer and immunological disorders.

<https://www.lih.lu/>

**Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program**

The organization: Luxembourg Institute of Health (LIH)
Status: public biomedical research organisation
Full Address: 1A-B, rue Thomas Edison, 1445 Strassen
Country: Luxembourg
Tel: + 352 26 970-1
Fax: +352 26970-719
Website: www.lih.lu


I, the undersigned, legal representative of LIH, hereby confirm that our institution, LIH, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monnet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of infection and immunity.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to design the next innovative track of the Master LIVE program, to educate future Data Scientists specialised in applying the latest advances in the fields of big data analytics and machine learning to relevant applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students (local rules for reimbursement apply).
 - Propose complete or partial PhD grant/positions and/or employment opportunities to highly qualified postgraduate LIVE Master students following a competitive selection process, to broaden the employability perspectives of the graduated students.

Therefore, I confirm that our organization LIH strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Prof. Dr. Markus Ollert.



Contact person
Prof. Dr. Markus Ollert
Director of the Department of
Infection and Immunity



Legal representative
Mr Marc Grabowski
CFAO of LIH and IBBL

Luxembourg, 27 February 2019

3.38 Mériex Alliance SA - Institut Mériex



Institut Mériex is contributing its experience in biology to improve medicine and public health across the globe. To fight against infectious diseases and cancer, the Institute imagines and develops new approaches in the fields of diagnostics, immunotherapy, food safety, and nutrition.

Its three bio-industrial companies (bioMérix, Transgene and Mérix NutriSciences), working closely with its entities devoted to innovation (such as ABL Inc. and Mérix Développement), have contributed to major advances in medicine and public health.

Institut Mérix employs 22,000 people around the world and is present in nearly 45 countries, with 4 billion euros in sales.

<http://www.institut-merieux.com/en/home/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: Institut Mérieux
Status: Public company
Full Address: 17 Rue Bourgelat – 69002 Lyon
Country: France
Tel: +33 4 78 87 70 70
Fax: +33 4 78 87 71 20
Website: www.institut-merieux.com

I, the undersigned, legal representative of Institut Mérieux, hereby confirm that our organization, Institut Mérieux, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of infectious diseases.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Propose a complete grant for Master non-EU student (35,000 euros total), not granted through the Erasmus+ grant scheme. The use of this funding (35,000 euros) will be framed by an agreement signed between our institution and UCBL.



Therefore, I confirm that our organization, Institut Mérieux, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Marc BONNEVILLE.

Signature of the Legal representative

Name: Bernard SINOUE

Position: CEO

Date: March 27, 2018

Place: Lyon

A handwritten signature in blue ink, appearing to be 'B. Sinoe', with a long horizontal stroke extending to the right.

Signature of the contact person

Name: Marc BONNEVILLE

Position: Vice President for Medical and Scientific Affairs

Date: March 27, 2018

Place: Lyon

A handwritten signature in blue ink, appearing to be 'M. Bonneville', with a large, stylized loop at the end.

3.39 Mikrobiologický Ústav - AVCR, V.V.I. - Institute of Microbiology of the CAS



The Institute of Microbiology of the CAS represents the largest scientific body extensively exploring life cycles, molecular mechanisms and regulatory systems of various microorganisms such as bacteria, yeast, fungi and algae) as well as mammalian cell lines with respect to basic research questions as well as their prospective practical exploitation in medicine and industry.

The main research interests of our Institute represent cellular and molecular microbiology, genetics and physiology of microorganisms and their resistance to antibiotics, production of microbial metabolites and their biotransformation, and grading up production strains by genetic modifications etc. Another main research direction is embodied by soil ecology, ecotoxicology and microbial degradation of organic pollutants in the natural environment. An immunological section of the Institute then studies the importance of microorganisms in phylogenetic and ontogenetic acquisition of immunity as well as during the onset of autoimmune diseases and, last but not least, it is also focused on immunotherapies of oncogenic diseases.

Institute of Microbiology of the CAS has an internationally recognized collection of basidiomycetes and its own biotechnological unit, which is mainly used to monitor microbiological and biotechnological processes at a semi-operational scale.

IM CAS has three satellite working units outside of Prague; the first of which is in Trebon (research on phototrophic microorganisms) the second is in Nový Hrádek (gnatobiology) and third is in Nove Hrády (Center for Nanobiology and Structural Biology).

Despite the fact that the Institute of Microbiology of the CAS is preferentially focused on the basic research, many of its outputs find or will find practical use in pharmaceutical as well as biotechnological industry as documented by a genuine interest of a number of private companies in our scientific work.

<http://mbucas.cz/en/>



Mikrobiologický ústav AV ČR, v.v.i.

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: **MIKROBIOLOGICKÝ ÚSTAV AV ČR, v.v.i.**
 Status: Public research institution founded by according to Czech Act No. 341/2005 Coll.
 Full Address: Vídeňská 1083, 142 20 Praha 4
 Country: Czech Republic
 Tel: +420 241 062 341
 Fax: +420 296 442 201
 Website: <http://mbucas.cz/en/>

I, the undersigned, legal representative of Institute of Microbiology of the CAS, v.v.i., hereby confirm that our institution, **MIKROBIOLOGICKÝ ÚSTAV AV ČR, v.v.i.**, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).


- 1) Within the program, our organization will offer support and expertise in the area of pertussis vaccine development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students

Therefore, I confirm that our organization, **MIKROBIOLOGICKÝ ÚSTAV AV ČR, v.v.i.**, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Prof. Peter Šebo

Signature of the Legal representative
 Name: Dr. Jiří Hašek
 Position: director
 Date: February 2, 2018
 Place: Prague



Signature of the contact person
 Name: Prof. Peter Šebo
 Position: Head of Laboratory
 Date: February 2, 2018
 Place: Prague



Vídeňská 1083, CZ-142 20 PRAHA - 4 Krč IČO: 61388971 DIČ: CZ61388971
 Tel.: +420 241 062 762 fax: +420 241 062 342 e-mail: mbu@biomed.cas.cz
<http://mbucas.cz>

3.40 Ministerio de Salud Publica



GUILLERMO LASSO
PRESIDENTE

The Ministry of Public Health is the National Health Authority that guarantees the right to health of the population in Ecuadorian territory, through governance, health promotion, disease prevention, surveillance, quality, research and provision of integrated and comprehensive care services.

The Ministry of Public Health, as the governing body, will be the reference institution for the entire National Health System, guaranteeing quality, inclusive and equitable health care, with an emphasis on health promotion and disease prevention for the full development of opportunities for the population.

<https://www.salud.gob.ec/>



Request to form National Immunization Director Teams, sent by the state: ECUADOR

De : Jacinto Esteban Bonilla Escobar <esteban.bonilla@msh.gob.ec>

Envoyé : lundi 28 novembre 2022 23:12

À : mylive@univ-lyon1.fr

Cc : Punt d'Informació <informacio@uab.cat>

Objet : Solicitud de información

Saludos.

Mi nombre es Esteban Bonilla, Director Nacional de Inmunizaciones del Ministerio de Salud Pública del Ecuador. Quisiera saber si se puede abrir una cohorte específica para un grupo de 10 a 15 personas, quizá con algún descuento o becas parciales. Los y las asistentes son responsables de inmunizaciones en las provincias del Ecuador y también del nivel nacional.

Muchas gracias.

Atentamente,

--

Esteban Bonilla

MSP-INMUNIZACIONES

Sr. Mgs. Jacinto Esteban Bonilla Escobar Especialista de Enfermedades Infecciosas con Potencial Epidémico y Pandémico 1

Ministerio de Salud Pública (MSP) Viceministerio de Gobernanza y Vigilancia de la Salud

GERENTE INSTITUCIONAL DE LA GESTIÓN DEL PLAN NACIONAL DE VACUNACIÓN

----- Translation

Greetings.

My name is Esteban Bonilla, National Director of Immunizations of the Ministry of Public Health of Ecuador. I would like to know if a specific cohort could be opened for a group of 10 to 15 people, perhaps with a discount or partial scholarships. The assistants are responsible for immunizations in the provinces of Ecuador and at the national level.

Thank you so much.

Sincerely,

--

Stephen Bonilla

MSP-IMMUNIZATIONS

Mr. Mgs. Jacinto Esteban Bonilla Escobar Specialist in Infectious Diseases with Epidemic and Pandemic Potential 1

Ministry of Public Health (MSP) Vice Ministry of Governance and Health Surveillance

INSTITUTIONAL MANAGER OF THE MANAGEMENT OF THE NATIONAL VACCINATION PLAN

3.41 Moderna Therapeutics



Moderna, Inc (formerly ModeRNA Therapeutics until 2018) is an American biotechnology company, founded in 2010 and based in Cambridge, Massachusetts, that aims to develop "protein therapies" based on messenger ribonucleic acid (messenger RNA) technology.

Our mission is to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. An mRNA can **teach the body** how to make a specific protein that can help your immune system prevent or treat certain **diseases**. Messenger RNA is not new technology, but we are discovering new ways to use it to treat and prevent illnesses and diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform.

In 2010, Moderna's name combines the words "modified" and "RNA", which happens to contain the word "modern". In 2011, Moderna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO. In 2014, New headquarters and labs open in Cambridge, Massachusetts. In 2015, Moderna initiates first-in-human dose of an mRNA vaccine (mRNA-1440), an H10N8 flu vaccine candidate. In 2016, Lease signed to build 200,000 sq ft GMP mRNA clinical manufacturing facility in Norwood, MA. In 2017, Moderna initiates first-in-human dosing for mRNA-1653, a combination vaccine with the potential to protect against more than one disease – human metapneumovirus (hMPV virus) and parainfluenza virus. In 2018, Moderna opens its state-of-the-art clinical development site in Norwood, MA. In 2019, Moderna announces dosing of the first antibody encoded by mRNA in a clinical trial. In 2020, The U.S. Centers for Disease Control and Prevention votes to recommend the use of the Moderna COVID-19 vaccine in people 18 years of age and older in the U.S. In 2022, The U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SPIKEVAX (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 18 years of age and older in the U.S.

<https://www.modernatx.com/>

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: ModernaTX, Inc.
Full Address: 200 Tech Square, Cambridge, MA 02139
Country: United States of America
Website: modernatx.com

I, the undersigned, legal representative of ModernaTX, Inc. (“Moderna”) hereby confirm that our institution is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of mRNA science.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of non-proprietary knowledge and skills from the industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate scientists with a vaccinology degree in order to create efficient data scientists in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students
 - *OTHER: Moderna will support the program in 2 ways:*



200 Tech Square • Cambridge, MA 02139
phone 617-714-6500 • fax 617-583-1998

1. *Offering internship opportunities to students in 2024. Moderna will hire up to 2 qualified interns that the company is able to sponsor to learn and work at Moderna in the United States under immigration guidelines*
2. *Moderna will offer industry speakers to speak with the students while in the program on chosen scientific topics. Therefore, I confirm that our organization Moderna supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Alesandra T. McLean, contact information below.*

Alesandra T. McLean

Signature

Name: Alesandra T. McLean

Position: Associate Director, Global University and Campus Programs

Date: February 10, 2023

Place: Cambridge, MA USA

3.42 MSD Vaccins – Pôle France



MSD is a global pharmaceutical company providing innovative healthcare solutions through its prescription medicines (mainly in oncology and infectious diseases), vaccines and animal health products.

For 130 years, MSD has been inventing for life, developing medicines and vaccines for many of the world's most challenging diseases as part of our mission to save and improve lives. We demonstrate our commitment to patients and population health by improving access to healthcare through far-reaching policies, programmes and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the world's leading research-based biopharmaceutical company.

Number of employees worldwide: about 74 000 – Number of employees in France: about 950

<https://www.msd-france.com/>



MSD Vaccins
S.A.S. au capital de 3.394.526,25 €
162, avenue Jean Jaurès
CS 50712
69367 Lyon cedex 07
Tél. : 04 37 28 40 00

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: MSD Vaccins
Status: company
Full Address: 162 Avenue Jean Jaures 69007 LYON
Country: FRANCE
Tel: 04 37 28 40 00
Website: www.msd.com

I, the undersigned, legal representative of MSD Vaccins, hereby confirm that our institution, MSD Vaccins, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccines and Vaccinology.
- 2) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis



MSD Vaccins
S.A.S. au capital de 3.394.526,25 €
162, avenue Jean Jaurès
CS 50712
69367 Lyon cedex 07
Tél. : 04 37 28 40 00

- Therefore, I confirm that our organization MSD Vaccins strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Rosybel Drury.

Signature of the Legal representative

Name: RUAULT Agnès

Position: Human Ressources Business Partners

Date: 01/12 /2020

Place: Lyon, France



Signature of the contact person

Name: Dr Rosybel Drury, PhD Position: Global Director, Medical Affairs

Date: 01 December 2020

Place: Lyon, France

3.43 National University of Life and Environmental Sciences of Ukraine*Faculty of Veterinary Medicine



The Faculty of Veterinary Medicine of National University of Life and Environmental Sciences of Ukraine carries out training of specialists in the field of "Veterinary Medicine" for the agro-industrial complex of Ukraine. Currently, the training is carried out in the educational degrees "Bachelor" and "Master". For now more than 1300 students study at the faculty. The Faculty of Veterinary Medicine is a scientific and methodological center of veterinary education for future students of this profile in Ukraine. Regular sessions of the scientific-methodical Commission of the Ministry of Agrarian Policy of Ukraine on the specialty "Veterinary Medicine", different scientific conferences, symposiums, meetings of a national and international character are held in our university.

<https://nubip.edu.ua/en/node/1662>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: National University of Life and Environmental Sciences of Ukraine, Faculty of Veterinary Medicine

Status: National University

Full Address: Heroyiv Oborony 15, Kyiv, 03041

Country: Ukraine

Tel: +38 (044) 527-82-42

Fax: +38 (044) 527-82-42

Website: www.nubip.edu.ua

I, the undersigned, legal representative of National University of Life and Environmental Sciences of Ukraine, Faculty of Veterinary Medicine, hereby confirm that our institution, National University of Life and Environmental Sciences of Ukraine, Faculty of Veterinary Medicine, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monnet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of International Vaccinology Education.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose short summer internships to the students (internships with our Faculty partners such as Ukrainian Laboratory of Quality and Safety of Agricultural Products which is part of our University, Institute of Veterinary Medicine, Bio-Test Laboratory, State Research Institute



for Laboratory Diagnostics and Veterinary and Sanitary Expertise, State Scientific-Control Institute of Biotechnology and Strains of Microorganisms. All these institutions are situated in Kyiv) or in some cases topics for master thesis and internship opportunities.

- Propose management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives.

Therefore, I confirm that our organization National University of Life and Environmental Sciences of Ukraine, Faculty of Veterinary Medicine strongly supports this LIVE Master program. The contact persons appointed to represent our company in the LIVE master will be Vadym Tkachuk, Vice-Rector for Scientific and Pedagogical Work, International Activity and Development of the National University of Life and Environmental Sciences of Ukraine; Vitalii Nedosekov, Head of the Department of Epizootology and Veterinary Business organization, Faculty of Veterinary Medicine National University of Life and Environmental Sciences of Ukraine and Maryna Galat, Coordinator of International Programs of the Faculty of Veterinary Medicine.

Signature of the Legal representative:

Name: Stanislav Nikolaienko



Position: Rector, National University of Life and Environmental Sciences of Ukraine

Date: 30/01/2019

Place: Kyiv, Ukraine

Signatures of the contact persons:

Contact person

Name: Vadym Tkachuk

Position: Vice-Rector for Scientific and Pedagogical Work, International Activity and Development of the National University of Life and Environmental Sciences of Ukraine

Date: 30/01/2019

Place: Kyiv, Ukraine

Additional contact persons

Name: Vitalii Nedosekov

Position: Chief of the Department of Epizootology and Veterinary Business Organization, Faculty of Veterinary Medicine National University of Life and Environmental Sciences of Ukraine

Date: 30/01/2019

Place: Kyiv, Ukraine

Name: Maryna Galat

Position: Coordinator of International Programs of the Faculty of Veterinary Medicine

Date: 30/01/2019

Place: Kyiv, Ukraine

3.44 Sanofi Pasteur SA

sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi's global vaccines business unit partners with the public health, medical and scientific communities to improve access to life-protecting vaccines and increase vaccination coverage, while striving to develop new and improved vaccines to enhance health and well-being.

Sanofi is listed on Euronext: SAN and NASDAQ: SNY

<https://www.sanofi.com/>



Letter of Support
The LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: Sanofi Pasteur SA
Status: Company
Full Address: 14 Espace Henry Vallée - 69007 Lyon
Country: France
Tel: +33 (0)4 37 37 01 00
Fax: +33 (0)4 37 37 77 37
Website: <https://www.sanofi.com/>

On behalf of Thomas Triomphe, Head of SANOFI PASTEUR, I, the undersigned, Paul-Alan Dollinger, hereby confirm that our company, SANOFI PASTEUR, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of vaccinology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.,) to the students
 - contribute to design the next innovative track of the Master LIVE,
 - propose topics for master thesis and internship opportunities (6 months during semester 4),
 - propose support for Master students, not granted through the Erasmus+ grant scheme, or propose funding support to the Master program organization and management, thereby contributing to the development strategy of the program, in particular its sustainability and enlargement perspectives. The use of this funding (9k€ in 2023) will be framed by a financial agreement signed between our institution and UCBL.

Therefore, I confirm that our company SANOFI PASTEUR, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Isabelle FUGIER.

Signature of the Legal representative
Name: *Paul-Alan Dollinger*
Position: *Directeur Général Délégué Sanofi Vaccins*
Date: January 12, 2023
Place: Lyon, Headquarters



Signature of the contact person
Name: *Isabelle Fugier*
Position: *Head Vaccines R&D Partnerships & Stakeholders Engagement in France*
Date: January 12, 2023
Place: Marcy l'Etoile



This letter of support is a non-binding document for Sanofi Pasteur. Any commitment by Sanofi Pasteur in this project must be the subject of a separate written agreement.

3.45 Société d'Exploitation de Produits Pour les Industries Chimiques SEPPIC



Seppic, an Air Liquide Healthcare company, has been a subsidiary of the Air Liquide Group since 1986. For over 75 years, Seppic has developed, manufactured, and marketed unique ingredients for cosmetic, nutraceutical, pharmaceutical, veterinary, and industrial products. Across the world, Seppic has created a vast team of women and men who love what they do in service to their customers, and to the health, well-being, and beauty of all. Seppic has 770 employees in 14 countries, 6 000 customers in 100 countries, 80 distributors, 5 production sites and 5 customer technical service centers.

<https://www.seppic.com/en>



SEPPIC PARIS

50 Boulevard National
92257 La Garenne
Colombes cedex
FRANCE
+33 (0)1 42 91 40 00
+33 (0)1 42 91 41 41

www.seppic.com

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Seppic

Status: SA

Full Address: 50 Bd national, 92250 La Garenne-Colombes

Country: France

PIC number : 891994444

Website: <https://www.seppic.com/en>

I, the undersigned, legal representative of Séverine LAFON, hereby confirm that our institution, Seppic, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccine Adjuvants.
- 2) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, case studies, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Propose internship opportunities (6 months during semester 4)
 - Participate in networking events with students

Therefore, I confirm that our organization Seppic strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Juliette BEN AROUS.

DocuSign Envelope ID: DAD06692-E906-4D84-B4A5-BF523B594846



Signature of the Legal representative

Name: LAFON Séverine

Position: Human Resources Director

Date: 03/01/2023

Place: La Garenne Colombes

DocuSigned by:

84ADF986593B4CA...

Signature of the contact person

Name: BEN AROUS Juliette

Position: Marketing Director - Human and Animal Health Ingredients

Date: 03/01/2023

Place: La Garenne Colombes

DocuSigned by:

0E37255120D14B0...

3.46 Speransa Therapeutics



Speransa Therapeutics is a clinical-stage Biotech with a Focus on COVID-19 Vaccine Development

Located at the heart of Frankfurt am Main, Speransa Therapeutics is led by a dedicated and highly-specialized team, with a strong background in biopharmaceutical research, development and manufacturing. The Company is backed by the Boehringer Ingelheim Venture Fund and partners with leading academic institutions such as the University Hospital Tübingen.

Prime-2-CoV_Beta, our lead COVID-19 vaccine candidate, was originally developed at the University of Tübingen, Germany. It is based on a highly attenuated and non-pathogenic live viral vector D1701-VrV derived from an ORF virus isolate. Used for 20 years in biomedical research and veterinary medicine, this vector has highly beneficial characteristics for the development of a COVID-19 vaccine.

<https://www.speransatherapeutics.com/>



Letter of Commitment

Speransa Therapeutics GmbH TowerOne (Spaces), Bruesseler Strasse 1-3, 60327 Frankfurt am Main, Germany

Letter of Commitment
To support the LIVE – “Leading International Vaccinology Education”
Joint Master Program

The organization: Speransa Therapeutics GmbH (“Speransa Therapeutics”)
Status: Clinical Stage Biotech
Full Address: TowerOne (Spaces), Bruesseler Strasse 1-3, 60327 Frankfurt am Main
Country: Germany
Website: www.speransatherapeutics.com

wI, the undersigned, legal representative of Speransa Therapeutics, hereby confirm that our institution, Speransa Therapeutics, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

Within the program, our organization will offer support and expertise in the area of prophylactic vaccine development.

In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.

Our organization also commits to:

1. contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
2. contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology as needed
3. propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.

Therefore, I confirm that our organization Speransa Therapeutics strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Madiha Derouazi.

--- signatures on following page ---

DocuSign Envelope ID: A022E8A6-9E94-4896-B9E4-94AFD94CDF98



DocuSigned by:

24AF2BA88E6D453

Signature of the Legal representative

Name: Florian Jope

Date: 30-Jan-2023 | 14:41 MEZ

Place: Frankfurt am Main

DocuSigned by:

3800862410D3405

Signature of the contact person

Name: Madiha Derouazi

Date: 30-Jan-2023 | 16:11 CET

Place: Frankfurt am Main

3.47 SPHERE CNRS



The Sphère unit (Sciences, Philosophy, History) UMR7219 was created in 2009 from the meeting of two units: the CHSPAM (Centre of History of Sciences and Arab and Medieval Philosophies, former UMR 7062), created in 1972, and REHSEIS (Epistemological and Historical Researches on

Exact Sciences and Scientific Institutions, former UMR 7596), created in 1984. This meeting concretizes the proximity and the complementarity of the scientific programs of these two units, whose works relate to a long duration ranging from the antiquity to the contemporary period, in different cultural contexts.

The unit includes, on a principal assignment, research professors from two university departments (Paris 1 and Université Paris Cité, previously from Paris, Paris Diderot, and Paris 7) and, as associates, a large number of research professors from other universities and institutions. This integration into the world of teaching is essential for the development of our activities.

We conceive our research as part of an international framework. SPHERE maintains links with researchers from all over the world, whose orientations vary considerably. It has the will to be an international place of exchange in the fields it gathers. This is evidenced by its involvement in the creation and animation of several international societies, the direction of international journals, cooperation agreements with foreign institutions, as well as the publications of its members.

The researchers of the Unit teach, and they do so at the most diverse academic levels. We welcome many French and foreign students for internships, and we strive to convince our students of the importance of international research integration. By encouraging them to do so, we give them the means to integrate the national and international scientific community.

<http://www.sphere.univ-paris-diderot.fr/?lang=en>

|

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: SPHERE

I, the undersigned, legal representative of SPHERE hereby confirm that our institution, SPHERE, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Social Sciences and Medicine in Vaccinology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - ***OTHER: contribute to the teaching for the students and to the students' control processes at the end of the teaching***
 - Therefore, I confirm that our organization SPHERE strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Anne Marie Moulin


Signature of the Legal representative

Name: Cristina Cerami

Position: Directrice de l'UMR SPHERE

Date : 16/02/2023

Place: Paris



Signature of the contact person

Name: Anne Marie Moulin

Position: Directrice de recherche émérite

Date: 10 Février 2023

Place: Paris

Anne Marie Moulin,

Directrice de recherche émérite,
UMR SPHERE/ CNRS/Paris-Cité

AM Moulin

3.48 Stichting TuBerculosis Vaccine Initiative TBVI



TuBerculosis Vaccine Initiative

The TuBerculosis Vaccine Initiative (TBVI) is a Research and Innovation partnership that facilitates the discovery and development of new, safe and effective TB vaccines that are accessible and affordable for all people.

As a non-profit foundation, TBVI creates an enabling environment for TB vaccine research and innovation (R&I) and product development. TBVI supports R&D partners to develop and move the most promising TB vaccine and biomarker candidates through the pipeline. To continue to innovate and diversify the pipeline and TB vaccine platforms, TBVI supports collaborative research and innovation by its R&D partners. TBVI adds value through providing services of technical advice for product development; project identification, development and management; and resource mobilisation. TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to strengthen Global and European cooperation and coordination and identifies gaps to move the field forward.

To make decisions to select/down select vaccine candidates in an objective and transparent manner and to use the available financial resources effectively, TBVI assesses and manages its portfolio based on criteria in its TB Vaccine Development Pathway tool. It seeks to align its R&I activities with other global efforts, in particular with Global partners in the Global TB Vaccine Partnership (GTBVP).

TBVI does not have its own commercial interests. Ownership of vaccine candidates and biomarkers, and any intellectual property rights remain with researchers and vaccine developers. This enables TBVI to be a neutral and honest broker among its R&D partners, global stakeholders and funders.

Access and affordability of TB vaccines is a statutory objective of TBVI and is a commitment that is part of each project grant agreement supported by TBVI. TBVI and its R&D partners have developed over 50% of the current candidates in the TB vaccine pipeline

TBVI's work focusses on:

- product development – moving current leading TB vaccine and biomarker candidates and fast followers through the pipeline
- collaborative research and innovation – continuing to innovate and diversify the TB vaccine and biomarker pipeline and TB vaccine platforms; develop and test alternative vaccine routes and delivery mechanisms; develop and validate pre-clinical models; develop human challenge models; develop next generation portfolio management tools; and harness the power of AI for TB vaccine and biomarker research and clinical trials.
- Global and European Cooperation and Coordination of TB vaccine R&I efforts, including identifying and addressing key gaps to move the TB vaccine R&I field forward.

<https://www.tbvi.eu/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: TBVI
Status: Not-for-profit
Full Address: Runderweg 6, 8219 PK, Lelystad
Country: The Netherlands
Tel: +310320 277550
Website: www.tbvi.eu

I, the undersigned, legal representative of TBVI, hereby confirm that our institution, TBVI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

1. Within the program, our organization will offer support and expertise in the area of tuberculosis vaccines R&D and the vaccine development pathway. This could include lectures to the students or contribution to the development of a Massive Open Online Course on Vaccinology.
2. Our organization will contribute to the overall promotion and implementation of the program.
3. Our organization could contribute to introducing students to the TB R&D community. This could include proposing topics for master thesis and providing internship/postgraduate opportunities in the field of tuberculosis.
4. Our organization will provide input for future grant applications to the EU.

Therefore, I confirm that our organization TBVI strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Elly van Riet.

Kind regards,

Signature of the legal representative



Name: Nick Drager
Position: Executive Director
Date: 25 October 2022

Signature of the contact person



Name: Elly van Riet
Position: Sr. Scientist
Date: 25 October 2022

3.49 THE Chancellor, Masters and Scholars of the University of Oxford - The Jenner Institute



The Jenner Institute is based within the Nuffield Department of Medicine, University of Oxford, and operates out of the Old Road Campus Research Building, in Headington, Oxford. It was formed in November 2005 through a partnership between the University of Oxford and the UK Institute for Animal Health. It is associated with the Nuffield Department of Medicine, in the Medical Sciences Division of Oxford University. The institute develops vaccines and

carries out clinical trials for diseases including malaria, tuberculosis (vaccine MVA85A), ebola, and MERS-Coronavirus. The Jenner Institute also supports senior vaccine scientists, known as Jenner Investigators, within many other departments across the University of Oxford, as well as externally within The Pirbright Institute and the Animal and Plant Health Agency. The Jenner Institute brings together investigators who are designing and developing numerous vaccines to generate an exceptional breadth of scientific know-how and critical mass, whilst still allowing the individual investigators to remain independent and accountable to their funders and stakeholders.

The Jenner Institute is supported by the Jenner Vaccine Foundation, a UK registered charity and is advised by the Jenner Institute Scientific Advisory Board.

In 2020, the institute successfully developed the Oxford–AstraZeneca COVID-19 vaccine, in a project backed by private companies including Oxford Sciences Innovation, Google Ventures, and Sequoia Capital, among others.

<https://www.jenner.ac.uk/>

THE JENNER INSTITUTE

Old Road Campus Research Building
Roosevelt Drive
Oxford OX3 7DQ
UK
+44 (0)1865 617600
www.jenner.ac.uk/



8 September 2022

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: Jenner Institute, University of Oxford
Status: Not for Profit
Full Address: ORCRB, Roosevelt Drive, Oxford, OX3 7DQ
Country: UK
Tel: +44 1865 617613
Website: www.jenner.ac.uk

I, the undersigned, legal representative of the Jenner Institute, hereby confirm that our institution, The Jenner Institute, University of Oxford, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccinology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students.
 - Contribute to the MOOC development related to vaccinology.
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.

THE JENNER INSTITUTE

Old Road Campus Research Building
Roosevelt Drive
Oxford OX3 7DQ
UK
+44 (0)1865 617600
www.jenner.ac.uk/



- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- Propose complete or partial PhD positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students.

Therefore, I confirm that our organization, The Jenner Institute, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr Anita Milicic.

Signature of the Legal representative



Name: Gary Strickland
Position: Business Manager
Date: 8 Sep 2022
Place: Oxford, UK

Signature of the contact person



Name: Anita Milicic
Position: Group Leader
Date: 8 Sep 2022
Place: Oxford, UK

3.50 The Pirbright Institute LBG



We are a world leading centre of excellence in research and surveillance of viral diseases of farm animals and viruses that spread from animals to humans. We receive strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), and work to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience. The Institute employs around 450 staff, research students and

visiting scientists, and has recently moved to one campus in Pirbright, Surrey, where investment by BBSRC has resulted in a redevelopment of the site and the construction of a high-level containment facility – the BBSRC National Virology Centre: The Plowright Building and a SAPO level two facility, The Jenner Building.

Our work has a huge impact both nationally and internationally as we fulfil our mission to be the world's leading innovative centre for preventing and controlling viral diseases of livestock. We play a crucial role in protecting UK livestock from viruses that have huge socio-economic impact with a unique combination of fundamental research and applied science in diagnostics and control.

The Institute is home to Reference Laboratories that focus on surveillance of viruses that are not endemic, but pose a threat to the UK. These include foot-and-mouth disease virus (FMDV) and bluetongue virus (BTV). We provide the UK with its capability to monitor current and future threats from exotic viruses, to inform national and international government and non-governmental agencies, and to lead with efforts to best control exotic viruses if and when they arrive in the UK.

<https://www.pirbright.ac.uk/our-science/impact-our-research>

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Programme

The organisation: The Pirbright Institute
Status: VALIDATED.
Not for profit charity limited by guarantee
Full Address: Ash Road, Pirbright, Woking, Surrey, GU24 0NF
Country: UK Tel: +44 (0)1483 232441 Fax: +44(0)1483 232448
Website: www.pirbright.ac.uk


I, the undersigned, legal representative of The Pirbright Institute, hereby confirm that our institution, The Pirbright Institute, is willing to support the LIVE Master programme coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the programme, our organisation will offer support and expertise in the area of Veterinary Virology research projects.
- 2) Our organisation also commits to:
 - Propose topics for master thesis and internship opportunities (6 months during semester 4),
 - Accept up to two self-funding students for 6-month research projects in any one academic year
 - Review the number of students accepted on an annual basis with the LIVE Master programme.

Therefore, I confirm that our organisation The Pirbright Institute strongly supports this LIVE Master programme. The contact person appointed to represent our company in the LIVE master will be Dr Tamara Jabbar (Head of Education).



Signature of the legal representation
Name: Helen Watts
Position: Director of Finance and Company Secretary
Date: 16.02.2023
Place: Pirbright, Woking, Surrey, UK



Signature of the contact person
Name: Tamara Jabbar
Position: Head of Education
Date: 16.02.2023
Place: Pirbright, Woking, Surrey, UK

The Pirbright Institute

3.51 Transgene SA



Transgene is a clinical-stage biotechnology company focused on designing and developing novel immunotherapeutics. Every day, we push the boundaries of innovation with our therapeutic vaccines and oncolytic viruses, to design better treatments for patients.

A pioneer in viral vectors engineering, we have one ambition: design innovative treatments in the fight against cancer. Our approach uses the mechanisms of the immune response to enable the patient's body to fight against disease.

<https://www.transgene.fr/en/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: TRANSGENE

Status: French corporation (“société anonyme”).

Full Address: 400 boulevard Gonthier d’Andernach, 67405 Illkirch Graffenstaden

Country: France

Tel: + 33 3 88 27 91 00

Website: <http://www.transgene.fr>

I, the undersigned, legal representative of Eric Quemeneur, hereby confirm that our institution, Transgene, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of oncology and immunotherapy.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I confirm that our organization Transgene strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Gaëlle STANDTLER.

DocuSign Envelope ID: 14175DF7-E0F6-4481-BBC0-3DA091389218



Signature of the Legal representative

Name: Eric QUEMENEUR

Position: Executive VP and VP, R&D

Date: 08/02/2023

Place: Illkirch

DocuSigned by:
Eric QUEMENEUR
E73CA69037C8409...

Signature of the contact person

Name: Gaëlle STANDTLER

Position: HRD

Date: 09/02/2023

Place: Illkirch

DocuSigned by:
Gaëlle Stadler
F6FED78FC70A45...

3.52 TRON – Translationale Onkologie Ander Universität Smedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige GMBH



TRON is an independent non-profit translational research organization. We pursue new diagnostics and drugs for the treatment of diseases with high medical need. We apply our transdisciplinary competencies in genomics and immunology to develop novel platforms for the identification and validation of 'omics'-based biomarkers, to modulate immune system components for use in personalized therapies. Collaborating with academia and industry, TRON executes research at the leading edge to support innovative drug design for human health. TRON's mission is to bridge the gap between fundamental science at universities and market-oriented research in the pharmaceutical industry. We turn innovative scientific concepts into treatments ready for clinical testing, thereby accelerating the translation of discoveries into progress for patients.

Translating scientific concepts into clinical applications is a major contemporary challenge in health care. Expiring patents, empty pipelines and the increasing complexity of product development in the era of individualized medicine mean that even large pharmaceutical companies cannot address these challenges alone. At the same time, increasing regulatory requirements and costs have seen public research organizations virtually suspend the clinical translation of new scientific insight. Here in Mainz, we believe mastering these challenges is possible through cooperation between our first-rate research institute and private companies specializing in innovative product development.

TRON was founded in 2010 as a non-profit limited liability company to address these challenges. Co-founders Ugur Sahin, Christoph Huber and Özlem Türeci's vision for TRON is to facilitate clinical translation of innovative science by interfacing between public and private stakeholders and bridging the gap between research insight and mature product development.

<https://tron-mainz.de/>



 [TRON gGmbH, Freiligrathstraße 12, D-55131 Mainz](#)

Pr Christine DELPRAT
LIVE Master program
Université Claude Bernard Lyon 1
Direction des Relations Internationales
Batiment principal - domaine de Rockefeller
8 avenue Rockefeller
69373 LYON Cedex 08
FRANCE

TRON gGmbH
Freiligrathstraße 12
D - 55131 Mainz

Dr. Andrée Rothermel
Managing Director
Tel.: +49 (0) 6131 / 2161 – 420
Fax: +49 (0) 6131 / 2161 – 100

andree.rothermel@tron-mainz.de
www.tron-mainz.de

Mainz, December 15, 2022

Letter of Commitment to support the LIVE – “Leading International Vaccinology Education” Joint Master Program

We, the undersigned, legal representative of TRON gGmbH, hereby confirm that we are willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, we will offer support and expertise in the area of mRNA vaccines against cancer, infectious diseases and autoimmune diseases as well as in bioinformatics.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement, which we hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills by proposing seminars or lectures to the students
 - propose internship opportunities (6 months during semester 4) to the students

Therefore, we confirm that TRON strongly supports this LIVE Master program.

The contact person appointed to represent our company in the LIVE master will be Dr. Nina Lölies.

Sincerely yours,



Dr. Andrée Rothermel
Managing Director



Michael Föhlings
Managing Director

Seite 1/1

3.53 Universidade de São Paulo



USP, as the major institution of higher learning and research in Brazil, is responsible for educating a large part of Brazilian Masters and Ph.D's.

The University of São Paulo (USP) is a public

university, maintained by the State of São Paulo and affiliated with the State Secretariat of Economic, Scientific and Technological Development. Various world rankings, created to measure the quality of universities according to various criteria, particularly those related to scientific productivity, have widely recognized the talent and dedication of USP professors, students and employees

USP offers courses in **all areas of knowledge**. In addition to the undergraduate, master's and doctorate courses, all free, the University also offers specializations, residences and free courses for all audiences. Since its foundation in 1934, USP has played a fundamental role in advancing research in the country, whether in the scientific, technological or social field, thanks to the work done by its students, employees and teachers. Currently, USP is responsible for more than 20% of all scientific production in Brazil.

USP is a Partner of the Butantan Institute, the major vaccine manufacturer of Brazil, which is an associated Partner of the LIVE.

<https://www5.usp.br/>



Gabinete do Diretor

Cidade Universitária "Armando de Salles Oliveira", Butantã, São Paulo, SP - Av. Professor Lineu Prestes, 2415 - ICB III - 05508-000
 Telefone (11) 3091-7438 / (11) 3091-8405 / (11) 3091-8494

February, 2nd 2018

The organization: University of São Paulo

Status: Active (PIC number 999844379)

Full Address: Av. Prof. Lineu Prestes, 1374

Country: Brazil

Tel: +5511-3091-7338

Fax: +5511-3091-7354

Website: <https://ww2.icb.usp.br/icb/>

I, the undersigned, legal representative of the Institute of Biomedical Sciences, hereby confirm that our organization, University of São Paulo, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Immunology and Vaccine Development.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating to the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to :
 - Contribute to transfer of knowledge and skills from industrial world to academic
 - Contribute to the MOOC development related to vaccinology
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.



- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students
- *OTHER: organization of a discipline in immunology and vaccinology to be offered to students engaged in the program and laboratory training in laboratories presently working with vaccine development at the University of São Paulo*
- Therefore, I confirm that our organization University of São Paulo strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE master will be Gustavo Amarantes-Mendes.

Therefore, I confirm that our organization, University of São Paulo, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Luis Carlos Ferreira.

Signature of the Legal representative

Name: Luís Carlos de Souza Ferreira

Position: Present Dean in activity of the Institute of Biomedical Sciences

Date: February, 2nd 2018

Place: São Paulo


 Prof. Dr. Luis Carlos de Souza Ferreira
 Diretor
 Instituto de Ciências Biomédicas - USP

3.54 Università Degli Studi di Firenze - UniFi



The University of Florence is an important and influential centre for research and higher training in Italy, with 1,800 lecturers and internal research staff, 1,600 technical and administrative staff, and over 1,600 research assistants and doctoral students.

It offers a wide range of study programmes at various levels and in all areas of knowledge.

Over 140 Degree courses (First and Second Cycle, corresponding to Bachelor's and Master's Degrees) organised in 10 Schools, with a population of about 51,000 enrolled students, one-fourth of which come from outside of Tuscany. There are over 9,000 degrees awarded each year in Florence. According to the alumni data, the percentage of students who are in the workforce one year after their First Level degree is above national average.

The University of Florence has a natural international vocation and the development of internationalization is one of its strategic priorities. It is one of the largest and most productive public research systems in Italy. This result is accomplished thanks to the number of permanent and temporary researchers working in a wide range of disciplinary and scientific fields, and the numerous junior scientists in training. It is also due to an intensive participation in research programmes of national and international relevance and to the significant scientific results achieved. External funds support the research and knowledge transfer activities. This combination of factors qualifies the Florentine institution as a modern research university and accounts for its excellent position in national and world rankings. Researchers at the University of Florence operate within 21 different departments and have at their disposal approximately 40 research structures comprising inter-departmental and inter-university centres as well as specialised research, knowledge transfer and advanced training centres.

In recent years the University of Florence has increasingly consolidated its ventures in the field of knowledge transfer: from the filing of patents to the setting up of joint workshops with businesses, through to participation in spin-off companies.

Knowledge transfer activities are coordinated by CSAVRI (Centro di Servizi di Ateneo per la Valorizzazione della Ricerca e la gestione dell'Incubatore universitario), the centre for the enhancement of research and management of the university's incubator.

<https://www.unifi.it/changelang-eng.html>



UNIVERSITÀ
DEGLI STUDI
FIRENZE

DIPARTIMENTO DI
MEDICINA SPERIMENTALE
E CLINICA

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Department of Experimental and Clinical Medicine

Status: academic

Full Address: Largo Brambilla 3, 50134 Firenze

Country: Italy

Tel: + 39 055 2758020

Fax: + 39 055 2758021

Website: <https://www.dmsc.unifi.it/>

I, the undersigned, legal representative of the Department of Experimental and Clinical Medicine- University of Firenze, hereby confirm that our institution, Department of Experimental and Clinical Medicine, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of immunology in cancer, toxicity related to vaccinology and epidemiology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students

Prof. Francesco Annunziato

Largo Brambilla, 3 – 50134 Firenze

Telefono +39 335 7185712 – Fax + 39 055 2758 021

e-mail: francesco.annunziato@unifi.it // direttore@dmsc.unifi.it // posta certificata: dmsc@pec.unifi.it –

Sito Web: www.dmsc.unifi.it

P.IVA | Cod. Fis. 01279680480



UNIVERSITÀ
DEGLI STUDI
FIRENZE

DIPARTIMENTO DI
MEDICINA SPERIMENTALE
E CLINICA

- contribute to the MOOC development related to vaccinology
- propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- In particular, the actions proposed by the members of our Department involved in the project are the following: Internship for master students (6 months at semester 4); 1 student per year; lecturers in the Live Program in agreement with the other partners; Oral site presentation (1 presentation per year) in agreement with the other partners.

Therefore, I confirm that our organization Department of Experimental and Clinical Medicine strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Prof. Annarosa Arcangeli.

Signature of the Legal representative

Name: Prof. Francesco Annunziato

Position: Full Professor-Head of the Department

Date: 18.04.2023

Place: Firenze

ANNUNZIATO
FRANCESCO
Regione
Toscana/01306030400
18.04.2023 11:18:46
GMT+01:00




Signature of the contact person

Name: Prof. Annarosa Arcangeli

Position: Full Professor

Date: 23.03. 2023

Place: Firenze



Prof. Francesco Annunziato
Largo Brambilla, 3 – 50134 Firenze
Telefono +39 335 7185712 – Fax + 39 055 2758 021
e-mail: francesco.annunziato@unifi.it // direttore@dm-sc.unifi.it // posta certificata: dm-sc@pec.unifi.it –
Sito Web: www.dm-sc.unifi.it
P.IVA | Cod. Fis. 01279680480

3.55 Université Libre de Bruxelles



With one-third of its students and researchers coming from abroad, Université libre de Bruxelles is one of the most multicultural Belgian universities. It has a long-held tradition of excellence, thanks to its more than 220 research units, 8 interdisciplinary institutes, over 2,000 PhD candidates and more than 3.600 researchers and members of academic staff in all fields. It received 4 scientific Nobel Prizes out of the 6 awarded to Belgians,

among them the 2013 Nobel Prize in Physics. Actively involved in the European Research Area, ULB has obtained to this day 47 ERC grants and received European funding (COFUND) to host international post-doctoral researchers. With its 12 faculties, Schools and Institutes, it trains students in all disciplines, closely combining cutting-edge research and education. ULB also recently spearheaded the creation of a large-scale university hospitals network and a scientific biopark dedicated to technological innovation. Open to the world, ULB has set up many partnerships with some of the world's top universities and is a proud member of the CIVIS European Alliance. Since its creation, ULB has been cultivating the flame of freedom. It has constantly demonstrated its independence and its commitment to the great struggles for democracy, individual liberties and human rights. Our outward-looking stance to Europe and the world has resulted in the creation of the CIVIS, Europe's Civic University Alliance.

<https://www.ulb.be/en/ulb-homepage>

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

Université libre de Bruxelles (ULB)
Higher education institution
Full Address: Avenue Franklin D. Roosevelt 50, 1050 Brussels
Belgium
+32-2-650.95.64
www.ulb.be

I, the undersigned, legal representative of ULB, hereby confirm that ULB is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of “Immunology and vaccinology at the extremes of age”.
- 2) ULB will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - participate in student exchanges to broaden their skills to grasp the changing world

Therefore, I confirm that ULB strongly supports this LIVE Master program. The contact person appointed to represent our university in the LIVE master will be Prof. Arnaud MARCHANT, Institute for Medical Immunology.

Signature of the Legal representative

Name: Prof. Annemie Schaus

Position: Rector

Date: 15 February 2023

Place: Brussels

A handwritten signature in blue ink, appearing to read 'A. Schaus', with a stylized flourish above it.

Signature of the contact person

Name: Prof. Arnaud Marchant

Position: Director, Institute of Medical Immunology

Date: 15 February 2023

Place: Gosselies

A handwritten signature in blue ink, appearing to read 'A. Marchant', with a stylized flourish below it.

3.56 Université Paris XII Val de Marne - Vaccine Research Institute - VRI



The Vaccine Research Institute (VRI), Laboratory of excellence, was established by the French National Agency for Research on AIDS and viral hepatitis (ANRS – France REcherche Nord & sud Sida-HIV Hépatites) and the University of Paris-Est Créteil (UPEC) to conduct research to accelerate the development of effective vaccines against HIV/AIDS, and (re)-emerging infectious diseases. The VRI's structure strengthens the links between

basic research and translational research, patient's associations and the socio-economic world, contributing to accelerating vaccine development.

The VRI is structured around research teams with multi-disciplinary expertise, a network of national and international thought leading scientists, a clinical network of physicians, core facilities and innovative immunomonitoring platform. The VRI is closely linked to the department of clinical immunopathology (Hospital CHU Mondor), which has been involved in more than 20 clinical trials in the field of HIV and primary immunodeficiencies.

More than 1200 HIV-infected patients are followed in this clinical department. Since 2007, the clinical department extended its clinical research program by the creation of Clinical Center for HIV Vaccinology aimed at recruiting healthy volunteers and developing HIV vaccine clinical trials.

The VRI Clinical Core in conjunction with the ANRS clinical center network, sets up the VRI Phase I/II vaccine clinical trials that aims to identify the prime/boost strategy to be developed in Phase IIb.

The scientific goals of the VRI offer significant opportunities for innovation as they intend to:

- develop and extend the portfolio of candidate vaccines for HIV and (re)-emerging infectious diseases to be tested in clinical trials
- improve the technology of immuno and viromonitoring for vaccine trials
- strengthen the partnership between immunologists, virologists, cell biologists, molecular biologists, pre-clinical model specialists and clinicians
- develop novel partnerships with industry
- pursue a social science program to analyze the specific issues related to communication on HIV and overall vaccinology
- bring strong expertise on regulatory, legal and ethical aspects
- provide the optimal environment for improved coordination of an integrated scientific program and of dedicated funding

<https://www.en.u-pec.fr/> ; <https://vaccine-research-institute.fr/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Vaccine Research Institute

Status: Labex

Full Address: CHU Henri Mondor 51 avenue Mal De Lattre de Tassigny 94000 Créteil

Country: France

Website: <http://vaccine-research-institute.fr/en/>

I, the undersigned, legal representative of VRI, hereby confirm that our institution, VRI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccine.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to transfer of knowledge and skills from industrial world to academic (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the MOOC development related to vaccinology
 - Contribute to design the next innovative track of the Master LIVE, to educate Data Scientist with a vaccinology degree in order to create efficient Data Scientist in Vaccinology, specialised in applying the latest advances in the fields of big data analytics and machine learning to vaccinology applications.
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose a complete (50,000 Euros / 2 years of study / 1 Master non-EU student; 35,000 Euros / 2 years of study / 1 Master EU student) or a partial grant for Master students, not granted through the Erasmus+ grant scheme, and/or propose funding support to the Master program organization and management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives. The use of this funding (50 000 €) will be framed by an agreement signed between our institution and UCBL.



- Propose complete or partial PhD grant/positions for postgraduate students, and/or employment opportunities to broaden the employability perspectives of the graduated students

Therefore, I, Pr Yves Lévy, confirm that our organization VRI strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Pr LELIEVRE Jean-Daniel

Signature of the Legal representative

Name: Pr Yves Lévy

Position: Director of the VRI

Date: 11 february 2023

Place: CRETEIL (France)



Signature of the contact person

Name: Pr Lelievre Jean-Daniel

Position: Head of clinical department of the VRI

Date: 11 february 2023

Place: CRETEIL (France)



3.57 Universiteit Antwerpen _ Center for the Evaluation of Vaccination – CEV



University of Antwerp

The CEV is a multidisciplinary research group, participating on a regular basis in (inter)national scientific vaccine research. The available expertise of the CEV holds a platform for conducting vaccine trials (phase 1-4) and is involved in policy research projects related to vaccination.

Research mission:

- Improve knowledge in several vaccine-related fields by performing different research projects, including clinical vaccine trials, epidemiological surveys and economic evaluations and infectious disease modelling.
- Spread knowledge on all aspects of vaccination by publishing results of the research projects, both through scientific and vulgarised publications, by offering teaching and training to (para)medical students and by organising vaccine-related courses to health care professionals.
- Support public health policy making, based on our expertise in Public Health, Youth Health, Social Medicine, Epidemiology, and Vaccinology.
- Support and help target vaccination policy and public health in Flanders, Belgium, and Europe, by written as well as oral communications.
- Offer consultancy services in vaccine-related fields, such as vaccine research, vaccine administration, vaccination programmes, and epidemiology of vaccine-preventable diseases.

<https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/>

Herman Van Goethem
Rector

Rectoraat

UAntwerpen - Rectoraat - M.A. 202 - Middelheimlaan 1, 2020 Antwerpen

LIVE – International Vaccinology

Campus Middelheim
Middelheimlaan 1
2020 Antwerpen
Herman.VanGoethem@uantwerpen.be

DATUM
datum

ONDERWERP
Letter of Commitment – Prof. Dr. Peter Delpitte en Prof. Dr. Pierre Van Damme

Geachte mevrouw, heer

Letter of Commitment To support the LIVE – “Leading International Vaccinology Education” Joint Master Program

The organization: The Centre for the Evaluation of Vaccination – Vaccine and Infectious Disease Institute,
University of Antwerp
Status: University Research Unit
Full Address: Universiteit Antwerpen, Campus Drie Eiken, Universiteitsplein 1, 2610 Antwerpen/Wilrijk
Country: Belgium
Tel: +32 3 265 2652
Fax: /

Website: <https://www.uantwerpen.be/en/research-groups/centre-for-evaluation-vaccination/>

I, the undersigned, legal representative of CEV-VAXINFECTIO, hereby confirm that our institution, CEV-VAXINFECTIO, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of Vaccinology.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - Contribute to the MOOC development related to vaccinology
 - Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - Propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates
 - OTHER:
 - * Participate actively in the S2 part of this program:

- Clinical Drug Research (3 credits), including all aspects of conduct of clinical trials, in particular vaccine trials, submission of Regulatory authorities and Ethics Committees, methodological aspects of trial conduct, how to draft an ICF, visits to phase 1-3 trial centers.
- Immune system in early life, pregnant women and elderly (3credits).
- Novel technology in vaccine administration routes and adjuvants (in collaboration with the industry) (3 credits).
- Summer School on Vaccinology for students (3 credits).

Therefore, I confirm that our organization CEV-VAXINFECTIO strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Pierre Van Damme.

Yours faithfully

DocuSigned by:

Herman Van Goethem

E4E980D262094B...

Signature of the Legal representative

Name: Herman Van Goethem

Position: Rector of University of Antwerp

Date: 15-2-2023

Place: Antwerp

DocuSigned by:

Pierre Van Damme

680050E74CC8435...

Signature of the contact person

Name: Pierre Van Damme

Position: full professor

Date: 15-2-2023

Place: Antwerp

3.58 UNIVERSITY OF SASKATCHEWAN - Vaccine and Infectious Disease Organization - VIDO



The Vaccine and Infectious Disease Organization (VIDO), Canada's Centre for Pandemic Research, operates one of the largest and most advanced high containment facilities with capacity to house a variety of small and large animal species from bats to bison. VIDO is a world leader in infectious disease research and vaccine development for humans and animals.

As part of the University of Saskatchewan, VIDO's expertise, infrastructure, and history put us at the forefront of innovation and make us a valuable resource and a source of pride for Canada. For over 45 years, we have trained graduate-level scientists and developed solutions to emerging diseases including eight commercially available vaccines, with several others in regulatory development. We have played a key role in Canada's response to the COVID-19 pandemic.

To strengthen Canada's preparedness for emerging infectious diseases, we are expanding our capabilities as Canada's Centre for Pandemic Research:

- Opening the Vaccine Development Centre, pilot scale biomanufacturing facility with flexibility to conduct process development and meet good manufacturing practice requirements for all vaccine platforms and a variety of protein biologics.
- Adding containment level 4 capacity, which will allow us to work with ANY pathogen.
- Building a new animal facility capable of housing a wider range of animals, which will expand our preclinical research and development capacity.
- Attracting new talent to expand our expertise and providing training opportunities to develop the next generation of scientists.

These important enhancements will support scientists from Canada and around the world to develop vaccines and therapeutics for humans and animals.

<https://www.vido.org/>



VACCINE AND INFECTIOUS DISEASE ORGANIZATION

Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

The organization: Vaccine and Infectious Disease Organization, University of Saskatchewan

Status: Academic Research Centre

Full Address: 120 Veterinary Road Saskatoon, SK, S7N 5E3 Canada

Country: Canada

Tel: +1 306 966 4136

Fax: +1 306 966 7478

Website: www.vido.org

I, the undersigned, legal representative of the Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, hereby confirm that our institution, VIDO, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & Universitat Autònoma de Barcelona (Barcelona, Spain), Universiteit Antwerpen (Antwerp, Belgium), Université Jean Monnet (Saint-Etienne, France).

- 1) Within the program, our organization will offer support and expertise in the area of infectious disease research in humans and animals.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating in the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to:
 - contribute to transfer of knowledge and skills from industrial world to academic e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc., to the students
 - contribute to the MOOC development related to vaccinology
 - contribute to design the next innovative track of the Master LIVE, to educate Data Scientist in vaccinology
 - propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
 - propose a complete (50,000 Euros / 2 years of study / 1 Master student) or a partial grant for Master student, not granted through the Erasmus+ grant scheme, and/or propose funding support to the Master program organization and management, thereby contributing the development strategy of the program, in particular its sustainability and enlargement perspectives. The use of this funding (approximately 25,000 Euros) will be framed by a financial agreement signed between our institution and UCBL.
 - propose full or partial (e.g. public/private partnership) PhD grant and/or positions, and/or opportunities to broaden the employability prospects of the LIVE graduates



VACCINE AND INFECTIOUS DISEASE ORGANIZATION

- participate in the financing of a specific cohort of 10 to 15 people, with partial scholarships in order to train the staff in charge of national immunization programs
- participate in student exchanges to broaden their skills to grasp the changing world
- *The Vaccine and Infectious Disease Organization (VIDO) is a Canadian Centre for Pandemic Research. Located at the University of Saskatchewan, VIDO is a leader in human and animal infectious disease research and vaccine development. For over 45 years we have trained graduate-level scientists and developed solutions to emerging diseases including eight commercially available vaccines, with several others in regulatory development. We are home to one of the largest and most advanced level 3 containment facilities capable of housing both small and large animals including rodents, poultry, pigs, cattle, and bison. We have expanded our specialized infrastructure to include a GMP vaccine manufacturing facility and are upgrading our capacity to include level 4 containment. Our vision includes the capacity to study any emerging disease in any animal model embracing a One Health approach to prevent emerging and re-emerging infectious disease of importance in human and veterinary health.*

Therefore, I confirm that our organization, VIDO at the University of Saskatchewan, strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Andrew Van Kessel, Director of Research, VIDO.

Signature of the Legal representative




Name: Alix Hayden

Position: Director, Innovation Mobilization & Partnerships

Date: January 4, 2023

Place: Saskatoon, Saskatchewan, Canada

Signature of the contact person



Name: Andrew Van Kessel

Position: Director of Research, VIDO

Date: January 4, 2023

Place: Saskatoon, Saskatchewan, Canada

3.59 Vaccine Formulation Institute (CH) - VFI



The Vaccine Formulation Institute is a not-for-profit company dedicated to the development of adjuvants and formulations, with state-of-the-art laboratories in Switzerland.

VFI was initially created in 2012 with the support of the World Health Organization in order to help the vaccine community to access more easily know-how and expertise in vaccine formulation and adjuvant technologies, in order to catalyzing the development of new-generation adjuvanted vaccines.

VFI's mission is to develop clinically-relevant adjuvants and vaccine formulations to fight diseases in all parts of the world on an open-access basis. Its main activities consist of research and development of innovative adjuvant technologies, provision of adjuvants to the vaccine community for preclinical and clinical evaluation of vaccines, technology transfer of adjuvant technologies to industry partners to make them broadly accessible and affordable, and provision of training on adjuvants and vaccine formulations to vaccinologists worldwide, with a specific focus on low- and middle-income countries.

VFI has recently completed the development of SWE, the first adjuvant for prophylactic human vaccines in open-access since the aluminium salts. SWE is an oil-in-water emulsion now commercialized by Seppic under the trademark Sepivac SWE™ which is under clinical evaluation by numerous institutions worldwide.

<https://www.vaccineformulationinstitute.org/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Vaccine Formulation Institute
 Status: Limited not-for-profit
 Full Address: Rue du Champ-Blanchod 4, 1228 Plan-les-Ouates
 Country: Switzerland
 Tel: +41 79 482 83 83
 Fax: N/A
 Website: www.vaccineformulationinstitute.org

I, the undersigned, legal representative of Vaccine Formulation Institute, hereby confirm that our institution, VFI, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (UCBL, France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of Adjuvants and Vaccine Formulation.
- 2) In respect of our missions, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through organizing workshops as further described hereunder.
- 3) Our organization commits to provide annual workshops on Adjuvants and Vaccine Formulation for the students of the programme. This workshop will aim to give an overview on different vaccine adjuvant systems. In addition, students will learn about best practices in vaccine-adjuvant formulation and will be introduced to assays for characterization and quality control of adjuvanted vaccines.

Therefore, I confirm that our organization Vaccine Formulation Institute strongly supports this LIVE Master program. The contact person appointed to represent our company in the LIVE master will be Dr. Maria LAWRENZ.

Signature of the Legal representative



Dec 13, 2022

Name: Dr. Nicolas Collin
 Position: CEO and Co-Founder
 Place: Plan-les-Ouates, Switzerland

Signature of the contact person



Dec 13, 2022

Name: Dr. Maria Lawrenz
 Position: Operations Director
 Place: Plan-les-Ouates, Switzerland

3.60 Vakzine Projekt Management GMBH



Within the last decade, Vakzine Projektmanagement GmbH (VPM) has successfully managed and consulted the development of promising biopharmaceutical candidates, ranging from small molecules, recombinant proteins up to gene-modified live vaccines and ATMPs. VPM brought these products for its customers in the pharmaceutical industry, academic research and small biotechnology companies, from preclinical phase through clinical phases I-III.

Since 2012 VPM has started its consulting and service business. Based on its in-depth experience and a strong network of reliable partners, VPM offers tailor-made hands-on services and consultancy. The clients are small, medium and large biopharmaceutical enterprises, as well as private funding organizations, and research groups. The consulting and service offers refer to the entire product development value chain as VPM has experienced and successfully mastered each of these value points for itself.

Since July 2018 Serum Institute of India (SIPL) is majority shareholder of VPM. SIPL is the world's largest vaccine manufacturer by number of doses produced and sold globally (more than 1.3 billion doses) which includes Polio vaccine as well as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. Vaccines manufactured by SIPL are accredited by the World Health Organization, Geneva and are being used in around 170 countries across the globe in their national immunization programs, saving millions of lives throughout the world. The acquisition through SIPL provides VPM and its clients a direct link to cost-effective GMP manufacturing.

Since the foundation of the company, VPM has also developed five own products and focused its resources then on the three main products: a) a bladder cancer immunotherapeutic (VPM1002BC), b) a novel tuberculosis vaccine candidate (VPM1002), and c) a CMV vaccine (VPM2001). These products have a combined target market of more than 6 billion Euros. All three products have been successfully out-licensed to pharmaceutical companies including R&D contracts to further pursue with the development.

Founded originally in August 2002, VPM was established following an initiative of the German Federal Ministry of Education and Research (BMBF) to promote the development of vaccines in Germany. Scope of the vaccine initiative was the funding of rapid transfer of results from basic research into the development of new vaccines. The BMBF provided VPM with 25.6 million euros funding between 2001 and 2010 to organize and finance the preclinical and clinical development of vaccines nationwide. To this end, VPM acquired proprietary rights to promising vaccine candidates from public German laboratories and managed their development until further licensing to industrial partners. In order to identify such promising vaccine candidates in Germany, a map of vaccine research with the associated technologies for research and development of vaccines was drawn up at the beginning of the BMBF funding and updated in 2006.

<https://www.vpm-consult.com/>



Letter of Commitment

To support the LIVE – “Leading International Vaccinology Education”

Joint Master Program

The organization: Vakzine Projekt Management GmbH

Status: GmbH

Full Address: Mellendorfer Straße 9, 30625 Hanover

Country: Germany

Tel: +49 (0) 511 169908-13

Fax: +49 (0) 511 169908-29

Website: www.vakzine-manager.de

I, the undersigned, legal representative of Vakzine Projekt Management GmbH, hereby confirm that our organization, Vakzine Projekt Management GmbH, is willing to support the LIVE Master program coordinated by the Université Claude Bernard Lyon 1 (France) in collaboration with the following higher education institutions: Universitat de Barcelona & the Universitat Autònoma de Barcelona (Spain), University of Antwerp (Belgium), Université Jean Monet Saint-Etienne (France).

- 1) Within the program, our organization will offer support and expertise in the area of organizing preclinical and clinical development of vaccines.
- 2) In respect of our mission, duties and roles undertaken in the LIVE Master, as detailed in the LIVE Consortium Agreement which I hereby endorse, our organization will contribute to the overall promotion and implementation of the program, in particular through participating to the project governance, and supporting the yearly recruitment campaigns.
- 3) Our organization also commits to :
 - Contribute to transfer of knowledge and skills from industrial to academic world (e.g. by proposing seminars, tutorials, lectures, specific practical training, visits to our site, etc.) to the students
 - Contribute to the : Massive Open Online Course (MOOC) development related to vaccinology
 - Propose employment opportunities to broaden the employability perspectives of the graduated students



- Propose topics for master thesis and internship opportunities (6 months during semester 4), and/or short summer internships to the students.
- *OTHER:* Vakzine Projekt Management GmbH will support the program e.g. by:

Offering traineeships and/or master thesis which are focused on project management of pharmaceutical development. The following subjects would be part of the students' work:

- i. Establishment of a target product profile
- ii. Preparation of a project plan including PERT and GANTT chart.
- iii. Identification of a projects' CRITICAL CHAIN
- iv. Definition of milestones and deliverables
- v. Preparation of budget plan for a project
- vi. Preparation of relevant documents for clinical trial application

Further trainings based on pharmaceutical development of vaccines and drugs which includes topics like:

- i. Legal and regulatory background
- ii. Regulatory authorities
- iii. GLP, GMP, GCP
- iv. Relevant documents for study application e.g. Clinical Trial Application (CTA), Clinical Trial Protocol (CTP), Informed Consent Form (ICF), Investigator Brochure (IB), and Investigational Medicinal Product Dossier (IMPD).

Therefore, I confirm that our organization of Vakzine Projekt Management GmbH strongly supports this LIVE Master program. The person appointed to represent our company (contact person) in the LIVE master will be Bernd Eisele.



Signature of the Legal representative

Name: Bernd Eisele, M.D.

Position: Chief Executive Officer

Date: 07.02.2018

Place: Hanover



Signature of the contact person

Name: Saskia Pötsch

Position: Assistance Project Management

Date: 07.02.2018

Place: Hanover

3.61 Valneva



Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize three vaccines and to rapidly advance a broad range of vaccine candidates into the clinic, including candidates against Lyme disease and the chikungunya virus.

Valneva's strategy stems from its vision to contribute to a world in which no one dies or suffers from a vaccine-preventable disease. Valneva aims to build a leading vaccines company with a portfolio of specialized assets targeting diseases with limited preventive or therapeutic treatment options.

<https://valneva.com/>




February 13th, 2018

Subject : Letter to support LIVE – « Leading International Vaccinology Education » - Joint Master Program

Valneva is supporting the initiative of the LIVE Master program coordinated by the University Claude Bernard Lyon (France) in collaboration with the following higher education institutions: University Jean Monnet Saint Etienne (France), Autonomous University of Barcelona (Spain), University of Antwerp (Belgium).

This program is an excellent initiative in order to foster high standard education in the vaccine field. In long term not only academia and industry will profit, but also health system and society.

Klaus Schwamborn
Vice President Global Research



3.62 World Health Organisation – Organisation Mondiale de la Santé - WHO / OMS



Founded in 1948, WHO is the United Nations agency that connects nations, partners and people to promote health, keep the world safe and serve the vulnerable – so everyone, everywhere can attain the highest level of health.

WHO leads global efforts to expand universal health coverage. We direct and coordinate the world's response to health emergencies. And we promote healthier lives – from pregnancy care through old age. Our Triple Billion targets outline an ambitious plan for the world to achieve good health for all using science-based policies and programmes. Our team of 8000+ professionals includes the world's leading public health experts, including doctors, epidemiologists, scientists and managers. Together, we coordinate the world's response to health emergencies, promote well-being, prevent disease and expand access to health care. By connecting nations, people and partners to scientific evidence they can rely on, we strive to give everyone an equal chance at a safe and healthy life.

From emerging epidemics such as COVID-19 and Zika to the persistent threat of communicable diseases including HIV, malaria and tuberculosis and chronic diseases such as diabetes, heart disease and cancer, we bring together 194 countries and work on the frontlines in 150+ locations to confront the biggest health challenges of our time and measurably advance the well-being of the world's people.

Every day, WHO's experts are dedicated to creating a world free from disease and addressing the social conditions that influence human health and well-being.

The Thirteenth General Programme of Work (GPW 13) defines WHO's strategy for the five-year period, 2019-2023. It focuses on [triple billion targets to achieve](#) measurable impacts on people's health at the country level.

The triple billion targets are to ensure by 2023:

- One billion more people are benefiting from universal health coverage
- One billion more people are better protected from health emergencies
- One billion more people are enjoying better health and well-being

<https://www.who.int/>



Tim Nguyen
MPH, Dipl.-Kfm (FH)
World Health Organization WHO
Who Division of Information, Evidence, Research and Innovation
Head of Unit High impact events preparedness

Development of INFODEMOLOGY training in LIVE3 at UCBL with WHO support

De : NGUYEN, Tim <NguyenT@who.int>

Envoyé : lundi 13 février 2023 10:10

À : Christine DELPRAT <christine.delprat@univ-lyon1.fr>

Cc : CAZACU, Ofelia <cazacuo@who.int>

Objet : RE: [EXT] INVITATION / WHO Technical Consultation on Building a Global University Curriculum for Infodemic Management / Belgrade, Serbia, 21-22 March 2023

Hi Christine, happy to do that.

However, processes have changed in WHO, so I need to pass this request to our external relations unit to do a due diligence check, we call it Non-state-actor review. This takes between 2-3 weeks.

I'll ask Ofelia to initiate the process and contact NAS team (Jill Meloni).

Kindest,

Tim

-

Tim Nguyen

World Health Organization WHO, Who Division of Information, Evidence, Research and Innovation
MPH, Dipl.-Kfm (FH)

From: Christine DELPRAT <christine.delprat@univ-lyon1.fr>

Sent: Sunday, February 12, 2023 4:22 PM

To: PURNAT, Tina <purnatt@who.int>; NGUYEN, Tim <NguyenT@who.int>; CAZACU, Ofelia <cazacuo@who.int>

Subject: [EXT] INVITATION / WHO Technical Consultation on Building a Global University Curriculum for Infodemic Management / Belgrade, Serbia, 21-22 March 2023

Dear Tina, Ofelia & Tim,

Thank you for the Belgrade invitation sent on Feb 10 by The World Health Organization Epidemic and Pandemic Preparedness and Prevention Department, and the WHO Regional Office for Europe, to participate in the "WHO Technical Consultation on Building a Global University Curriculum for Infodemic Management". Not sure I will be able to answer by Feb 15, but in the next days. Good to read that the WHO infodemic management team is convening a global meeting on defining and formulating a plan for streamlining infodemic management into curricula.

Just to share: Concerning infodemiology, as a logical follow-up to the infodemiology morning of the VaxInLIVE 2021 meeting, we have introduced and started this academic year 2022-2023 in the Master LIVE, a module called "Vaccinology and Infodemiology" in the LIVE S3-M2 curriculum.

In order to help with more implementation, in collaboration with WHO, and also to report to EACEA what we are doing together, I will need a letter to support the development of infodemiology at UCBL.

Best regards,

Prof. Christine DELPRAT

Professor of Immunology – PU CL.EX., University of Lyon – UCBL, France, Master LIVE Coordinator



Co-funded by the
Erasmus+ Programme
of the European Union



(new logo) <https://live.univ-lyon1.fr>

VaxInLIVE 2021 e-Symposium

OPEN DAY CONFERENCE PROGRAM

May 19, 2021 – GENERAL OPEN DAY

TRENDS IN VACCINOLOGY FOR (RE)EMERGING PATHOGENS

Website to register: <http://vaxinlive.univ-lyon1.fr>

| 10:30 – 12:00 | Session 2: <u>Infodemiology – the practice and science</u> Sakshi Jindal & Tim Nguyen |  |
|---------------|--|---|
| 10:30 – 10:45 | Christine CZERNIAK , PhD, Technical Lead for Infodemic Management, WHO, Geneva (CH) <i>Introduction to <u>infodemic management</u></i> | |
| 10:45 – 11:00 | Sara RUBINELLI , Professor of Health Communication, Department of Health Sciences and Medicine, University of Lucerne (CH) <i>Infodemic management <u>competency framework</u></i> | |
| 11:00 – 11:15 | Lynette PHUONG , MPH, Technical Officer for Infodemic Management, WHO, Geneva (CH) <i>Overview of <u>training opportunities</u></i> | |
| 11:15 – 11:30 | Cherstyn HURLEY , PhD, National Immunisation programme publications manager, Public Health England (UK) <i>Applying <u>infodemiology to increase vaccine uptake</u></i> | |
| 11:30 – 11:45 | Avichal MAHAJAN , PhD, Technical Officer for Data Management, WHO, Geneva (CH) <i>Knowledge <u>gaps – Infodemic research agenda</u></i> | |
| 11:45 – 12:00 | Q & A on <u>infodemiology</u> | |